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Introduction to the thesis 
machinery, yielding cancer cell variants that are no longer effectively recognized by the 
immune system. Ultimately, these mutations may allow certain cancer cell variants to 
enter the escape phase, where cancer cells escape from immune prosecution and prog-
ress to a clinically apparent disease. 
Tumor progression may additionally promote the induction of an immunosuppressive 
and/or tumor-promoting inflammatory microenvironment. In the latter case innate im-
mune cells such as tumor-associated macrophages appear to stimulate cancer cell prolif-
eration and survival, and suppress adaptive immune responses.14 Accordingly, presence 
of such myeloid suppressor cells associates with poor prognosis in several cancer types.15, 
16 It has therefore become increasingly clear that immune suppression in the tumor 
microenvironment can hamper the efficacy of therapeutic strategies aimed to improve 
anticancer immunity. Therefore, many approaches to overcome immune suppression 
at the tumor site have been developed in recent years. Especially immunotherapeutic 
agents targeting so-called immune checkpoint interactions have yielded unprecedented 
response rates and even cure, particularly in melanoma.17 
However, immune checkpoint molecules are not exclusively expressed on cancer cells 
and ubiquitous (re)activation of immune cells can therefore associate with severe au-
toimmune-related side effects.18 In addition, conventional cytotoxic therapies such as 
radio- and chemotherapy, that remain the basis of cancer treatment in advanced stage 
cancer patients, frequently cause severe systemic side effects as they basically target all 
rapidly dividing cells.19 Fortunately, the improved understanding of cancer biology and 
breakthroughs in biotechnology have led to the development of therapeutic strategies 
that selectively target cancer cells using antibodies. In this thesis, we pre-clinically eval-
uated various novel antibody-based agents that were designed to improve the tumor-se-
lective action of cancer immunotherapy.
Outline of the thesis
In Chapter 2, we review recent developments in the field of antibody-based cancer ther-
apy. Due to their high binding affinity and selectivity, antibodies are prominent candi-
dates for targeted cancer therapy. Indeed, more than 20 antibodies have been approved 
for cancer therapy in the US and Europe, and this number is expected to rapidly expand 
in the near future. However, tumor antigens that are exclusively present on cancer cells 
are rare. Hence, most (if not all) currently available antibodies are directed against tu-
mor-associated antigens rather than to tumor-specific antigens, which may associate 
with on-target/off-tumor side effects. 
With the advent of recombinant DNA engineering, a large variety of advanced ratio-
nally-designed molecular formats of antibody-derived agents have become available, 
including antibody fragments, CAR-transfected T cells, antibody-cytokine fusion proteins 
and recombinant bispecific antibodies. As detailed in Chapter 2, these novel antibody 
formats can have enhanced tumor selectivity. For example, a bispecific antibody directed 
against HER-3 and the insulin-like growth factor I receptor, showed superior anticancer 
activity compared to control monospecific or combination antibody treatment in pre-clin-
ical studies.20 
General introduction
In the general public domain, cancer is often believed to be a ‘modern’ and rapidly in-
creasing disease. However, the earliest medical records describing cases of cancer are 
papyri dating back as early as 2500 B.C.1-3 Indeed, cancer has been detected in Egyptian 
mummies using modern medical technology.4, 5 
However, in ancient times the incidence of cancer appears to have been relatively low 
compared to current numbers. This may be due to a significant increase in life expec-
tancy and radical changes in life style and environmental factors.5 Nowadays, cancer is 
among the leading causes of death worldwide and the number of new cancer cases is 
expected to increase with 70% in the next two decades.6 Fortunately, the understanding 
of cancer has tremendously increased. In addition to well-known fundamental charac-
teristics of cancer cells such as genetic instability, chronic proliferation and replicative 
immortality,7 it has become increasingly clear that the immune system is involved in both 
tumor suppression and progression.8 
According to the initial cancer immunosurveillance concept proposed by Paul Ehrlich 
and further developed by Burnett and Thomas, the immune system continuously scans 
the body to identify and eliminate transformed cells before they can develop into an 
uncontrollable disease. During tumor progression, malignant cells accumulate mutations 
some of which may directly affect their immunogenicity. Presentation of tumor-specific 
antigens (peptides) may result in the induction of humoral (antibodies) and/or cellular 
anticancer immune responses.9 Indeed, ‘spontaneous’ regressions have been described 
in cancer patients,10 particularly in patients that were suffering from fulminant infections 
with pyogenic microorganisms. It is thought that such an infection boosts the natural 
anticancer immune response. This phenomenon inspired the development of various 
rudimentary cancer immunotherapies, with a history spanning hundreds of years.11 A 
prominent example is ‘Coley’s toxin’, a cancer vaccine containing killed bacteria that was 
developed in the late 1800s.12, 13
However, cancer cells and tumors arise in the presence of an apparently fully functional 
immune system. Apparently, cancer cells have or acquire the ability to modulate and 
eventually escape elimination by the immune system. The current paradigm for this pro-
cess, termed the immunoediting concept, builds on the immune surveillance paradigm 
and integrates the immune system’s dual role in cancer development. The immunoedit-
ing concept consists of 3 phases: elimination, equilibrium, and escape.8 Essentially, the 
elimination phase resembles the cancer immunosurveillance concept. Herein innate and 
adaptive immunity work together to detect and destroy transformed cells long before 
they become clinically apparent. However, some cancer cell variants may not be com-
pletely eliminated in this phase and may subsequently enter into the equilibrium phase in 
which the immune system is able to control tumor outgrowth. In this phase, cancer cell 
populations are kept in a state of functional dormancy through constant interaction with 
cells of the immune system. However, immune effector cells provide selection pressure 
for the genetically unstable cancer cells by effectively recognizing and eliminating cancer 
cells with highly immunogenic antigens. Thus, cancer cells may gradually acquire muta-
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antibody fragment targeting the melanoma-associated chondroitin sulfate proteoglycan 
(MCSP), and a human IgG1 Fc domain. MCSP is overexpressed on most melanomas and 
promotes adhesion, growth and tissue invasion of melanoma cells.31 Bispecific antibody 
(bsAb) MCSPxDR5 was designed to selectively induce TRAIL-R2-mediated apoptosis in 
MCSP-positive melanoma cells. In line with this, bsAb MCSPxDR5 induced potent MC-
SP-restricted TRAIL-R2 mediated apoptosis in a panel of melanoma cell lines and primary 
patient-derived melanoma cells. Moreover, cross-linking of its IgG domain, using either 
artificial cross-linker or Fc receptors on immune effector cells, significantly enhanced its 
anticancer activity. Taken together, bsAb MCSPxDR5 has promising MCSP-directed and 
DR5-restricted anticancer activity, which warrants its further pre-clinical development for 
the treatment of melanoma and other MCSP-positive malignancies.
Alternatively, the efficacy of soluble TRAIL can be enhanced using the aforementioned 
scFv:TRAIL fusion protein format. Our group has previously validated this concept with 
TRAIL fusion proteins directed against several tumor antigens including MCSP, EGFR or 
EpCAM, which selectively deliver TRAIL to the cancer cell surface.32-34 Treatment with 
such scFv:TRAIL fusion proteins triggered target antigen-selective binding and triggered 
apoptosis in vitro and in vivo. Depending on the biology of its respective target antigen, 
a TRAIL fusion protein can have additional anticancer effects such as blockade of EGFR- 
or MCSP-mediated protumorigenic signaling32, 33 or blockade of CD47-mediated “don’t 
eat me” signaling.35 Alternatively, the scFv:TRAIL fusion protein format can be used to 
arm immune effector cells with exogenous membrane-bound TRAIL. We have previously 
shown that CD3- and CD7-targeted TRAIL fusion proteins greatly enhance the anticancer 
efficacy of T cells, both in vitro and in mouse tumor models.36 Importantly, CD3-targeted 
TRAIL formulations potently activate CD3-signalling in T cells, thereby enhancing their 
anticancer activity. 
In this thesis, we explored whether TRAIL fusion proteins can be exploited to block the 
PD-L1/PD-1 immune checkpoint. This immune checkpoint is hijacked by cancer cells to 
suppress and overcome natural anticancer immunity17 (Figure 1). 
Figure 1: The interaction between Programmed Death Ligand 1 (PD-L1) and its receptor PD-1 on 
activated T cells normally ensures timely down-regulation of an immune response to prevent collat-
eral damage of healthy cells.37 However, cancer cells can also upregulate PD-L1 expression, either via 
oncogenic signaling pathways or in response to IFN-γ produced in the tumor microenvironment.38, 39 
Interaction between PD-L1 and PD-1 suppresses the antitumor activity of tumor-infiltrating T cells, 
allowing cancer cells to escape from the immune system.38, 40 
Bispecific antibodies can also be designed to redirect immune effector cells to cancer 
cells, thereby exploiting their intrinsic anticancer activity. Currently, two bispecific an-
tibodies that combine specificity for CD3-epsilon (part of the T cell receptor signaling 
complex) with a tumor-associated cell surface antigen have been approved for clinical 
use. Additionally, many other bispecific antibodies are currently in (pre)clinical develop-
ment.21 
Alternatively, antibody-based agents can be exploited to selectively deliver immune ef-
fector molecules such as cytokines to the tumor site. Cytokines are major regulators of 
the immune system and can have significant anticancer effects. For example, treatment 
with recombinant IL-2 induces complete remission in a subset of patients with melanoma 
and renal cell carcinoma.22 However, since most cytokines have no intrinsic selectivity for 
cancer cells, the amount of e.g. non-targeted IL-2 that needs to be injected to achieve 
adequate anticancer activity is relatively high and associates with severe side effects.23 
To overcome this issue, antibody-cytokine fusion proteins have been generated with the 
aim of combining the high target selectivity of antibodies with tumor-localised stimu-
lation of the immune system.24 In this respect, TNF-related Apoptosis Inducing Ligand 
(TRAIL) is a particularly interesting candidate for cancer therapy as it can selectively 
induce programmed cell death (apoptosis) in cancer cells while sparing normal cells.25 
TRAIL is expressed on the surface of various immune effector cells and can bind to 4 
TRAIL receptors (TRAIL-R). TRAIL-R1 and TRAIL-R2 are capable of inducing cell death, 
while TRAIL-R3 and TRAIL-R4 are thought to have a decoy function. The anticancer ef-
ficacy of both recombinant soluble TRAIL and agonistic antibodies specific for TRAIL-R1 
or TRAIL-R2 has been evaluated in early stage clinical trials where favorable safety 
profiles were observed.26 However, these first-generation TRAIL-R agonists had limited 
clinical efficacy, possibly due to intrinsic resistance to TRAIL and/or acquired resistance 
upon treatment with TRAIL-R agonists. Furthermore, TRAIL receptors are ubiquitously 
expressed throughout the body,27 limiting the accumulation of TRAIL-R agonists at the 
tumor site. Additional issues include a short half-life and rapid clearance from the circu-
lation of recombinant soluble TRAIL.28, 29 
Of note, unlike membrane-bound TRAIL, soluble TRAIL requires cross-linking to effi-
ciently activate TRAIL-R2. Similarly, conventional TRAIL-R2 targeted antibodies require 
additional cross-linking by Fc-receptor positive cells for effective induction of apopto-
sis.30 scFv:TRAIL fusion proteins, in which antibody fragments targeting a tumor antigen 
are genetically fused to soluble TRAIL, can provide the required cross-linking to induce 
TRAIL-R2 mediated apoptosis. In this format, binding of the antibody fragment to the 
target antigen converts the essentially inactive soluble TRAIL domain to a membrane-like 
form of TRAIL that effectively induces apoptosis. Similarly, bispecific antibodies can se-
lectively deliver a TRAIL-R2 targeted antibody fragment to a tumor antigen and provide 
cross-linking upon binding to the target antigen.
In Chapter 3, we describe such a novel bispecific antibody-based strategy that may 
improve the efficacy of TRAIL-R2 targeted therapy. We constructed MCSPxDR5, a bispe-
cific tetravalent antibody that comprises a scFv fragment derived from tigatuzumab, a 
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tumor-selective PD-L1-blocking immunotherapy.
Bispecific antibody PD-L1xEGFR was designed to selectively target PD-L1/PD-1 check-
point inhibition to EGFR-positive cancer cells. On EGFR-positive cells, bsAb PD-L1xE-
GFR inhibited the PD-L1/PD-1 interaction with similar efficacy as a conventional PD-
L1 antibody. However, our data showed that treatment of EGFR/PD-L1-positive cancer 
cells with bsAb PD-L1xEGFR resulted in EGFR-directed blocking of PD-L1, which result-
ed in both enhanced anticancer activity and IFN-γ production of T cells. Additionally, 
bsAb PD-L1xEGFR enhanced NK cell-mediated Antibody Dependent Cellular Cytotoxicity 
(ADCC) towards cancer cells via its human IgG1 Fc domain and reduced the viability of 
EGFR-positive cancer cells by blocking oncogenic EGFR-signaling. Indeed, bsAb PD-L1x-
EGFR selectively enhanced the anticancer activity of T cells towards EGFR-positive cells 
and as such outperformed a PD-L1-blocking antibody that is in clinical use. In conclu-
sion, the promising multi-fold EGFR-restricted anticancer activity of bsAb PD-L1xEGFR 
may provide possibilities to improve clinical efficacy and reduce side effects compared to 
conventional PD-L1/PD-1 antibodies. 
Finally, Chapter 6 provides a summary of the work presented in this thesis and pro-
vides perspectives on further development of tumor-selective blockade of the PD-L1/
PD-1 checkpoint axis and improving the tumor-selective efficacy of PD-L1 and TRAIL-R 
targeted agents.
Correspondingly, expression of PD-L1 on cancer cells often correlates with an unfavor-
able prognosis.41, 42 Antibodies that block the PD-L1/PD-1 interaction can restore the 
anticancer activity of functionally impaired tumor-infiltrating lymphocytes (TILs), spe-
cifically cytotoxic T cells. Although treatment with such antibodies has led to unprece-
dented response rates, particularly in advanced melanoma,43, 44 there is ample room for 
improvement as these responses are limited to a minority of cancer patients and a select 
set of malignancies. 
In Chapter 4, we describe a bi-functional scFv:TRAIL fusion protein, designated anti-
PD-L1:TRAIL, that comprises a PD-L1 blocking scFv antibody fragment genetically fused 
to soluble TRAIL. Fusion protein anti-PD-L1:TRAIL was designed to selectively induce 
TRAIL-mediated apoptosis in PD-L1-positive cancer cells while simultaneously reactivat-
ing anticancer immunity via blockade of the PD-L1/PD-1 immune checkpoint. Indeed, 
we demonstrated that fusion protein anti-PD-L1:TRAIL selectively induced apoptosis in 
PD-L1-positive cancer cell lines and in primary patient-derived melanoma cells. At the 
same time, anti-PD-L1:TRAIL enhanced anticancer activity and IFN-γ production of T 
cells via blockade of the PD-L1/PD-1 interaction. Since IFN-γ increases PD-L1 expres-
sion and sensitizes cancer cells to TRAIL-mediated apoptosis,39, 45, 46 anti-PD-L1:TRAIL 
may trigger a feed-forward loop of increasing IFN-γ, increasing PD-L1 expression and 
increasing TRAIL sensitivity. In line with this, IFN-γ enhanced anti-PD-L1:TRAIL-mediat-
ed apoptosis in cell lines and in primary patient-derived melanoma cells. Furthermore, 
anti-PD-L1:TRAIL converted PD-L1-expressing and thus potentially immune suppressive 
myeloid cells into TRAIL-displaying effector cells that induced TRAIL-mediated apoptosis 
in cancer cell lines. In conclusion, fusion protein anti-PD-L1:TRAIL has promising multi-
fold and mutually reinforcing therapeutic effects comprised of PD-L1 checkpoint blockade 
and simultaneous tumor-selective induction of TRAIL-mediated apoptosis. This new fu-
sion protein may provide possibilities to enhance the efficacy of therapeutic PD-L1/PD-1 
checkpoint inhibition alone or in combination with other immunotherapeutic strategies.
Since PD-1 and PD-L1 are broadly expressed on normal tissues, antibodies blocking 
either PD-1 or PD-L1 are not inherently tumor-selective. Indeed, autoimmune-related 
adverse effects have been observed for PD-L1 blocking antibodies.43 In Chapter 5, we 
describe a novel bispecific antibody-based strategy to improve the selectivity of PD-L1/
PD-1 checkpoint blockade. Selectively delivery of PD-L1/PD-1 blockade to a tumor-as-
sociated target antigen may improve the tumor-selective action of PD-L1/PD-1 blocking 
immunotherapy, potentially with increased efficacy and safety. Hereto, we constructed a 
human IgG1 bispecific antibody, PD-L1xEGFR, that comprises a PD-L1 blocking scFv an-
tibody fragment and an epidermal growth factor receptor (EGFR) targeted scFv antibody 
fragment. EGFR is a well-established tumor target antigen that is overexpressed by vari-
ous malignancies in which it correlates with poor prognosis.47, 48 Aberrant EGFR-signaling 
plays crucial roles in the pathogenesis of cancer by initiating the early stages of tumor 
development, sustaining tumor growth, promoting infiltration, and mediating resistance 
to therapy.49 Moreover, mutations that activate EGFR-signaling were recently reported to 
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Since their discovery, antibodies have been viewed as ideal candidates or ‘magic bullets’ 
for use in targeted therapy in the fields of cancer, autoimmunity and chronic inflamma-
tory disorders. A wave of antibody-dedicated research followed, which resulted in the 
clinical ap proval of a first generation of monoclonal antibodies for cancer therapy such 
as rituximab (1997) and cetuximab (2004), and infliximab (2002) for the treatment 
of auto im mune dis eases.  More recently, the development of antibodies that prevent 
checkpoint-mediated inhibition of T cell re sponses invigorated the field of cancer im-
munotherapy. Such antibodies induced unprecedented long-term remissions in patients 
with advanced stage malignancies, most notably melanoma and lung cancer, that do not 
respond to conventional therapies. In this chapter, we will recapitulate the development 
of antibody-based therapy, and detail recent advances and new functions, particularly 
in the field of cancer im mu notherapy. With the advent of recombinant DNA engineering, 
a number of rationally-designed molecular formats of antibodies and antibody-derived 
agents have be come available, and we will dis cuss various molecular formats including 
monoclonal antibodies, bispecific an ti bo dies, antibody-cytokine fusion proteins, and T 
cells genetically mo di fied with chimeric antigen receptors. With these exciting advances, 
new antibody-based treatment options will likely enter clinical practice and pave the way 
towards more suc cess ful control of malignant diseases.
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Antibodies are key components of the humoral immune response and are characterised 
by a high specificity and binding affinity for a specific antigenic epitope. Antibodies have 
been held to be of therapeutic interest, already since their original postulation by Paul 
Ehrlich in the late 1800s. Indeed, antibodies have been viewed as ideal candidates or 
‘magic bullets’ for the use of targeted therapy in various fields of medicine, with initial 
studies on the clinical application of an ti bodies performed with polyclonal antisera, e.g. 
for the treatment of infectious diseases and of snake- and spider-bites (Calmette 1895). 
Also in the areas of stem cell- and organ trans plantation and in the treatment of anaplas-
tic anaemia, polyclonal anti-Lymphocyte- and anti-Thy mocyte- sera and anti-IgG helped 
to prevent graft versus host disease (Finke et al. 2009). The subsequent dis co ve ry of 
a production method for monoclonal anti bo dies (mAbs) in 1975 (Kohler et al. 1975) 
started the exploration of antibodies as highly specific tar ge ting and eff ec tor molecules 
for cancer therapy. The first attempts at mAb-based cancer therapy made use of murine 
mAbs, but often showed dis ap poin ting activity in clinical trials (reviewed by (Vaickus et 
al. 1991)). This outcome was fre quent ly due to the development of neutralising antibod-
ies against the therapeutic antibody pro du ced by the host. However, with the advent of 
antibody engineering many modifications to mAbs became possible and significant steps 
forward were made. 
The first major step was the development of chimeric antibodies in which a human Ig 
Fc-domain was fused to murine antigen recognition domains (LoBuglio et al. 1989). By 
virtue of this human Fc-domain, chimeric antibodies resemble human antibodies more 
closely and in ter act better with effector cells to trigger their anticancer activity. Further, 
chimeric mAbs are less immunogenic, less likely inactivated by neutralising host an-
ti bodies, and have a serum half-life closer to that of fully human antibodies, typically 
ranging from 2 to 4 weeks. Chimeric mAbs were the first clinically successful antibodies 
in oncology as illustrated by the FDA-approval of the CD20 antibody rituximab for the 
treatment of B cell lymphomas (1997), which opened the field of an ti bo dy-based cancer 
therapy (Maloney et al. 1997). Rituximab is a chimeric human IgG1 containing mo -
noclonal antibody (Reff et al. 1994) that binds to the tetraspanin CD20, an integral trans-
mem brane protein expressed on the surface of normal and malignant B-lineage cells. 
Soon afterwards, the chimeric EGFR antibody cetuximab was approved for the treatment 
of colo rec tal cancer (Cunningham et al. 2004). The growth factor receptor EGFR is ex-
pressed on epithelial cells and is often over ex pressed in epithelial malignancies. Blocking 
of this receptor with the antibody deprives the cancer cell of essential growth factor 
signals needed for its survival. At present (July 2016), more than 47 mAbs are approved 
for therapy in the US and Europe (Reichert 2015).
Many other antibody modifications and antibody-derived therapeutic agents have been 
developed, including Fc-engineered antibodies with optimised effector functions, bi-
specific antibodies, bispecific fusion proteins of antibody-fragments, antibody fragments 
carrying toxins or cytokines, and tri- or tetra-specific antibody-derivatives. Finally, in 
Chimeric Antigen Receptors (CAR)-transfected T cells, antibody fragments are used to 
redirect T cells to ma lig nant target cells.
Here we review some of the major molecular formats of antibody-derived molecules, 
including mAbs, antibody-cytokine fu sion proteins, bi spe cific antibodies and CAR T cells. 
We will review the use of agents designed in these molecular for mats for direct targeting 
of malignant cells and for the recruitment of immune effector cells to initiate in nate and/
or adaptive anticancer immunity. With the latter approach, remarkable pro gress has 
been achieved in the past few years, with new antibodies that target so-called immune 
checkpoint inducing previously unheard of long-term remissions in hard-to-treat can cers 
such as melanoma (Brahmer et al.2012, Topalian et al. 2012). Additionally, the use of 
CAR-transfected T cells for B-lineage Acute Lymphoblastic Leukaemia has resulted in 
unprecedented clinical responses in early clinical trials (Maude et al. 2014).
Monoclonal antibodies
Antibodies are composed of distinct functional domains (Figure 1A), with the variable 
(Fab) domains being responsible for high affinity binding to the target antigen. The 
constant Fc domain is res pon sible for binding to and interaction with components of the 
immune system. 
Figure 1: Antibody classification. Antibodies comprise a variable (Fab) domain that is responsible for 
antigen recognition and binding, and a (Fc) domain that interacts with components of the immune 
system. There are different classes of antibodies being: IgG,  IgD,  IgE, IgA  or IgM, which differ in 
abundancy, structure, and function. A) IgG and IgD contain the general heavy (H) chain constant 
domain defined as CH1-CH2-CH3. B) IgE contains an additional CH4 domain. C) IgA has the same 
H chain constant domain structure as IgG and IgD, but forms dimers, that are connected via the 
joining (J) chain. D) IgM has a similar amount of H chain constant domains as IgE, but appears in a 




































In a cancer patient, the therapeutic effects of mAbs can be achieved by several mech-
anisms, mainly Anti bo dy Dependent Cellular Cytotoxicity (ADCC) (Clynes et al. 1998), 
Antibody De pen dent Cellular Phagocytosis (ADCP) (Horton et al. 2008, Gül et al. 2014), 
and Com ple ment Dependent Cytotoxicity (CDC) (Introna et al. 2009). Furthermore, 
depending on the antigen, inhibition or activation of intracellular signalling mediated 
through the target antigen can be a major effector mechanism. The relative contribution 
of each of these eff ec tor mechanisms is difficult to dissect in patients and likely varies for 
different antibodies. Indeed, even different mAbs targeting the same target antigen can 
have distinct modes-of-action. Further, the contributions of these mechanisms is likely 
further influenced by patient characteristics such as in di vidual allelic variants of Fc re-
ceptors. Never the less, the relative contributions of these mechanisms can be separately 
stu died in vitro by laboratory experimentation.
The most frequently used constant Fc domain for therapeutic mAbs is derived from the 
IgG1 subclass of human Igs, although other immunoglobulin heavy chain subclasses also 
offer features of interest for mAb-based therapy. In brief, antibodies can be of the IgM, 
IgD, IgA, IgE or IgG class (Figure 1A-D), with the IgG class comprising four different iso-
types (IgG1, IgG2, IgG3 and IgG4). These isotypes differ in their amino acid sequences 
in the Fc domain and the hinge region, which leads to functional diff erences that can 
be exploited for the design of mAb-based therapy (reviewed in Jefferis et al. 2012). For 
instance, the IgG1 isotype can efficiently trigger ADCC and CDC, making it the isotype of 
choice for targeting malignant cells for destruction, e.g. by the CD20 antibody rituximab 
(Dall’Ozzo et al. 2004). In contrast, the IgG4 isotype has a strongly reduced capacity 
to induce ADCC and CDC. Therefore, the IgG4 Fc-domain is preferentially used for the 
de sign of immunomodulatory antibodies that block or activate receptors on immune ef-
fector cells to avoid elimination of these effector cells by ADCC/CDC (Wang et al. 2014). 
Prominent examples are PD-1 targeting antibodies, such as nivolumab, which block in-
hibitory signalling through PD-1 on the surface of tumor-re active T cells. 
Effector mechanisms and activity of tumor targeting antibodies 
Antibody Dependent Cellular Cytotoxicity 
Antibody Dependent Cellular Cytotoxicity (ADCC) is triggered when Fc-receptor- (FcR-) 
bearing eff ec tor cells recognise a target cell that has been opsonised by antibodies. The 
main effector cells me dia ting ADCC are NK cells, although other FcR-bearing cells such as 
monocytes/macrophages,  gra nu lo cytes and γδ T cells also contribute to ADCC-mediated 
elimination of target cells (Dall’Ozzo et al. 2004, Lefebvre et al. 2006, Hernandez et al. 
2003, Tokuyama et al. 2008, Capietto et al. 2011, Gogoi et al. 2013, Seidel et al. 2014). 
Briefly, binding of the Fc do main of a mAb, typically an IgG1, activates the effector cell 
to release cytokines such as IFN-γ and cytotoxic molecules such as perforin and gran-
zymes which lyse the target cell (Figure 2A) (Bowles et al. 2005).The IgG Fc domain 
triggers ADCC by binding to the activating re cep tors FcγRI, FcγRIIa, FcγRIIc, FcγRIIIa 
and FcγRIIIb (Bruhns et al. 2009). Conversely, binding to FcγRIIb creates an in hibitory 
sig nal (Clynes et al. 2000, Nimmerjahn et al. 2008). The binding pro file of individual IgG 
subclasses to these FcγRs differs and thus can impact the outcome of signalling and is 
an important consideration for the design of therapeutic mAbs.
Figure 2: Antibody  effector functions. A) Target cells that have been opsonised by antibodies can 
be killed via  Antibody Dependent Cellular Cytotoxicity (ADCC). During ADCC, the Fc domain of the 
antibody binds to activating Fc receptors (FcR) on FcR-positive immune cells like NK cells, monocytes, 
macrophages, and granulocytes. This antibody-FcR interaction triggers release of cytokines such as 
IFN-γ as well as cytotoxic molecules such as perforin and granzymes that lyse the targeted cell. Of 
note, clustering of mAb is required for complement activation and binding to low affinity FcR. B) 
During Antibody Dependent Cellular Phagocytosis (ADCP), the interaction between the Fc domain of 
the antibody and activating FcRs on phagocytes triggers engulfment of the opsonised cells, which 
eventually leads to degradation of the target cell. C) Complement Dependent Cytotoxicity (CDC) is 
triggered upon binding of complement factor C1q to antibody opsonised cells, followed by formation 
of the C1 complex that initiates the complement cascade. Briefly, cleavage of C4 and C2 results in for-
mation of the C4b-C2a complex that acts as C3-convertase. Binding of C3b to the C4b-C2a complex 
leads to formation of C5b, the initiator protein for the so-called membrane-attack complex (MAC). 
The MAC comprises C5b, C6, C7, C8 and C9, and forms a pore in the cell membrane that promotes 
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Antibody Dependent Cellular Phagocytosis 
Although most of the cellular cytotoxic activity induced by mAbs has been attributed to 
ADCC, An ti bo dy Dependent Cellular Phagocytosis (ADCP) is also an important mecha-
nism for the removal of can cer cells during mAb therapy. In brief, ADCP is initiated upon 
recognition of the Fc domain of an antibody opsonising a target cell by FcR-bearing 
effector cells, such as mo no cytes, macrophages and neutrophils (Braster et al. 2014). 
Subsequently, the op so nised cells or cellular fragments are taken up by phagocytes lead-
ing to their final degradation (Fi gure 2B). The importance of ADCP has been illustrated 
by studies in mouse models in which the re mo val of malignant B lymphoma cells by 
therapeutic CD20 mAbs depended on the presence of liver ma crophages (Oflazoglu et 
al. 2007). Further, depletion of macrophages, but not of NK cells (im por tant for ADCC), 
inhibited removal of lymphoma cells treated with a CD30 mAb. These experimental fin-
dings are consistent with the observation that a polymorphism in FcγRIIa, expressed on 
myeloid eff ec tor cells but not NK cells, was correlated with clinical responses to rituximab 
(Weng et al. 2003). Im portantly, although macrophages can also trigger ADCC, recent 
observations suggest that phago cy tosis of opsonised cancer cells and their fragments 
likely is a major effector mechanism of mAb treat ment contributed by macrophages. It is 
still unclear, however, whether macrophages first en gulf en tire cancer cells and only then 
fragment them intracellularly, or whether they first fragment them in the extracellular 
space and subsequently engulf fragments (Gül et al. 2014, Gül et al. 2015). Specifically, 
depletion of rituximab-treated leukemic B-lineage cells from the circulation in mice was 
mainly due to rapid uptake of op sonised cancer cells and their fragments by Kupffer 
cells, a liver-resident subset of macrophages (Montalvao et al. 2013). Kupffer cells also 
efficiently removed opsonised circulating tumor cells and prevented formation of liver 
me ta stases in a mouse melanoma model (Gül et al. 2014). Along the same line, treat-
ment with the CD38 antibody daratumumab triggered macrophage-mediated depletion 
of multiple myeloma (MM) cells in 11 of 12 samples of primary cells from MM patients 
and a similar depletion contributed to the in vivo therapeutic effect of this antibody to-
wards xenografted leukemic cells in mice (Overdijk et al. 2015).
The relative importance of neutrophils in ADCP in patients under mAb therapy is less 
clear, because the IgG1 Fc do main typically used in mAbs only poorly triggers neu-
trophil-mediated ADCP. In contrast, Fc do mains of the IgA isotype trigger very effec-
tive ADCP through their cognate Fc alpha receptor (Huls et al. 1999).  Furthermore, 
engineering of Fc domains can augment neutrophil-mediated phagocytosis. An exam-
ple hereof is the CD20 antibody obinutuzumab, a glycoengineered IgG1, which triggers 
more effective phagocytosis of opsonised cancer cells than rituximab (Golay et al. 2013).
Of note, induction of ADCP by therapeutic mAbs may also provide a crucial link to adap-
tive im mu ne responses. Specifically, uptake of cancer cells and their fragments by mac-
rophages and dendritic cells (DCs) can lead to the pre sentation of tumor-derived pep-
tides on MHC class II, thereby priming spe cific antitumor responses by CD4-positive 
helper T cells (Gül et al. 2014). Moreover, cross-pre sen tation of tumor-derived peptides 
on MHC class I can prime protective immunity by cytotoxic CD8 T cells.
Protective T cell responses developing under mAb therapy have been observed in a 
mouse model of xe no graf ted B-lineage leukaemia cells, where treatment with a CD20 
mAb triggered protective helper- and cytolytic T cell immunity (Abes et al. 2010). DCs 
are the major type of pro fes sio nal antigen presenting cells (APC) that are capable of 
priming immune responses by naive T cells (Banchereau et al. 1998, Amigorena 2002, 
Dhodapkar et al. 2008), although neutrophils may also provide MHC-I mediated cross-
pri ming of naive T cells with induction of specific CD8 T cell responses reported in a 
mouse model (Beauvillain et al. 2007). 
Complement Dependent Cytotoxicity 
Complement Dependent Cytotoxicity (CDC) in mAb-based therapy is initiated by binding 
of the com ple ment protein C1q to the Fc domain of mAbs opsonising a target cell (Intro-
na et al. 2009). Binding of C1q triggers the activation of the complement cascade and 
leads to the for ma tion of the membrane attack complex (MAC), which forms pores caus-
ing the lysis of target cells (Figure 2C). CDC is effectively triggered by the Fc-domains 
of IgM and IgG1 antibodies, but poorly by the IgG2 isotype and not at all by antibodies 
of the IgG4 isotype.
The exact contribution of CDC to therapeutic effects in patients under therapy with mAbs 
is unclear. For instance, depending on the mouse model the depletion of B cells by CD20 
mAbs can be both CDC-in dependent (Uchida et al. 2004) and CDC-dependent (Di Gaeta-
no et al. 2003). Nevertheless, the ability of mAbs to trigger CDC is relevant for therapy, as 
illustrated by the next-ge ne ration CD20 antibody ofatumumab, which generates greater 
CDC activity than rituximab (Teeling et al. 2004). Activation of CDC by rituximab can be 
augmented by selective targeting and down-modu lation of CD46, a mem brane-bound 
regulatory protein of complement activation that blocks CDC at the level of C3 (Zell et al. 
2007). Briefly, treatment with the small protein Ad35K++ selectively down-modulated 
surface-expressed CD46 and augmented CDC in vivo triggered by rituximab (Richter 
et al. 2016). Therefore, Ad35K++ acted as an adjuvant to enhance the CDC ac ti vity of 
rituximab, a potentially useful approach also for other therapeutic mAbs. This advantage 
may however be restricted to par ticular situations, such as the case described for ritux-
imab, as com plement activation is usually accompanied by pro-inflammatory responses 
that may yield detrimental off-target effects.
Signalling modulation
Binding of a therapeutic mAb to its target can also activate or inhibit signalling if the 
target antigen is a signalling receptor. A prominent example is rituximab, which binds to 
the extracellular loop of CD20, a tetraspanin protein with no known receptor or ligand 
(reviewed in Pescovitz et al. 2006). The physiological role of CD20 is poorly understood 
although it has been reported to among others act as a calcium channel (Koslowski et al. 
2008). Binding of rituximab to CD20 can directly trig ger apo ptosis in malignant B cells 
and is reportedly associated with a relocalisation of CD20 to membrane mi cro domains 
(Figure 3A) (Deans et al. 2002). This direct pro-apoptotic effect of ri tuxi mab may also 
occur in patients, because malignant B-lymphoid cells freshly isolated from ri tu xi mab-











anti bo dies targeting different epitopes than Rituximab that do not trigger re lo ca li sa tion 
of CD20 to rafts are more effective in triggering apoptotic cell death (Teeling et al. 2004).
A second prominent example is the targeting of the EGFR with cetuximab, a mAb block-
ing EGF binding to EGFR, whereby pro-survival mitogenic signalling through this recep-
tor is abrogated (Figure 3B) (Cunningham et al. 2004). In vitro, cetuximab treatment 
strongly inhibits growth of EGFR-bearing cancer cells (Prewett et al. 2002). In patients 
treated with cetuximab, the contribution of EGFR-blockade to the overall therapeutic 
effect relative to other effects, such as ADCC and ADCP, is still unclear. A third example 
are antibodies targeting agonistic TRAIL re cep tors, either TRAIL-R1 or TRAIL-R2, which 
induce apoptosis in many types of cancer cells after activation (Figure 3C) (reviewed in 
Ashkenazi et al. 2008). Binding of these mAbs to their target cross-links the receptor 
and ini tia tes the extrinsic pathway of apoptosis, which can be augmented through the Fc 
domain of the the ra peu tic protein. This effect is achieved through further cross-linking 
of the TRAIL-receptors on the target cell in trans mediated by Fc-receptors carried by 
effector cells.
Clinical experience
The initial intent of mAb-based cancer therapy was the direct targeting and elimination 
of malignant cells, and the drug approval of rituximab (anti-CD20) and trastuzumab 
(anti-HER2) delivered im por tant proof-of-concept (Maloney et al. 1997, Piccart-Gebhart 
et al. 2005). Combination of rituximab with established che mo the ra peu tic re gi mens such 
as CHOP (Cyclophosphamide, Hydroxydaunorubicin, Oncovin Prednisone) en han ced the 
cli ni cal efficacy in various malignancies, including follicular lymphoma (FL) (Oers et al. 
2006), chro nic lym phocytic leukaemia (CLL) (Hillmen et al. 2014), diffuse large B cell 
lym pho ma (DLBCL) (Coiffier et al. 2002), mantle cell lymphoma (MCL; (Kluin-Nelemans 
et al. 2012), and ag gres sive ma lig nan cies such as Burkitt’s lymphoma (Barnes et al. 
2011). Furthermore, maintenance therapy with ri tu xi mab was effective in the long-term 
control of FL (Oers et al. 2010) and CLL (Abrisqueta et al. 2013). Rituximab also binds 
to and depletes non-malignant B cells, but the toxicity of rituximab treat ment in cancer 
patients is tolerable, especially with regard to infectious com pli cations. In deed, the de-
pletion of non-malignant B cells mediated by rituximab has been successfully im ple men-
ted in the treatment of various B-cell-mediated diseases, including rheumatoid arthritis 
(RA) (re view ed in Liossis et al. 2008).
The success of rituximab inspired the development of more advanced antibody formats, 
such as the ful ly humanised CD20 antibodies ofatumumab and obinutuzumab, receiving 
FDA approval in 2009 and 2013 for the treatment of CLL and FL, respectively, and finally 
of fully human antibodies ge nerated by the immunization of mice transgenic for human 
immunoglobulin genes or by panning of libraries of fully human antibody fragments with 
the appropriate antigen. Ofatumumab has higher CDC activity than rituximab (Teeling 
et al. 2004) and is effective in FL and CLL patients previously trea ted with rituximab 
(Coiffier et al. 2008, Hagenbeek et al. 2008). Obinutuzumab was also de signed to in-
duce potent CDC and was superior to rituximab in patients with newly diagnosed CLL 
treated with Chlorambucil (Goede et al. 2014) and in patients with indolent non-Hodgkin 
lym pho ma (Sehn et al. 2016). Further, obinutuzumab triggered more effective neutro-
phil-mediated pha go cytosis through enhanced binding to FcγRIIIb (Golay et al. 2013).  
Beyond CD20 various other leukaemia-associated antigens, such as CD38, CD52 and 
SLAMF7, are being explored for direct mAb-ba sed the rapy. Recently, the an tibody dara-
tu mu mab, that targets CD38 on the surface of MM cells, was found to have potent an-
ti-MM activity as a single-agent in heavily pretreated MM patients (Lokhorst et al. 2015). 
Additional stu dies are ongo ing to evaluate its potential benefits in combination treat-
ments with cur rent ly avai la ble chemo the ra peu tic agents. The paradigm for beneficial 
combinatorial eff ects be tween anti bo dies and chemotherapeutic agents is the treatment 
of B-CLL in younger pa tients with flu darabine and cyclo phos pha mide combined with rit-
uximab (Weiner et al. 2010, Beck et al. 2010, Scott et al. 2012).
mAb-based therapy of solid tumors began in 1998 with the approval of trastuzumab for 
the treatment of breast cancer that overexpresses the HER2 surface antigen. Trastu-
zumab was used after adjuvant chemotherapy for one year, which improved disease-free 
survival but produced no be nefit in overall survival (Piccart-Gebhart et al. 2005). Unfor-
tunately, a significant proportion of patients treated with trastuzumab did not respond to 
Figure 3: Antibody-mediated modulation of target antigen signalling. A) Binding of rituximab to 
CD20 can directly trigger apoptotic elimination of malignant B cells. B) Antibodies can be used to in-
hibit tumourigenic signalling as provided by for instance epithelial growth factor (EGF).  By binding to 
the EGF receptor (EGFR), cetuximab blocks the interaction between EGF and EGFR, thereby inducing 
growth arrest. C) Agonistic antibodies targeting the tumor necrosis factor-related apoptosis-inducing 
ligand (TRAIL) receptor (TRAILR) induce cross-linking of agonistic TRAILRs which triggers the induc-






































the treatment. Further, trastuzumab was associa ted with cardiotoxicity in up to 0.5 per-
cent of treated women, especially when combined with an thra cy cli nes (Piccart-Gebhart 
et al. 2005). Another antibody widely used in the treatment of solid tumors is ce tuximab, 
a chimeric antibody targeting the epidermal growth factor receptor EGFR (Jonker et al. 
2007). Ce tu xi mab received FDA approval in 2004 for patients with advanced colorectal 
cancer (Jonker et al. 2007). Since its initial approval, cetuximab has been included in 
the treatment of triple negative breast cancers (Carey et al. 2012) and in chemo-radio-
therapy regimens for head and neck cancers (Bonner et al. 2006). In colorectal cancers, 
cetuximab is mostly effective in patients with out mutations in K- or N-RAS (Karapetis et 
al. 2008).  In addition to cetuximab, the ful ly human EGFR antibody panitumumab was 
recently approved by the FDA for the same indications. Panitumumab and cetuximab ap-
pear to have a similar activity profile in patients, but panitumumab has a more favorable 
toxicity profile (Price et al. 2014).
Immunomodulatory antibodies
In recent years, major progress in mAb-based therapy has been made through the use of 
immu no mo dulatory mAbs, most notably those targeting immune checkpoints. Immune 
checkpoints are re cep tor/ligand pairs that transmit inhibitory signalling to effector cells 
and antibodies that block these check points (checkpoint inhibitors) can (re)activate tu-
mor-specific T cell immu nity (Figure 4A). Of note, such antibodies typi cal ly contain IgG4 
Fc domains with low binding affinity for Fc-re cep tors on myeloid effectors and NK cells, 
designed to prevent elimination of the T cells by other effector cells through ADCC or 
CDC. Reversely, immunomodulatory antibodies can be targeted to activate co-stimulato-
ry members of the TNF-receptor (TNFR) superfamily (Figure 4B). This TNFR superfamily 
provides im portant co-sti mu la to ry signals required for the induction of adaptive immu-
nity at all stages of the immune responses and targeted activation of these signals can 
augment anti-tumor activity.
Checkpoint blocking mAbs
The first immune checkpoint targeted antibody to enter clinical practice was directed 
against the protein CTLA4. CTLA4 is an in hi bi to ry receptor expressed on activated T 
cells that inhibits T cell co-stimulation by competing with CD28 for CD80/86 interaction 
on APCs (Krummel et al. 1995). CTLA4 has a higher affinity than CD28 and thus com-
petitively inhibits CD28-mediated co-stimulatory signalling (Linsley et al. 1994). The 
CTLA4-blocking antibody ipilimumab was the first checkpoint inhibitor to be approved by 
the FDA (in 2011) for the treatment of melanoma. Ipilimumab triggered strong durable 
responses in patients with previously treated metastatic melanoma, with 1 and 2 year 
survival rates of 46% and 24% respectively (Hodi et al. 2010). Similarly, combination of 
ipilimumab with paclitaxel and carboplatin improved progression free survival in chemo-
therapy-naïve NSCLC patients (Lynch et al. 2012). 
A second prominent example of immune checkpoints is PD-1, an inhi bi to ry receptor 
expressed on T cells, which inhibits T cell activity after binding to its ligand PD-L1 on 
the surface of a cancer cell or on antigen presenting cells (APCs) (Freeman et al. 2000). 
Antibodies blocking this inhibitory interaction restored the antitumor activity of T cells in 
murine models (Figure 4A) (Wang et al. 2014). Under homeostatic physiological con di-
tions the PD-1/PD-L1 receptor/ligand pair en sures a timely shut-down of T cell responses 
(reviewed in Keir et al. 2008). During in flam ma tion, ex pres sion of PD-L1 is induced on 
APCs, such as DCs, and on myeloid sup pres sor cells by locally produced IFN-γ (Freeman 
et al. 2000, Loke et al. 2003, Kuang et al. 2009). At the same time, activated T cells 
upregulate PD-1 (Nishimura et al. 1999), whereby T cell activity is inhibited via PD-1/
PD-L1 interactions (Freeman et al. 2000). 
Many types of cancer cells (over)express PD-L1 either constitutively, through oncogen-
ic signalling path ways, or in response to tumor micro-environmental IFN-γ (Taube et 
al. 2012, Dong et al. 2002). Due to the PD1/PD-L1 interaction, infiltrating T cells are 
silenced in the tumor micro-environment, which al lows the escape and growth even of 
immunogenic cancers such as melanoma (Ahmadzadeh et al. 2009, Taube et al. 2012). 
Figure 4: Immunomodulatory antibodies. A) The PD-1/PDL-1 checkpoint interaction counteracts 
activation of T cells and this inhibitory pathway is overactivated in PDL-1 overexpressing tumors. 
Therefore, PD-1/PDL-1 blocking antibodies reactivate T cells, inducing cancer cell lysis. B) Members 
of the tumor necrosis factor receptor (TNFR) superfamily provide important co-stimulatory signals 
required for the induction of antitumor immunity. In the absence of co-stimulation, T cell activation is 







































Consequently, elevated expression of PD-L1 correlated with poor prognosis (Thompson 
et al. 2004, Massi et al. 2014). Both PD-1 and PD-L1 blocking antibodies can restore the 
ability of functionally impaired T cells to eliminate cancer cells (Figure 4A). Treatment 
with the PD-1 blocking antibody nivolumab achieved unprecedented objective response 
rates of >30% (Larkin et al. 2015). A PD-L1 blocking antibody produced objective re-
sponses in up to 17% of patients with advanced stage cutaneous melanoma (Brahmer et 
al. 2012), although long term remissions were obtained only for a minority of patients. 
Response rates in other ma lig nan cies, especially in haematological malignancies, were 
sub-optimal, although new results point to a pro mi sing activity in patients with Hodgkin’s 
lymphoma refractory to the antibody-drug conjugate brentuximab vedotin (Ansell et al. 
2015, Armand et al. 2016, Westin et al. 2014). 
Importantly, treatment of melanoma patients with a combination of the PD-1-blocking 
antibody nivolumab and ipilimumab significantly enhanced response rates (Larkin et al. 
2015). Therefore, the use of com bi nation therapies may significantly improve the impact 
of checkpoint inhibition as a treatment mo da li ty for selected pa tients. The increased 
response rates however were also accompanied by a sharp in crease in systemic tox-
icity, and therefore, combination therapies with several different checkpoint inhibiting 
antibodies may present benefits only for restricted subgroups of patients. Various other 
checkpoints have been identified, including TIM-3, TIGIT, LAG3, and CD28, and are 
currently ex plo red as po ten ti al targets for mAb-based therapy. These may also help to 
expand the impact and scope of (com bi na to ri al) checkpoint inhibition.
Immunostimulatory mAbs that target the TNFR superfamily
The TNFR superfamily provides crucial co-stimulatory signals in a spatiotemporally reg-
ulated manner that drives development of effective immune responses (Croft 2009, 
Sanmamed et al. 2015). These co-stimulatory receptors are either constitutively ex-
pressed, such as CD27, or expression is induced upon antigen recognition as is the case 
for 4-1BB, GITR, OX40. Most of these receptors are being evaluated as targets for cancer 
immunotherapy, with a few prominent examples being highlighted below.
A prominent immunotherapeutic TNFR target on T cells is 4-1BB. T cells re s pon ding to 
their cognate antigen rapidly and transiently upregulate 4-1BB on their cell surface. In-
teraction of T cell expressed 4-1BB with 4-1BBL on activated APCs induces proliferation, 
cytokine production as well as up-regulation of survival genes and inhibition of activa-
tion-induced cell death in T cells (DeBenedette et al. 1997, Arch et al. 1998, Starck et al. 
2005). Thus, 4-1BB activation enables T cell expansion and persistence. Of note, 4-1BB 
signalling triggers a stronger proliferative response in CD8 cytotoxic T cells than in CD4 
T-helper cells, particularly in vivo (Shuford et al. 1997). 4-1BB is therefore considered 
to be a bona fide CD8 T cell activating molecule (Takahashi et al. 1999), with 4-1BB ex-
pression specifically detected on tumor infiltrating T cells (Ju et al. 2005). Furthermore, 
T cells responding to cognate antigen upregulate 4-1BB, yielding co-stimulatory signal-
ling for antigen-specific CD8 T cell responses (Choi et al. 2014). All these characteristics 
make 4-1BB an interesting target for cancer immunotherapy. Indeed, already over a 
decade ago treatment of mice with a soluble 4-1BB agonist was found to induce tumor 
regression of established and poorly immunogenic sarcoma (Melero et al. 1997). To date, 
a large body of preclinical data supports the use of 4-1BB agonists for cancer immuno-
therapy, both as single agents and in combination with e.g. vaccine-based strategies 
(Sharma et al. 2010). Agonistic anti bo dies that target 4-1BB re-ac ti va te and restore T 
cell mediated antitumor immunity in various animal stu dies  (Melero et al. 1997, Kim 
et al. 2001) (Figure 4B). However, ubiquitously active ago nis tic antibodies that trigger 
co-stimulatory TNFR signalling frequently associate with dose-limiting toxicities. For ex-
ample, treatment of patients with the 4-1BB antibody urelumab produced severe and 
fatal liver toxi city at the highest dose tested, leading to termination of a phase II clinical 
trial (reviewed in Bartkowiak et al. 2015). Nevertheless, a subsequent dose-escalation 
study with a 4-1BB antibody has been performed (NCT01471210) and 4-1BB mAbs are 
currently evaluated in clinical trials focused on combination stra te gies, e.g. combina-
tions with PD-1 antibodies (NCT02179918) or with agonistic antibodies that target the 
co-stimulatory TNFR OX40 (NCT02315066).
A second TNFR target is OX40. OX40 is transiently upregulated on antigen stimulated 
CD4 and CD8 T cells, and its ligand OX40L is transiently expressed on activated APCs 
(reviewed in Croft et al. 2009). OX40 signaling is involved in T cell survival and the gen-
eration and reactivation of memory T cells (Rogers et al. 2001, Gramaglia et al. 2000). 
Combination of OX40 agonists and antibodies targeting PD-1 or CTLA4 induced potent 
antitumor immunity in preclinical models (Redmond et al. 2014, Guo et al. 2014).
A third TNFR being targeted with agonistic mAbs is GITR. GITR is highly expressed on 
regulatory T cells, and while low levels are present on naïve and memory T cells, GITR 
expression is rapidly upregulated upon activation (Gurney et al. 1999, Zhan et al. 2004). 
Its ligand, GITRL is predominantly expressed on activated APCs (Tone et al. 2003). GITR 
agonists have promising antitumor activity in vivo by expanding effector T cells, while 
simultaneously inhibiting regulatory T cells (Kim et al. 2015a; Coe et al. 2010). Similarly, 
single agent dose-escalation studies of GITR as well as combinations with PD-1 anti-
bodies are currently ongoing in solid malignancies including melanoma (NCT01239134) 
(reviewed in Knee et al. 2016).
The final TNFR target discussed here is CD40, which is expressed on APCs and interacts 
with CD40L on CD4 T-helper cells. This interaction is crucial for induction of adaptive 
immune responses as the absence of CD40 signalling can induce anergy or lead to for-
mation of regulatory T cells (reviewed in Melief et al. 2008). Agonistic CD40 antibodies 
strongly induced DC maturation and antitumor activity in preclinical models (reviewed 
in (Khong et al. 2012) and although dose-limiting toxicities have been observed, CD40 
agonists can be effective at tolerable doses (Johnson et al. 2015b, Vonderheide et al. 
2007). Clinical trials evaluating CD40 agonists alone (NCT02482168, NCT02376699) or 
in combination with CTLA4 antibody (NCT01103635) are currently ongoing.
As outlined above, various therapeutic regimens that combine checkpoint targeting an-
tagonistic an ti bo dies with agonistic TNFR antibodies are currently being explored. This 
strategy is appealing as it may boost antitumor immunity by complementing blockade 
of inhibitory signalling with simultaneous co-stimulation. However, since both TNFR ag-











toxicities, combinatorial strategies need to be carefully designed to avoid greatly in-
creased toxicities.
Of note, the therapeutic effect of checkpoint blocking antibodies and TNFR agonists may 
also partly be independent of signalling modulation. For example, the efficacy of ipilim-
umab is co-defined by Fc-dependent depletion of regulatory T cells by macrophages in 
the tumor microenvironment (Simpson et al. 2013). Similar modes of action may con-
tribute to TNFR agonists efficacy as TNFRs CD27, GITR, OX40 and 4-1BB are expressed 
on regulatory T cells (Sanmamed et al. 2015). Therefore, optimal design of therapeutic 




Recombinant DNA technology has enabled scientists to design many different antibody 
formats based on conventional mAbs (Figure 1A), including bispecific antibodies, dia-, 
tri- and tetra-bodies, triplebodies, minibodies, nanobodies, Fabs, F(ab’)2 and scFv-frag-
ments (reviewed in Spiess et al. 2015 & Carter et al. 2006), some of which will be dis-
cussed below. Of particular relevance to the field is the so-called single chain fragment of 
variable regions (scFv) antibody fragment (Glockshuber et al. 1990). In brief, an scFv is 
a single polypeptide comprising the VH and VL regions of an antibody connected through 
a flexible linker (Figure 5A). The scFv antibody fragment has been used as a ‘building 
block’ in many different antibody-based drug formats discussed later in this chapter, in-
cluding bispecific antibodies, immunocytokines and CAR T cells. An additional engineered 
antibody domain of interest is the so-called antigen-binding Fc fragment (Fcab), in which 
the C-terminal loops of the IgG1 Fc domains have been engineered to bind antigens 
(Figure 5B) (Wozniak-Knopp et al. 2010). An Fcab thus comprises only the Fc domain 
and is smaller in size, more stable, and can be used as a building block for engineering 
of bispecific antibodies. Differently engineered Fcabs can have increased or reduced af-
finity for Fc receptors, which can be used to optimise specific effector functions (Kainer 
et al. 2012). Nanobodies, the smallest naturally-occurring antigen-binding domains, are 
derived from ‘heavy-chain-only antibodies’ expressed by camelids and sharks (reviewed 
in Muyldermans 2013). Nanobodies consist of heavy chain subunits only and are almost 
10-times smaller than regular mAbs (mass of ~15 kDa vs. 150 kDa, respectively) (Figure 
5C). Nanobodies are stable and have good solubility and are interesting building blocks 
for the design of bi/tri or multi-specific antibody-based drugs (reviewed in Steeland et 
al. 2016). 
Bispecific antibodies
Bispecific antibodies (bsAbs) combine the binding specificities of two antibodies (Figure 
5D) and can be designed to retarget immune effector cells to cancer cells to trigger 
target cell elimination. Further, bsAbs can be used for dual targeting of cancer cells, 
whereby e.g. signalling by two growth factors can be simultaneously blocked (reviewed 
in Kontermann et al. 2015, Spiess et al. 2015). Approximately 30 different bsAbs and 
bispecific fusion proteins of mAb-fragments are cur rently in clinical evaluation. In the 
following section, we will review recent advances in both im mune retargeting and tumor 
targeting bsAbs and bispecific fusions of mAb-fragments, and highlight some of the suc-
cesses and challenges. 
Figure 5: Alternative antibody formats. A) A single chain fragment of variable regions (scFv) anti-
body fragment is a single polypeptide, comprising the VH and VL regions of an antibody connected 
through a flexible linker. B) Antigen-binding Fc fragments or Fcabs, are engineered antibodies in 
which the C-terminal loops of the IgG1 Fc domain have been modified to bind antigens. C) Nanobod-
ies are the smallest naturally-occurring antigen-binding fragments normally expressed by camelids. 
Nanobodies solely comprise heavy chain subunits and are almost a factor 10 smaller than regular 
mAbs (size of ~15kDa vs. 150kDa, respectively). D) A bispecific antibody is constructed by merging 
two different antibodies together. It contains two heavy and two light chains, one each from two dif-
ferent antibodies, and thereby has specificity for two antigens. E) Fcab antibodies can be constructed 
in a bispecific format, containing an engineered terminal CH3 loop to induce the ability to bind anti-
gens. F) A Bispecific T cell Engager (BiTE) contains an scFv antibody fragment specific for CD3 and 
a second scFv recognising a tumor antigen connected by a flexible peptide linker. These scFvs allow 
the antibody to induce T cell activation via CD3-mediate cross-linking and specifically recruit  the 
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Although initial studies with bispecific antibodies were hampered by issues with he-
terogeneity of antibody formulations, the use of quadroma technology permitted the 
production, pu rification and clinical development of hybrid (rat-mouse) bsAbs (Lindhofer 
et al. 1995). The first cli nically approved bsAb, catumaxomab (Seimetz et al. 2010), was 
such a chimeric rat-mouse antibody comprising a murine antibody domain (one H- and 
one L-chain) specific for CD3 and a rat an ti body domain spe cific for EpCAM. The mouse 
IgG2a and rat IgG2b H-chains carried in the hetero-dimer can bind to the activating hu-
man Fcγ receptors FcγRI, FcγRIIA and FcγRIII. Thus, catumaxomab re-tar gets CD3-pos-
itive T cells to EpCAM whereupon an immunological synapse is formed. Cross-linking 
of CD3 activates the T cell and directs its full cytolytic potential towards the target cell, 
including the release of perforin and granzymes, FasL and the release of cytokines such 
as IFN-γ, leading to eli mi na tion of the target cell. In addition, catumaxomab recruits 
FcγR-bearing effector cells including NK cells and macrophages that induce ADCC and 
ADCP. This multi-component mode-of-action was very effective in pre-clinical and clinical 
studies, and led to drug approval of catumaxomab in the EU for the treat ment of ma lig-
nant ascites in patients with EpCAM-positive carcinomas in 2009 (Seimetz et al. 2010). 
However, the chimeric rat-mouse Fc-domain triggered the pro duc tion of neutralising hu-
man anti-mouse (HAMA) and human anti-rat antibodies (HARA) in most patients, which 
li mi ted its clinical usefulness, although HAMA/HARA responses were reported not to be 
associated with safety concerns or reduced cli nical activity (Ruf et al. 2010). Production 
of HAMAs after treatment with catu ma xo mab was positively correlated with clinical out-
come in patients with ma lignant ascites, likely re flec ting an active immune response (Ott 
et al. 2012). A second bsAb of this format, FBTA05 or Lympho mun, was recently eval-
uated in a clinical trial with patients suffering from refractory B cell malig nan cies. Nine 
of ten patients showed a clinical response, including 5 complete remissions (Schuster 
et al. 2015). Finally, a third bsAb of the same format, ertumaxomab, selectively targets 
the breast carcinoma antigen HER2 and produced antitumor re spon ses in a clinical trial 
in 5 out of 15 evalu able patients with manageable toxicity (Kiewe et al. 2006). However, 
clinical development of ertumaxomab was halted due to non-scientific reasons.
Additional and newer bispecific molecular formats of antibody-derived agents have been 
developed and some have proven to be successful in clinical trials. Front-runner in this 
field is the so-called Bispecific T cell Engager (BiTE) format. A BiTE comprises an scFv 
antibody fragment recognising CD3 and a second scFv frag ment recognising a tumor 
antigen, connected through a flexible peptide linker which allows the scFv domains to 
rotate and bind their targets (reviewed in Huehls et al. 2015) (Figure 5F). BiTEs do not 
contain Fc domains and therefore selectively recruit CD3+ T cells to the an ti gen-bearing 
cell, where an immunological synapse is formed and the target cell is killed. The re tar ge-
ted T cells, still decorated by the BiTE protein, can move on to a next target and perform 
serial lysis of up to a dozen target cells (Hoffman et al. 2005). The BiTE-induced synapse 
resembles a stan dard immunological synapse generated through MHC/TCR interaction 
(Offner et al. 2006). Further, the antitumor activity of a BiTE crucially depends on the 
cell-to-cell distance re sul ting from binding of the CD3- and tumor-specific scFvs. In this 
respect, the melanoma antigen MCSP proved to be too bulky to permit the formation of 
a sufficiently tight and pro duc tive synapse between the melanoma-target and effector 
cells (Bluemel et al. 2010). This spatial re quirement for the formation of a functional 
synapse likely holds true for other molecular formats of bispecific agents. Thus, antigen 
size and the position of the epitope within the antigenic sur face protein are important 
considerations for the design of T cell retargeting agents. 
Various other BiTEs have been evaluated in pre-clinical and some in clinical studies, 
including a CD33-di rected BiTE called AMG 330, de signed to target Acute Myeloid Leu-
kaemia (AML) (Mills et al. 2015), an MCSP-directed BiTE to target melanoma (Bluemel et 
al. 2010), EpCAM- and CEA-specific BiTEs to target carcinoma (Schlereth et al. 2005), a 
PSMA-directed BiTE to target prostate cancer (Friedrich et al. 2012) and a CD19-specific 
BiTE to target B-lineage leukaemia and lymphoma (Sheridan et al. 2015). The lat ter 
BiTE, termed blinatumomab, retargets T cells to CD19-bearing tumor cells and accom-
plished a 43% complete remission rate in a phase II clinical trial in patients with B-li ne-
age Acute Lymphoblastic Leukaemia (B-ALL) (Topp et al. 2015, Zugmaier et al. 2015). 
Grade 3 and 4 ad verse effects occurred in a subset of patients, including neurotoxicity 
and cytokine-release syn drome (Topp et al. 2015). Nevertheless, overall results were 
sufficiently positive to lead to fast-track ap proval of blinatumomab by the US FDA for 
second-line treatment of relapsed or refractory B-ALL in 2014, which has since been 
converted into a definitive approval. Blinatumomab is further being evaluated for the 
treatment of Non-Hodgkin Lymphoma (NHL) and Diffuse Large B cell lymphoma (DLB-
CL) (Zugmaier et al. 2015). Of note, the small size of BiTEs results in im proved tumor 
penetration, but also in a short serum half-life of less than 2 hrs, as determined for bli -
na tu momab (Zugmaier et al. 2015). For comparison, the Fc-containing bsAb catumax-
omab has a serum half-life of 2.5 days (Seimetz et al. 2010), and IgGs have half-lives of 
approx. 20 days in healthy human individuals. 
Efforts to improve on the BiTE format have been made by using so-called “Dual Affinity 
Retargeting T cell” engaging agents (DARTs). DARTs consist of 2 covalently linked VH/
VL po ly peptide chains, which upon heterodimerization form the two antigen binding 
do mains. Compared to BiTEs, DARTs have a more flexible configuration and contain an 
additional inter-chain disulfide bond to increase stability (Moore et al. 2011). In a side-
by-side evaluation of blinatumomab with a DART carrying the corresponding scFvs, the 
DART agent had a higher affinity. Further, the DART mediated a strongly im pro ved cy-
tolytic activity of T cells against B-lineage leukaemia target cells, with an approximately 
60-fold reduction in EC50 using freshly isolated peripheral blood mononuclear cells as 
the source of eff ec tors (Moore et al. 2011). Many DARTs have been generated and some 
are currently in preclinical and early clinical evaluation, including a DART targeting the 
AML marker CD123 (Al-Hussaini et al. 2016, Chichili et al. 2015) and a DART targeting 
the colorectal carcinoma marker gpA33 (NCT 02248805).
Other interesting molecular formats of bispecific agents include the so-called Duobody 
format (Labrijn et al. 2014), the Crossmab format (Klein et al. 2016),  the DVD-IgG for-
mat (Gu et al. 2012), and the single-chain triplebody format (Kugler et al. 2010, Braciak 











recently by Kontermann & Brinkmann and Spiess, Zhai & Carter. A duobody exploits 
single amino acid mutations in the IgG1 do main to trigger controlled Fab arm exchange 
to yield a homogeneous IgG1 bsAb preparation (Labrijn et al. 2014). An agent of this 
duobody class has recently advanced into clinical evaluation (NCT02758392). 
In a triplebody, three scFv domains are genetically fused in tandem, with the central 
domain being either a CD3-specific scFv to recruit T cells or a CD16-directed scFv to re-
cruit NK- and γδ T cells as effectors. This triplebody format enables dual-targeting of two 
tumor associated target antigens on the same cancer cell, to which T cells or NK cells can 
be preferentially directed. Proof-of-concept for this approach was recently reported for a 
CD19-CD3-CD33 triplebody, which induced preferential elimination of CD19/CD33 dou-
ble-positive biphenotypic B/myeloid leukaemia cells over CD19 or CD33 single-positive 
cells (Roskopf et al. 2016). Further, the triplebody 19-16-19, carrying two scFv binding 
sites for CD19 and one for CD16, was recently reported to recruit γδ T cells as potent 
cytolytic effectors to malignant B-lineage target cells in vitro (Schiller et al. 2016).
Other effector cells, most notably NK cells, are also evaluated in the context of tumor 
retargeting. NK cells are very potent cytotoxic lymphocytes cri ti cally involved in tu-
mor immunosurveillance and have among others been retargeted to CD133, a pro posed 
cancer stem cell marker, using the so-called Bispecific Killer Engager (BiKE) approach 
(Schmohl et al. 2016). A BiKE has a similar tandem diabody format as BiTEs, but instead 
of a CD3-di rec ted scFv contains a CD16-specific scFv to recruit and activate NK cells. 
The CD133 BiKE eff ec ti ve ly triggered NK cell mediated lysis of target cells in vitro and in 
vivo. Similarly, an EpCAM BiKE strongly potentiated NK cytotoxicity towards EpCAM-ex-
pressing cells in vitro (Vallera et al. 2013). An additional NK cell retargeting therapeutic, 
designated AFM 13, is a tetravalent construct with two scFv binding domains each for 
CD30 and CD16 (Rothe et al. 2015). 
As al rea dy mentioned above, the triplebody format can also be used to retarget NK cells 
and γδ T cells, by in cor po rating a CD16-specific scFv. Using a CD19-CD16-HLA-DR triple-
body, NK cells were suc cess ful ly redirected in vitro to trigger a preferential elimination 
of CD19/HLA-DR double-positive cancer cells over single-positive leukemic cells present 
in the same reaction environment (Schubert et al. 2012). This triplebody format can 
thus be used to enhance tumor-selectivity, by selection of target antigen combinations 
that are unique to a certain malignancy, such as CD33- and CD123-double-positive AML. 
Using this approach, off-target toxicity towards normal single antigen-positive cells is ex-
pected to be reduced. In addition, retargeting of other effector cell populations such as 
monocytes and T cells are being evaluated, although EGFR-retargeting of FcγRI-positive 
effector cells failed to yield clinical benefit in a phase I trial (Fury et al. 2008).
A final bispecific format of interest to mention is based on the Fcab format (Figure 5E) 
(re viewed in Lobner et al. 2016). For instance, fusion of an Fcab with specificity for HER2 
with an scFv specific for CD3 resulted in the bispecific Fcab fusion FcabCD3 (Wang et al. 
2013). This agent induced specific T cell-mediated tumor cell lysis in vitro, which was 
more potent than treatment with either trastuzumab or the parental Fcab alone. Also in 
animal studies, FcabCD3 reduced tumor growth.
Of note, it was recently found that immune-inhibitory mechanisms in the tumor mi-
cro-environment can inhibit the therapeutic activity of T cell retargeting by bispecific 
agents. For instance, in a blinatumomab resistant patient with B cell acute lymphoblastic 
leukaemia (B-ALL), the percentage of PD-L1 expressing B-ALL blasts was strongly in-
creased (Kohnke et al. 2015). This increase in PD-L1 expression also strongly reduced 
the efficacy of bli na tu momab-mediated lysis of target cells ex vivo. In line with this, 
treatment of primary AML cells with the CD33-directed BiTE AMG 330 ex vivo triggered 
strong up-regulation of PD-L1 on the AML blasts (Krupka et al. 2016). Combination treat-
ment with this BiTE and a PD-L1 check point inhibiting antibody induced synergistic tumor 
cell lysis in vitro. Similar results were obtained for a CEA-specific BiTE (Osada et al. 
2015). In line with these findings, in vivo activity of a full-length HER2/CD3 bsAb was li-
mi ted by expression of PD-L1, an effect abrogated by treatment with a PD-L1 mAb (Junt-
tila et al. 2014). Along the same line, the activity of CD20- and EGFR-targeted bsAbs 
was optimised by inhibition of CTLA4 using ipilimumab (Yano et al. 2014). Similarly, 
combination treatment with a BiTE-agent and a co-stimulatory antibody targeting CD28 
or 4-1BB also augmented T cell-me di ated tumor cell lysis (Laszlo et al. 2015, Aliperta 
et al. 2015). Using an EpCAM-directed BiTE, additional inhibitory mechanisms including 
IDO expression on the target cells and secretion of TGF-β were identified (Deisting et 
al. 2015). Since signalling through co-in hi bi tory and co-stimulatory pathways may affect 
the therapeutic efficacy of antibody-de ri ved agents relying on immune effector cells for 
their therapeutic activity, this issue is an important consideration in the design of com-
binatorial treatment strategies.
Direct tumor targeting with bsAbs
In addition to redirecting immune effector cells, a variety of bsAbs inhibit growth fac-
tor receptor signalling via dual targeting of cancerous cells. For instance, based on the 
finding that HER3 signalling represents an important resistance mechanism for HER2 in-
hibitors, bispecific agent MM-111 comprising HER2 and HER3 targeted scFvs and human 
serum albumin was generated (McDonagh et al. 2012). MM-111 was found to overcome 
HER2 resistance and block HER3 signalling through formation of an inactive MM-111/
HER2/HER3 complex. MM-111 synergised with HER2 inhibitor trastuzumab in several 
xenograft models and has been evaluated in early phase clinical trials (NCT01304784/ 
NCT01774851). However, disappointing preliminary results of a phase II study in gastric 
cancer, possibly due to low HER2 expression, prompted abandonment of MM-111 for this 
indication.
Targeting of HER2 has also been explored using MM-141, comprising scFvs targeting 
HER3 and insulin-like growth factor I receptor (IGFR-IR) fused to an IgG1 constant 
domain, with superior activity compared to control single or combination antibody ther-
apy in preclinical studies (Fitzgerald et al. 2014). Recent preliminary reports on clinical 
activity in patients with advanced solid cancer were suggestive of clinical activity, with 
patients having the potential eligibility biomarker of elevated serum IGF-I remaining on 
treatment longer. Further, IGF-IR and HER3 expression levels decreased upon treatment 
with MM-141 (Isakoff et al. 2015). A more clinically advanced HER3 targeting bispecific 











DAF is created by mutagenesis of a Fab of a monospecific antibody into a dual recogni-
tion antibody, in the case of duligotuzumab for EGFR and HER3 (Eigenbrot et al. 2013, 
Schaefer et al. 2011). Duligotuzumab overcomes acquired resistance to EGFR and radi-
ation in preclinical models (Huang et al. 2013) and had comparable antitumor activity 
to cetuximab in patients with head and neck cancer, although the risk of adverse effects 
was slightly increased (Fayette et al. 2014). Clinical trials in epithelial cancers and head 
and neck cancer are ongoing (NCT01911598/ NCT01207323).
Several other formats for direct tumor-targeted bispecific agents are in clinical devel-
opment including the so-called DVD-Ig format, in which the variable domains of two 
monoclonal antibodies are genetically fused, yielding a tetravalent bispecific antibody 
(Gu et al. 2012). For instance, simultaneous binding of a DVD-Ig that selectively targets 
CD20 and HLA-DR on B cell leukaemic cells potently induced both ADCC and CDC (Zeng 
et al. 2015).
Bispecifics can also be designed to overcome two immune-inhibitory mechanisms asso-
ciated with mAb-based therapy. An example hereof is a bispecific tetravalent antibody 
that blocks CD47 by selective delivery to B cell expressed CD20 (Piccione et al. 2015). 
CD47 is an important don’t eat me signal on tumor cells that inhibits phagocytic removal, 
hence CD47 blocking mAbs can enhance phagocytic removal of cancer cells and syner-
gise with other antibodies like rituximab (Chao et al. 2010). The CD20/CD47 bispecific 
antibody had an increased selectivity for CD20/CD47 double-positive cancer cells and 
augmented their phagocytic removal in vivo (Piccione et al. 2015).
Finally, we recently reported application of the bispecific format to enhance the tumor-se-
lective activity of TRAIL-receptor 2 antibody-based therapy, using a tetravalent bispecific 
agent comprised of an scFv targeting MCSP and an scFv derived from TRAIL-R2 agonist 
tigatuzumab (He et al. 2016, Chapter 3 this thesis). TRAIL-R2 mAbs such as tigatuzumab 
are well tolerated in patients (reviewed in (Fox et al. 2010), but have minimal clinical 
benefit. This lack of activity may be due to the widespread expression of TRAIL-R2, limit-
ing tumor accretion, and the fact that TRAIL-R2 mAbs require additional cross-linking by 
Fc-receptor positive cells for effective induction of apoptosis. In this respect, a tetrava-
lent nanobody (TAS266) did not require such secondary cross-linking for induction (Huet 
et al. 2014), but this nanobody yielded unexpected hepatotoxicity in a phase I clinical 
trial in patients with solid malignancies leading to termination of the trial (Papadopoulos 
et al. 2015). Thus, ubiquitous maximal cross-linking and signalling by TRAIL-R2 may 
associate with unwanted toxicity. In contrast, MCSPxDR5 had high binding specificity 
for MCSP-positive melanoma cells and potently triggered apoptosis only in MCSP-pos-
itive cancer cells, including primary patient-derived melanoma cells (He et al. 2016). 
Similarly, a FAP-targeted TRAIL-R2 bispecific agent, RG7386, was reported to have po-
tent antitumor activity superior to conventional non-targeted TRAIL-R2 mAb. Apoptotic 
activity of RG7386 strictly depended on binding to FAP and did not require additional 
FcR-mediated cross-linking (Brunker et al. 2016). This increase in tumor-selectivity as 
well as the increased target antigen-restricted agonist activity is anticipated to augment 
the therapeutic potential of TRAIL receptor agonist antibody-based approaches.
Antibody-cytokine fusion proteins 
Cytokines are major regulators of the immune system and were among the first success 
stories in cancer immunotherapy. Specifically, two of the most researched cytokines, 
interferon-α (IFN-α) and interleukin-2 (IL-2), were found to have a significant positive 
impact on progression free and overall survival in several clinical trials in melanoma and 
renal cell carcinoma (RCC) (Rosenberg et al. 1994, Kirkwood et al. 2001). Consequently, 
recombinant IL-2 and IFN-α were FDA-approved for these malignancies in the 1990s 
and have since become an important part of the treatment protocol. However, cytokines 
have a multifaceted impact on many components of the immune system. Therefore, it 
has proven difficult to harness the biological effect of many promising cytokines, such 
as IL-12 and IL-15, due to toxicity in humans in spite of promising pre-clinical efficacy 
in animal models. Indeed, as cytokines have no intrinsic selectivity for the tumor, the 
concentration of non-targeted cytokine needed for antitumor activity is typically too high 
to achieve without also causing dose-limiting toxicity.
To overcome this drawback, antibody-cytokine fusion proteins have been generated with 
the aim of combining the high target selectivity of antibodies with tumor-localised ac-
tivation of immunity by the selected cytokine (reviewed in Young et al. 2014). In the 
following section of the manuscript, we will first discuss antibody-based targeting of key 
cytokines such as interferons and interleukins. Second, we will discuss studies aimed at 
exploiting anticancer signalling through the prominent immunomodulatory Tumor Necro-
sis Factor (TNF) ligand and TNF receptor superfamily. These TNF ligands hold consider-
able promise for activation of anti-cancer immunity and, as will be detailed below, are 
ideally suited for incorporation into antibody-based targeting strategies.
Interferons 
IFN-α and β are type I interferons, a class of cytokines that can stimulate antitumor im-
munity via distinct mechanisms. For instance, IFN-α drives differentiation of monocytes 
into DCs (Hervas-Stubbs et al. 2011) and enhances cross-presentation of tumor-derived 
antigenic peptides in MHC-I by Dendritic Cells (DCs) (Gallucci et al. 1999, Ito et al. 
2001). Further, IFN-α directly stimulates CD8 T cell expansion and acquisition of effector 
function (Hervas-Stubbs et al. 2010 & 2012). Additionally, IFN-α negatively regulates 
proliferation of regulatory T cells and blocks immunosuppressive activity of MDSCs (Pace 
et al. 2010, Zoglmeier et al. 2011). Furthermore, IFNs have direct antitumor effects such 
as inhibition of proliferation and induction of apoptosis (reviewed in Parker et al. 2016).
Type I IFNs are of clear importance for immunosurveillance, as e.g. demonstrated in 
murine models of carcinogen-induced cancer (Dunn et al. 2005). In line with this, mel-
anoma metastases spontaneously infiltrated with T cells also express a set of type I IFN 
regulated genes (Fuertes et al. 2011). In mouse models, this type I IFN signalling, spe-
cifically of IFN-β, was required for spontaneous cross-priming of tumor antigen-specific 
CD8 T cells by DCs. Thus, type I IFNs link innate immunity to development of adaptive 
immunity. Reversely, type I IFN can also induce expression of immune checkpoint ligand 











et al. 2004). This latter effect may actually suppress T cell immune responses. The po-
tential importance of type I IFNs in patients was further recently highlighted by the pos-
itive correlation of IFN expression levels with clinical immune responses against cancer 
(Fuertes et al. 2011).
Of note, type I IFN signalling also impacts on the therapeutic efficacy of direct tumor 
targeting mAbs, such as those targeting HER2 (Yang et al. 2014). Specifically, blocking 
of type I IFN signalling intratumorally inhibited the antitumor activity of HER2 mAb in a 
mouse model, suggesting that  type I IFNs may be essential cytokines for the antitumor 
efficacy of antibodies. Correspondingly, cancer cells resistant to EGFR mAb treatment 
did not produce type I IFNs. Thus, combination of type I IFNs with therapeutic mAbs 
could help improve clinical outcome. Although recombinant IFN-α was the first cytokine 
approved for treatment of human cancer (Quesada et al. 1986), identification of the op-
timal treatment regimen for IFN-α has proven difficult in view of its dose-limiting toxicity 
and modest activity in a variety in human cancers (reviewed in Parker et al. 2016). Spe-
cific problems are the short serum half-life of IFN-α (only 5 hours in pre-clinical models), 
with only 0.01% of the injected dose reaching the tumor site (Suzuki et al. 2003).
To overcome the shortcomings of non-targeted recombinant IFN-α, IFN-α has been ge-
netically fused to the C-terminus of an HER2 antibody (Huang et al. 2007), as well as 
a CD20 antibody (Xuan et al. 2010). Such antibody-cytokine constructs have reduced 
IFN-α activity compared to non-targeted IFN-α in vitro. However, anti-proliferative activi-
ty of anti-CD20-IFN-α towards a CD20-positive tumor cell line is increased approximately 
1000-fold compared to non-targeted IFN-α. Correspondingly, treatment with anti-CD20-
IFN-α cured established tumors of human NHL in all of the mice. Similarly, a murine 
anti-CD20-IFN-α eliminated established xenografts, whereas a non-targeted IFN-α fu-
sion protein combined with a CD20 mAb did not significantly improve survival compared 
to anti-CD20 treatment alone (Xuan et al. 2010). A CD20-targeted human IgG1 IFN-α 
fusion protein (IGN002) is currently evaluated in a phase I clinical trial in relapsed or 
refractory NHL patients (NCT02519270). Additionally, antibody-based targeting of IFN-α 
is explored in Multiple Myeloma (MM), where treatment of MM xenograft models with an 
anti-CD138-IFN-α immunocytokine in combination with proteasome inhibitor bortezomib 
achieved cure in the vast majority of mice (Vasuthasawat  et al. 2016).
Antibody-mediated targeting of IFN-β has also been pre-clinically validated, most no-
tably for EGFR (Yang et al. 2014). An anti-EGFR-IFN-β immunocytokine accreted to 
EGFR-positive tumors in mice and was strongly retained intra-tumorally for up to 7 days 
post-injection. Furthermore, no significant toxicity was detected, with no increase in 
AST and ALT serum levels and only a minor increase in circulating levels of pro-inflam-
matory cytokines IFN-γ and MCP-1. Importantly, anti-EGFR-IFN-β more effectively in-
hibited tumor growth than treatment with EGFR mAb alone and facilitated DC-mediated 
cross-priming and induction of adaptive CD8-positive T cell immunity. Indeed, induction 
of adaptive immunity was required for the therapeutic effect of anti-EGFR-IFN-β. This 
finding is in line with a study in which the in vivo therapeutic activity of HER2 mAbs was 
found to be crucially dependent on type I IFN signalling, as well as on IFN-γ–producing 
CD8 T cells (Stagg et al. 2011). Similar to EGFR-targeted IFN-β, a murine anti-CD20 
fusion protein containing mouse IFN-β proved effective in xenografted tumors with lower 
interferon-α/β receptor expression that were resistant to non-targeted IFN-α (Trinh et 
al. 2013). Thus, both type I IFNs may be used in antibody-based targeting strategies 
to enhance the intra-tumoral concentration, reduce off-target activity, and augment the 
efficacy of therapeutic mAbs. In this respect it is interesting to note that type I IFNs 
can also directly upregulate expression of certain tumor-associated membrane antigens, 
such as Carcinoembryonic Antigen (CEA) (Greiner et al. 1984), which may be of use for 
rational design of new type I IFN-containing immunocytokines. 
In addition to the standard antibody formats described above, alternative engineered 
mAb formats are also being explored for selective delivery of type I IFNs. For instance, 
using a dock-and-lock system an anti-CD20 immunocytokine containing 4 IFN-α units 
was constructed (Rossi et al. 2009). This immunocytokine, termed 20-2b, effectively 
depleted lymphoma cells from human blood and was more effective in treatment of 
lymphoma xenografts than parental CD20 mAb veltuzumab and a non-targeted IFN-α-
mAb immunocytokine. In a similar dock-and-lock approach, an anti-HLA-DR IFN-α im-
munocytokine was generated, essentially yielding an analogous, but HLA-DR-restricted 
therapeutic profile (Rossi et al. 2011).
Interleukins
Interleukin-2 (IL-2) is normally secreted by activated CD4 and CD8 T cells in response 
to antigen as well as by NK cells. Binding of IL-2 to the high affinity IL-2 receptor among 
others expands CD8-positive effector T cells. Treatment with recombinant IL-2 induces 
complete remission in a subset of patients with melanoma and renal cell carcinoma 
(Rosenberg et al. 1994 & 1998, Dillman et al. 1993). However, relatively high doses are 
needed to obtain clinical responses, which is associated with severe side effects such 
as VLS (Atkins et al. 1999, Vial et al. 1992). Systemic use of IL-2 in cancer therapy is 
further hindered by its short serum half-life and associated rapid clearance (Lotze et al. 
1985), as well as by the expansion of regulatory T cells upon IL-2 therapy (Ahmadzadeh 
et al. 2006). Efforts to improve its circulation time include incorporation into micelles 
(Miki et al. 2014). Further, so-called superkines that have high affinity for IL-2Rβ and 
circumvent the functional requirement of CD25 receptor for normal IL-2 signalling have 
been designed to improve activity (Levin et al. 2012).
In order to increase tumor-selectivity, various antibody-targeted IL-2 immunocytokines 
have been developed, including a CD20 targeted IL-2 fusion protein (Gillies et al. 2005). 
This immunocytokine had superior activity towards xenografts of B cell leukaemia com-
pared to a combination of non-targeted IL-2 and rituximab (Gillies et al. 2005), a com-
binatorial approach that was previously reported to yield superior antitumor activity in 
patients (Friedberg et al. 2002). Of note, fusion of IL-2 to the C-terminus of the antibody 
did not affect ADCC activity or induction of CD20-dependent apoptosis, but did inhibit 
induction of CDC. Similarly, an EpCAM-targeted IL-2 immunocytokine, comprised of an 
EpCAM mAb and two copies of IL-2, had an acceptable toxicity profile in a phase I trial 
at doses at which IL-2-mediated biological effects such as increased NK cell counts and 











cinoma patients, the acceptable safety profile of this immunocytokine was confirmed, 
although no clinical responses were detected in this study (Connor et al. 2013). In line 
with this, treatment of melanoma patients with a GD2-targeted IL-2 immunocytokine 
was similarly associated with manageable toxicities (King et al. 2004). Treatment with 
anti-GD2-IL-2 was characterised by activation of immunity, with e.g. increased NK cell 
activity, NK cell numbers and elevated levels of soluble interleukin-2 receptor, leading 
to stable disease in a subset of patients. These results were corroborated in a phase II 
trial where out of 14 patients, 1 patient had a partial response and 4 had stable disease 
(Albertini et al. 2012).
In addition to full mAb-IL-2 fusions, scFv-based IL-2 fusion proteins have been evalu-
ated. For instance, the immunocytokine F16-IL-2, which targets an alternatively spliced 
variant of extracellular matrix protein Tenascin-C using the scFv antibody fragment F16. 
This Tenascin-C variant is expressed in the stroma of various tumors, but not in normal 
tissues. F16-IL2 selectively localized to xenografted breast cancer cell line MDA-MB-231 
and had promising antitumor activity when combined with doxorubicin or paclitaxel (Mar-
lind et al. 2008). In a subsequent dose escalation study, the combination of F16-IL2 with 
doxorubicin was associated with an acceptable toxicity profile and promising antitumor 
activity (Catania et al. 2015). Similarly, targeting of an alternatively spliced extracellular 
domain B of fibronectin, specifically found in tumor vasculature and stroma, was evalu-
ated using IL-2 fused to scFv L19. Treatment with L19-IL-2 was associated with typical 
IL-2 toxicities that were manageable and transient. Importantly, although objective re-
sponses were not reported, L19-IL-2 treatment associated with stable disease in 51% of 
all patients and in 83% of patients with advanced RCC (Johannsen et al. 2010). In all of 
these trials, the circulation time of IL-2 immunocytokines was much improved compared 
to the 20 min serum half-life of non-targeted IL-2, ranging from 2-3 h for L19-IL-2, 4 h 
or more for EpCAM-IL-2 and GD2-IL-2 to up to 13 h for F16-IL-2.
To further improve IL-2 immunocytokines, engineering of recombinant IL-2 to increase 
selectively for the high affinity IL-2 receptor, expressed on activated T and NK cells, has 
been performed. The rationale for this approach lies in the fact that signalling through 
the intermediate βγ IL-2 receptor, e.g. on circulating cells in the vasculature, is thought 
to be at least one of the underlying causes for VLS (Shanafelt et al. 2000). In a recent 
study, mutation of the aspartic acid to threonine at position 20 was found to highly 
increase selectivity of mAb-targeted IL-2 for the high affinity αβγ IL-2R (Gillies et al. 
2011). Of note, this aspartic acid is part of a three amino acid toxin-like domain of IL-2 
thought to be responsible, at least in part, for its vascular toxicity (Baluna et al. 1999). 
This IL-2-D20T-based immunocytokine retained prominent antitumor activity in murine 
models and had an improved toxicity profile in cynomolgus monkeys. 
IL-2 cytokines were also generated by fusing IL-2 to the C-terminus of the light chain in-
stead of the typical fusion to the heavy chain of the antibody (Gillies et al. 2013). Such a 
melanoma-targeted IL-2 immunotoxin had a longer half-life and retained ADCC and CDC 
activity compared to standard HC-based IL-2 fusion proteins. Importantly, activation of 
the high affinity αβγ IL2R was retained, whereas activation of the intermediate affinity 
βγ IL2R was reduced. The latter was attributed to steric hindrance of binding of the IL-2 
Asp20 residue to the β-chain of the intermediate affinity IL2R in this format. Of note, in 
a recent study with three different immunocytokines, where IL-2 was fused to the IgG 
light-chain, it was found that these cytokines did not have improved tumor homing or 
recruitment of effector functions such as ADCC, but that efficacy of the immunocyto-
kines was related to the increased circulation time (Tzeng et al. 2015). Thus, improved 
circulation time may prove to be the key determinant for IL-2-based immunotherapy. In 
this respect, conjugation of IL-2 to 6 releasable polyethylene glycol (PEG) chains was 
recently reported to yield sustained low levels of active IL-2 conjugates by virtue of the 
slow release of PEG chains (with a reported half-life of ~20 hours for each release step 
in vitro) (Charych et al. 2016). Using this approach, the sustained release of active IL-2 
increased tumor accumulation of IL-2 and induced superior antitumor activity in mouse 
melanoma models, with synergistic activity in combination with anti-CTLA4 treatment. 
In addition, depletion of regulatory T cells significantly potentiated IL-2-induced antican-
cer immune responses in a mouse model of colon adenocarcinoma (Imai et al. 2007).
Other interleukins of interest for antibody-based targeting include IL-15, which like IL-2 
binds to IL-2 receptor β and γ, but has unique binding to IL-15Rα (Budagian et al. 2006). 
Unlike IL-2, IL-15 does not trigger expansion of regulatory T cells, but is required for 
the generation and maintenance of CD8 memory T cells as well as NK cells (Berger et 
al. 2009). Furthermore, treatment with high dose IL-15 did not associate with VLS in 
mice and IL-15 treatment of macaques revealed an improved toxicity profile compared 
to IL-2 (Munger et al. 1995, Berger et al. 2009). Based on these favorable characteris-
tics, IL-15 was targeted to the tumor vasculature-associated EDB domain of fibronectin, 
using the above-described scFv F19. F19-IL-15 triggered potent antitumor activity in 
immunocompetent mice that was dependent on CD8 T cell activity and was superior to 
mock scFv-IL-15 fusion protein (Kaspar et al. 2007). In addition, targeting to melanoma 
marker GD2 was explored using an IL-15 fusion construct containing the so-called sushi 
domain of human IL-15Rα (Vincent et al. 2013). This IL-15/IL-15Rα fusion, termed RLI, 
was previously established to have more potent immunostimulatory effects than IL-15 
alone (Mortier et al. 2006, Bessard et al. 2009). The GD2-RLI antibody-cytokine retained 
cytokine activity, as well as melanoma-selective binding activity and was able to activate 
ADCC through the GD2 mAb. In addition, GD2-RLI proved to have superior activity com-
pared to combination of RLI and anti-GD2 in mouse syngeneic tumor models.
To further improve on IL-15-based immunotherapy, a tri-functional antibody fusion pro-
tein comprising an antibody fused to RLI and the extracellular domain of 4-1BBL was 
generated (Kermer et al. 2014). This immunocytokine reduced metastasis formation 
more effectively than corresponding tumor-targeted RLI and 4-1BBL fusion proteins in a 
murine melanoma model. More recently, IL-15 was incorporated into the so-called BiKE 
format, yielding a so-called trispecific killer engager (TriKE) molecule comprised of a 
CD16 scFv to recruit NK cells, IL-15 to activate NK cells, and a CD33 scFv to target AML 
(Vallera et al. 2016). This CD33-targeted TriKE was more effective than an analogous 
anti-CD16/anti-CD33 BiKE in activating NK cell-mediated ADCC towards primary AML 
cells. Importantly, the CD33-targeted TriKE also triggered the proliferation of NK cells in 











reduced NK cell functionality after HSCT (Foley et al. 2011).
An additional interleukin of particular interest is IL-21, which proved to be well tolerated 
in patients in early clinical trials, with evidence of clinical activity including a complete 
response in MM and four partial responses in RCC (Thompson et al. 2008). Interestingly, 
long-term disease-free survival upon trastuzumab treatment in breast cancer patients 
depends on innate and adaptive immune signalling (Park et al. 2010), and was recently 
found to associate with increased IL-21 receptor (IL-21R) expression (Mittal et al. 2016). 
In line with this, treatment with recombinant IL-21 and HER2 mAb in mice yielded supe-
rior antitumor activity towards primary tumors and metastases (Mittal et al. 2016), with 
expression of IL-21R on CD8 T cells being important for HER2 mAb treatment efficacy. 
In line with this, combination treatment of indolent B cell lymphomas with rituximab and 
recombinant IL-21 yielded clinical activity in 42% of patients, with some responses being 
more durable than that of previous rituximab treatment (Timmerman et al. 2012). Thus, 
combination strategies of therapeutic mAbs with IL-21 or inclusion of this cytokine into 
an immunocytokine strategy appear promising. In this respect, a CD20-targeted IL-21 
fusion protein possessed enhanced antitumor efficacy compared to rituximab or IL-21 
combinations in vitro and may thus yield synergistic activity.
Various other interleukins are of interest for incorporation into the immunocytokine for-
mat, including IL-12 for which among others fibronectin and CD30-targeted immuno-
cytokines are already in (pre)clinical development (Lo et al.  2007, Heuser et al. 2003, 
Rudman et al. 2011), and IL-7 which is currently in clinical trials for several cancers 
including breast cancer (Tredan et al. 2015).
Tumor Necrosis Factor superfamily ligands
The superfamily of Tumor Necrosis Factor (TNF)-related proteins (TNFSF) comprises 
27 members mediating multiple regulatory functions in the immune system, ranging 
from induction of apoptosis in superfluous cells to providing co-stimulatory signalling at 
various stages of the immune response. All TNFSF-members contain the hallmark TNF 
homology domain (THD) in the extracellular region and typically exist as non-covalent 
homotrimeric type II transmembrane proteins (reviewed in Bodmer et al. 2002). How-
ever, most of the TNSF members can be processed into a soluble ligand comprising the 
extracellular domain. TNF ligands bind to cognate members of the TNF receptor (TNFR) 
superfamily, typically type I transmembrane proteins characterised by extracellular cys-
teine-rich domains (CRDs).
One of the functions of the TNFSF family is the induction of apoptotic cell death in target 
cells, which is governed by a subgroup of TNFSF members termed the Death Inducing 
Ligands (reviewed in Walczak et al. 2013). This subgroup consists of TNF, FasL and TRAIL 
and activates the extrinsic pathway of apoptosis through cognate TNFRs called Death 
Receptors (DRs). A second pivotal function of the TNFSF is the temporally coordinated 
induction of co-stimulatory signals that drive various stages of the adaptive immune 
response. Here, binding of a TNFSF to a cognate TNFR induces the recruitment of so-
called TNF receptor associated factors (TRAFs) that subsequently trigger a multitude of 
pro-inflammatory signalling pathways, such as NFκB, PI3K, and PKB. 
Membrane TNFSF ligands effectively trigger activation of cognate receptors (Figure 6A). 
In contrast, soluble TNFSF ligands typically bind their cognate receptor(s), but are less 
effective in activation of downstream receptor signalling (Figure 6A). Importantly, as 
demonstrated using recombinant affinity tagged sTNFSF members, this soluble and inac-
tive TNFSF ligand can gain full signalling activity by secondary cross-linking, e.g. with tag 
antibodies. Similarly, agonistic TNF receptor antibodies can directly bind to and cross-link 
TNF receptors, which typically required FcR-mediated (cellular) cross-linking for effective 
downstream signaling (Figure 6A). This differential activity profile of soluble vs. mem-
brane TNFSF can be exploited for immunotherapy by genetic fusion of a soluble TNFSF 
ligand to a high affinity scFv antibody fragment (reviewed in Bremer 2013). In brief, high 
affinity binding of the scFv to its target antigen leads to display of the TNFSF on the cell 
membrane. This ‘membrane-like’ TNFSF can now provide the requisite cross-linking to 
achieve optimal activation of the cognate TNFRSF. Importantly, the soluble scFv:TNFSF 
ligand is relatively inactive in solution while ‘en route’, thus reducing the chance of sys-
temic toxicity (Figure 6B). This concept has been applied to antibody-based targeting 
of a variety of TNF ligands, including FasL and co-stimulatory TNFSF ligands, like CD40L 
and 4-1BBL (not included here), and TRAIL as discussed below.
Figure 6: Antibody-based targeting of TNF superfamily members. A) Binding of TNF ligands to their 
receptors induces receptor cross-linking, which triggers potent death signalling. In contrast, soluble 
TNF ligands typically bind their cognate receptor(s), but are less effective in activation of downstream 
receptor signalling. However, agonistic TNF receptor antibodies do induce sufficient cross-linking of 
the TNF receptors inducing normal or hyper-activation of death signalling. B) TNF-ligand fusion pro-
teins comprising a tumor specific scFv genetically fused to a TNF ligand show low activity en route, 
as binding of the TNF ligand only is insufficient for triggering receptor cross-linking and activation. 
After binding of the scFv to its recognising antigen expressed on tumor cells, the soluble TNF ligand 
is converted into membrane bound TNF. Thereby, the TNF receptor can be efficiently be cross-linked, 









































TNF-related apoptosis inducing ligand (TRAIL)
TNF-related apoptosis inducing ligand (TRAIL) is an important immune effector mol-
ecule, among others involved in peripheral tolerance, NK and T cell cytotoxicity and 
immunosurveillance of circulating cancer cells (Kayagaki et al. 1999, Martinez-Lorenzo 
et al. 1998). TRAIL is unique among the Death Inducing Ligand subgroup of TNFSF as it 
selectively induces apoptosis in cancer cells, with no to minimal activity towards healthy 
normal cells. TRAIL induces caspase-8 mediated apoptosis via activation of its agonistic 
receptors TRAIL-R1 and TRAIL-R2. TRAIL-R2 has a higher affinity for TRAIL, but cannot 
be effectively activated by soluble TRAIL as it requires secondary cross-linking (Wajant 
et al. 2001). In contrast, TRAIL-R1 is efficiently activated by soluble TRAIL (Wajant et al. 
2001). TRAIL additionally interacts with antagonistic receptors TRAIL-R3 and TRAIL-R4, 
which are believed to function as decoy receptors, and the soluble receptor osteopro-
tegrin (Almasan et al. 2003). TRAIL-R1 and TRAIL-R2 are highly expressed in many 
malignancies (Strater et al. 2002, Spierings et al. 2003, Kurbanov et al. 2005), which 
combined with the apparent tumor-selective activity of sTRAIL makes this regulatory 
axis an attractive target for antibody-based cancer therapy. 
In line with the lack of toxicity in preclinical studies, dulanermin, a recombinant form 
of TRAIL, was well tolerated in patients in phase I/II clinical trials with no dose-limiting 
toxicity (reviewed in Fox et al. 2010). In a multicentre clinical trial, dulanermin induced 
partial responses and stable disease at higher doses of 8 mg/kg and yielded 2 complete 
and 1 partial response in Non-Hodgkin Lymphoma patients when combined with antibody 
rituximab (Ashkenazi,A. 2008a & 2008b). The latter is in agreement with the synergy 
observed upon in vitro treatment with rituximab and TRAIL (Daniel et al.  2007). Unfor-
tunately, dulanermin lacked activity in a phase II trial in non-small cell lung cancer pa-
tients and is not being further developed at the moment (Soria et al. 2011). This disap-
pointing outcome may among others be due to instability and rapid clearance (Kelley et 
al. 2001, Herbst et al. 2010), as well as intrinsic and acquired resistance to TRAIL as e.g. 
observed after treatment with suboptimal doses of an TRAIL-R2 antibody (Li et al. 2006).
Several strategies have been developed to increase the therapeutic potential of TRAIL-
based drugs (reviewed in de Miguel et al. 2016). These include the use of zipper motifs 
(Ganten et al. 2006) and oligomerization domains (Berg et al. 2007), whereby the tri-
meric conformation is stabilised, as well as covalent linkage to polyethylene glycol (PEG) 
(Chae et al. 2010). Other recent strategies include immobilizing TRAIL onto the surface 
of nanoparticles or encapsulation of TRAIL inside nanoparticles (de Miguel et al. 2015, 
Kim et al. 2011). To increase tumor-selectivity, nanoparticles can be further equipped 
with scFv antibody fragments (Bae et al. 2012, Seifert et al. 2014). Furthermore, 
nanoparticles containing drugs that synergise with TRAIL, such as doxorubicin, greatly 
enhanced therapeutic efficacy in mouse models in the absence of systemic toxicity (Jiang 
et al. 2011). Interestingly, combined treatment of cancer cells with recombinant TRAIL 
and TRAIL-R2 agonist also yielded a strong synergistic effect comparable to the effect of 
isoleucine zipper-TRAIL in preclinical studies (Tuthill et al. 2015), highlighting a non-re-
dundant role for different TRAIL-R agonists. 
TRAIL has also been used by various groups as effector moiety for an immunocytokine 
approach, typically by fusion of sTRAIL to a high affinity scFv antibody fragment or 
peptides that selectively deliver TRAIL to the tumor cell surface. Such fusion proteins 
convert soluble TRAIL into membrane-bound TRAIL via high affinity and tumor selective 
binding of the antibody fragment, inducing tumor-selective apoptosis via activation of 
both TRAIL-R1 and TRAIL-R2 (Wajant et al. 2001, de Bruyn et al. 2013). Of note, upon 
target antigen binding to a cancer cell, such an scFv:TRAIL fusion protein can also trig-
ger apoptosis in neighbouring target antigen-negative cells via the so-called bystander 
effect, thereby potentially reducing the risk of escape of target-antigen negative cancer 
cells (Bremer et al. 2004).
Importantly, rational choice for an antibody fragment with an intrinsic tumoricidal sig-
nalling activity can be used to optimise the therapeutic effect of scFv:TRAIL fusion pro-
teins. For instance, a blocking EGFR antibody fragment can trigger inhibition of EGFR 
pro-mitogenic signalling and simultaneously activate TRAIL-mediated apoptosis (Bremer 
et al. 2005, Bremer et al. 2008, Bremer et al. 2008), leading to prominent in vitro and 
in vivo antitumor activity. Similarly, an MCSP-blocking antibody fragment can deliver 
pro-apoptotic TRAIL while simultaneously inhibiting pro-metastatic MCSP signalling (de 
Bruyn et al. 2010). Furthermore, inhibition of CD47/SIRPα don’t eat me signalling using 
a CD47-blocking antibody fragment triggers CD47-selective apoptosis while simultane-
ously optimising phagocytic removal of cancer cells (Wiersma et al. 2014). In addition, 
scFv-mediated targeting of TRAIL to TNFRs overexpressed on cancer cells, such as CD70 
and CD40, induced CD70- and CD40-selective apoptosis in malignant cells (Trebing et 
al. 2014, El-Mesery et al. 2013). Although not investigated, targeting of these immuno-
stimulatory receptors may also yield immunomodulatory effects on antitumor immune 
responses.
In order to further increase the activity and stability of scFv:TRAIL fusion proteins, high-
ly stable single polypeptide chain TRAIL variants (scTRAIL) have been generated. In 
scTRAIL, three monomers have been genetically fused, which upon production leads 
to formation of a single polypeptide TRAIL trimer (Schneider et al. 2010). Such sc-
TRAIL constructs have also been used in scFv-based fusion proteins, e.g. by targeting 
the EGFR, and have potent tumoricidal activity. An important distinction between the 
scFv:scTRAIL and scFv:TRAIL format is the presence of a single targeting scFv vs. three 
targeting scFvs, which in case of the latter may yield an increase in avidity. In addi-
tion, fusion proteins that dimerize TRAIL trimers have been developed using diabodies 
(Siegemund et al. 2012) and Fc-mediated dimerization (Gieffers et al. 2013, Seifert et 
al. 2014), leading to optimal cross-linking and activation of TRAIL-receptor signalling. 
Additional efforts to further increase the tumor-selective activity of TRAIL include the use 
of immunoglobulin E (IgE) heavy-chain domain 2 (EHD2) to covalently link and homod-
imerize scTRAIL with an EGFR scFv. The concomitant tetravalent scTRAIL molecule had 
increased thermal stability, solubility and antitumor activity compared to non-targeted 
EHD2-scTRAIL (Siegemund et al. 2016).
Of note, scFv-based targeting of TRAIL can also be used to selectively target immune 
effector cells to enhance their tumoricidal activity. Delivery of TRAIL to CD3 or CD7 











increased survival ~6-fold in vivo (de Bruyn et al. 2011). Of note, targeted delivery of 
TRAIL to CD3 also triggered additional T cell activation, thereby yielding a dual signalling 
effect of scFvCD3:TRAIL. In a similar fashion, granulocytes were armed with CLL1-tar-
geted TRAIL, which enhanced both the induction of TRAIL-mediated apoptosis in CLL-1 
positive cancer cells and augmented induction of ADCP by therapeutic antibodies such as 
rituximab (Wiersma et al. 2015). 
Recently, we generated another immunomodulatory scFv:TRAIL fusion protein by using 
an scFv antibody fragment targeting PD-L1 (Hendriks et al. 2016, Chapter 4 this thesis). 
This PD-L1:TRAIL fusion protein directly triggered TRAIL-mediated apoptosis in PD-L1+ 
tumor cells, but also armed PD-L1-expressing myeloid cells, such as DCs and macro-
phages. Hereby, PD-L1:TRAIL converted possibly immunosuppressive myeloid cells into 
pro-apoptotic tumoricidal platforms. PD-L1:TRAIL additionally inhibited PD-1/PD-L1 in-
teraction and thereby augmented the anticancer activity of T cells. An interesting feature 
of PD-L1:TRAIL is the fact that by virtue of PD-L1/PD-1 inhibition, T cell secretion of 
IFN-γ secretion is augmented, which on tumor cells also increased expression of PD-L1, 
a well-established effect of IFN-γ (Dong et al. 2002). Further, IFN-γ sensitised tumor 
cells to TRAIL-mediated apoptosis, another well-established effect of IFN-γ (Langaas et 
al. 2001). Thus, PD-L1:TRAIL treatment essentially creates a feed-forward loop, with 
increased target antigen and increased sensitivity to apoptotic elimination. 
Although TRAIL fusion proteins have not yet been tested in clinical trials, a favourable 
toxicity profile of such fusion proteins is anticipated, with optimal target antigen-re-
stricted activation of apoptosis, and an improved serum half-life due to the increase in 
molecular weight compared to soluble TRAIL. Furthermore, combinatorial regimes with 
chemotherapeutic drugs that sensitise cancer cells to TRAIL-mediated apoptosis further 
increase their potential. In this respect, combination of bortezomib and an EGFR-tar-
geted scTRAIL fusion protein had promising tumor-selective activity in hepatocellular 
carcinoma, with no apparent hepatotoxicity (Wahl et al. 2013). Similarly, combination 
of CD33-targeted TRAIL with histone deacytelase inhibitors also synergistically induced 
apoptosis (ten Cate et al. 2009).
In conclusion, antibody-cytokines can solve many of the issues frustrating the appli-
cation of non-targeted cytokines in cancer therapy, including severe systemic toxicity 
and short serum half-life. Correspondingly, some immunocytokines have already shown 
promising activity in clinical trials. Unlike antibody-drug-conjugates (reviewed in Polakis 
2016), antibody-cytokines do not require target antigen-mediated internalisation for 
their efficacy. Therefore, the repertoire of target antigens to choose from includes tumor 
microenvironmental as well as immune effector cell antigens. The choice for a particular 
target antigen will depend on both the intended target cell and the anticipated antitu-
mor effect, i.e. direct antitumor activity vs. induction of antitumor immunity. Further, 
depending on target and cytokine, immunocytokines may bridge innate and adaptive im-
munity and may combine direct antitumor activity with activation of adaptive immunity, 
as e.g. illustrated for the PD-L1:TRAIL immunocytokine. 
CAR-transfected T cells
An additional exciting development in the field of antibody-based therapy are so-called 
Chimeric Antigen Receptor (CAR)-modified T cells. A CAR is comprised of an extracellular 
scFv domain, a transmembrane domain, and intracellular T cell co-stimulatory domains. 
CAR-modified T cells are generated by transducing isolated peripheral blood T cells from a 
patient with the CAR construct. Hereby, the entire T cell repertoire is redirected to cancer 
cells (Figure 7A). Upon binding to the specific tumor-associated antigen, the CAR T cells 
proliferate and mount an immune response, leading to killing of the tumor cells. Thus, 
CAR T cells harness the power of both antibody-mediated target antigen recognition and 
selective delivery of the full cytotoxic T cell armament. The currently used and clinically 
active CARs are of the so-called second generation and comprise an extracellular scFv 
antibody fragment, a transmembrane domain, the CD3ζ chain, and either the CD28 or 
4-1BB co-stimulatory signalling domain (Figure 7A) (Maude et al. 2014, Kochenderfer 
et al. 2015). Which of these co-stimulatory signalling domains is superior, and whether 
further engineering of co-stimulatory domain composition can increase activity, remains 
to be determined. In this respect, third generation CARs containing CD28 and 4-1BB or 
OX40 co-stimulatory domains are being evaluated (pre)clinically (Pule et al. 2005).
Figure 7: Chimeric antibody receptor (CAR) T cells. A) Chimeric antigen-receptors (CAR) T cells 
comprise a tumor specific scFv to redirect the T cells to target antigens expressed on tumor cells. First 
generation CARs only contained such a scFv fused to the CD3-zeta transmembrane and endodomain. 
However, second generation CAR T cells that are currently being evaluated in the clinic are CARs that 
also comprise a co-stimulatory signalling domain like CD28 or 4-1BB. Third generation CAR T cells 
contain co-stimulatory molecules two instead of one, which will provide the CAR with additional acti-
vation and survival signalling. B) The tumor micro environment is generally immune silencing, which 
may hamper the efficacy of CAR T cells. To overcome this problem, additionally “armed” CAR T cells 
that are engineered to secrete cytokines have been developed. C) Targeting of a single tumor antigen 
with CAR T cells can lead to relapse of target antigen-negative disease. To overcome this problem, 

















































Initial striking successes have been made in the field of B cell malignancies using CARs 
that recognise B cell marker CD19. In patients with relapsed and refractory B-ALL, treat-
ment with CD19 CAR T cells resulted in a complete response in 27 out of 30 patients 
(90%) 1 month after infusion, with 19 patients having a sustained remission (Maude et 
al. 2014). CD19-targeted CAR T cells have also been used in patients with other B cell 
malignancies, such as relapsed and refractory CLL yielding a 57% response rate with 4 
complete and 4 partial responses out of 14 patients (Porter et al. 2015). Additionally, 
complete remissions were reported in 8 out of 15 patients with DLBCL (Kochenderfer et 
al. 2015) and a sustained complete response was reported in a patient with advanced 
MM receiving CD19 CAR T cells together with autologous transplantation (Garfall et al. 
2015). Of note, sustained clinical responses have been thought to be associated with 
persistence of CD19 CAR T cells, although persistence does not necessarily correlate with 
response in certain trials (Maude et al. 2014, Lee et al. 2015).
Many other target antigens on haematological malignancies are being considered, in-
cluding a CD30-targeted CAR to treat patients with Hodgkin lymphoma and CD30-pos-
itive non-Hodgkin lymphoma (NCT01316146), a CD138-targeted  CAR  for MM that in-
duced stable disease in four out of five patients (Guo et al. 2016), and AML targeted 
CARs directed at CD33 and CD123 (NCT01864902, NCT02159495). 
Although less clinically advanced, CAR T cells are also being evaluated against many 
solid tumor targets, including mesothelin, HER2, CEA and EGFR (reviewed in Jackson et 
al. 2016). Of interest here are CARs directed at EGFRvIII (Johnson et al. 2015a, Morgan 
et al. 2012), a tumor-specific mutant of the EGFR among others expressed on glioblas-
toma. EGFRvIII-targeted CARs are being evaluated in clinical trials of glioblastoma and 
other brain tumors (NCT02209376, NCT01454596). Since EGFRvIII is a tumor-specific 
antigen, EGFRvIII-targeted CAR T cells are likely to have a good safety profile. Indeed, 
safety is a particularly important issue for CAR-based therapy of solid cancers such as 
epithelial malignancies, as many of the targets are overexpressed on cancerous cells 
but also present on healthy epithelial cells. Indeed, major risks of CAR T cell treatment 
include on-target/off-tumor activity toward healthy antigen-expression cells (reviewed 
in Brudno et al. 2016). CAR T cell therapy may also associate with on-target/on-tumor 
toxicity such as tumor lysis syndrome (TLS) or cytokine release syndrome (CRS), al-
though the latter also appears to correlate with clinical activity for CAR-based therapy 
(Davila et al. 2014). In line with this, treatment-related deaths have been reported for 
second generation CD19 CAR T cells containing the CD28 domain and third generation 
HER2 CAR T cells containing CD28 and 4-1BB co-stimulatory domains (Figure 8A) (Park 
et al. 2010, Morgan et al. 2010).
Thus, identifying the optimal window for antitumor activity in the absence of immuno-
pathology is critical and inclusion of mechanisms to ensure timely shut-down of CAR T 
cells are being explored in order to improve safety. Specifically, various types of suicide 
gene approaches enable timed elimination of CARs. Of particular interest is the induc-
ible caspase-9 (iCasp9) system (Di Stasi et al. 2011), which upon treatment with a 
caspase-9 inducer drug yields a 90% reduction in CD20 CAR T cell numbers within 12 
h (Budde et al. 2013). Various iCasp9-expressing CAR T cells are currently being evalu-
ated, including a GD2-specific iCasp9-expressing CAR (GD2-iCAR) (Gargett et al. 2015) 
which is currently tested a phase I trial in neuroblastoma patients (NCT01822652).
CAR transduced T cells are, particularly in solid cancers, still subjected to immune in-
hibitory pathways present in the tumor micro-environment. Indeed, mouse studies with 
established tumors identified a multifactorial inhibition of infiltrating CAR T cells, due 
to upregulation of intrinsic T cell inhibitory enzymes, such as diacylglycerol kinase, the 
expression of inhibitory receptors, such as PD-1, LAG3 and TIM3 (Moon et al. 2014), and 
immunosuppressive mediators, such as prostaglandin E2 (PGE2) (Newick et al. 2016). 
These immunosuppressive effects can be abrogated by CAR engineering, whereby ther-
apeutic activity is augmented in preclinical models (Newick et al. 2016). An additional 
approach to overcome this problem are the so-called armoured CAR T cells that are 
engineered to secrete cytokines or express ligands that prevent immune silencing, such 
as secretion of interleukin-12 (IL-12), or co-expression of CD40L or 4-1BBL (reviewed in 
Yeku et al. 2016) (Figure 7B). Alternatively, CAR T cells can be combined with checkpoint 
inhibitor antibodies targeting e.g. PD-1, to augment therapeutic efficacy. In this respect, 
a CAR construct in which extracellular domain of PD1 was fused to the transmembrane 
and cytoplasmic co-stimulatory CD28 domain has recently been described (Liu et al. 
2016). Hereby, PD-L1/PD-1 interaction is converted into a co-stimulatory signal, which 
enhanced CAR infiltration into the tumor and induced tumor regression. Such PD-1:CD28 
CAR T cells were less susceptible to silencing in the tumor micro-environment.
Another important consideration for CAR T cells is that retargeting of patient T cells 
towards a single tumor target antigen using a high affinity CAR may lead to relapse of 
target antigen-negative disease, as for instance reported for CD19 CAR therapy (Grupp 
et al. 2013). Although this seems to be a relatively rare event for CD19, it is an import-
ant issue when targeting solid cancers where target antigen expression can be highly 
variable between disease stage, tumor subtype, and most importantly within lesions of 
a single patient (Sottoriva et al. 2013, Navin et al. 2011, Thirlwell et al. 2010). There-
fore, the targeted delivery of CAR-transfected T cells to a single target antigen is likely 
to eliminate only a subset of malignant cells. To overcome this issue, a dual specificity 
CAR, termed tandem CAR (TanCAR) that simultaneously targets CD19 and HER-2 was 
developed in a proof of concept study (Figure 7C) (Grada et al. 2013). This CAR redi-
rected T cell reactivity to either of the antigens and induced synergistic cytolytic T cell 
activity upon simultaneous binding to CD19 and HER2. Similarly, a TanCAR directed 
against HER2 and IL-13Rα2 displayed superior activity upon binding to both antigens 
and effectively eliminated glioblastoma in a mouse model (Hegde et al. 2016). Alterna-
tively, CARs that recognise universal tags such as fluorescein isothiocyanate (FITC) and 
biotin have been developed (Tamada et al. 2012, Urbanska et al. 2012). FITC-targeted 
CAR T cells could be selectively targeted to folate receptor-overexpressing cancers using 
FITC-labelled folate (Kim et al. 2015b) and could be dual targeted to CD19 and CD22 
(Ma et al. 2016), as well as HER2 and CD20 (Tamada et al. 2012). For heterogeneous 
cancers, simultaneously targeting of two or more antigens with a universal CAR may be 
crucial to increase the therapeutic efficacy.











important step to achieve optimal activity with CAR-based therapy (Golubovskaya et al. 
2016). For instance, a subset of CD19 CAR-transfected T cells that is characterised by 
CD8/CD45RA/CCR7 expression, resembling so-called T memory stem cells, is associated 
with in vivo expansion of CD19 CAR T cells in patients. This phenotype could be selec-
tively induced in vitro, using cytokines IL-7 and IL-15, and was associated with improved 
function and survival in pre-clinical CAR T cell infusion models (Xu et al. 2014). In an 
alternative approach, so-called induced pluripotent stem cell clones (iPSCs) were used 
to generate CD19-targeted CAR T cells, which yielded potent cytotoxic activity toward 
CD19+ cancer cells (Themeli et al. 2013). Intriguingly, a recent paper reported the gen-
eration of an allogeneic universal CAR T cell formulation, by using the CRISPR/Cas9 
system to disrupt multiple genomic loci to yield CAR T cells deficient in endogenous TCR, 
HLA class I (HLA-I) and PD-1 (Ren et al. 2015). Such allogeneic engineered CAR T cells 
did not induce GVHD and may thus provide a universal platform for CAR T cells as an 
alternative to autologous CAR T cells.
In conclusion, a combinatorial approach including selection of specific T cell populations 
to generate universal and optimally active allogeneic CAR T cells and CAR design to 
circumvent tumor escape and tumor immune-silencing is anticipated to improve the 
therapeutic applicability of CAR-based cancer immunotherapy.
Conclusions
Antibody-based therapy has clearly come of age, with all the different approaches de-
scribed in this review having yielded lead candidates that show promising clinical activity, 
mostly in trials with heavily pretreated and refractory patients. The continued progress in 
design, engineering and insights in the tumor-immune interaction will aid further optimi-
sation of antibody-based approaches. One of the important challenges in the upcoming 
years is to incorporate the advances in antibody-engineering into optimal combinations 
with standard-of-care treatment such as chemo and/or radiotherapy, to achieve curative 
treatment. In this respect, it is important to consider that patients treated with high-
dose chemotherapy are likely to have only low levels of immune effector cells, which may 
at least in part explain the limited success of mAb treatment in AML. This also highlights 
the importance of identification of optimal timing and dosing strategies for each indi-
vidual therapeutic combination. Importantly, rational choice of chemotherapy may help 
to augment antitumor immunity, with e.g. doxorubicin inducing so-called immunogenic 
cell death (ICD) that can induce T cell immune responses (Fucikova et al. 2011). Thus, 
combining ICD inducers with immunomodulatory antibodies such as CTLA-4 antibody 
ipilimumab may provide a ‘natural’ vaccination effect that can (re)educate and steer 
antitumor immunity (NCT01524991). In addition, anticancer immune responses may be 
enhanced by depletion of immunosuppressive regulatory T cells. This approach (using 
CD25-targeted daclizumab) has proven beneficial in the clinic without the development 
of autoimmunity  when applied in parallel with tumor antigen vaccination (Rech et al. 
2009 & 2012).
Similarly, combination therapy with immune-modulatory drugs (IMiDs), such as the tha-
lidomide analogue lenalidomide, can enhance the therapeutic effect of tumor-targeting 
mAbs, as evidenced by augmented NK cell-mediated ADCC upon combination treatment 
of lenalidomide with daratumumab (van der Veer et al. 2011). Such synergy can also be 
achieved by combining tumor-targeting mAbs such as rituximab with immunomodulato-
ry mAbs such as 4-1BB mAb urelumab (Kohrt et al. 2013). Combinations of checkpoint 
inhibitors and immunostimulatory mAbs are already evaluated in clinical trials and are 
anticipated to augment anticancer immunity. Furthermore, combinations of CAR T cells 
with immunomodulatory antibodies and cytokines can help to ensure induction of cura-
tive immunity even in the immunosuppressive tumor microenvironment.
In the future, these advances are anticipated to lead to the development of effective 
new antibody-based therapeutic approa ches for a growing number of patients and an 
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Agonistic anti-DR5 antibodies, alone or in combination with other treatment modalities, 
show promising activity towards a variety of cancer types, including malignant mela-
noma. However, the therapeutic efficacy of current anti-DR5 antibodies is potentially 
limited as they indiscriminately interact with DR5 that is broadly present on normal 
cells. Therefore, we developed a novel bispecific antibody-based approach that promotes 
melanoma-directed pro-apoptotic activation of DR5. We engineered a novel recombinant 
bispecific antibody, designated MCSPxDR5, which combines high binding affinity for the 
melanoma-associated antigen MCSP with potent agonistic activity towards DR5. The 
mode of action of MCSPxDR5 involves high-affinity binding to tumor cell surface-ex-
pressed MCSP with concomitant locally enhanced cross-linking of DR5. MCSPxDR5 
showed potent MCSP-directed pro-apoptotic activity towards MCSP-positive melanoma 
cells with essentially no or minimal toxicity towards normal cells. The antitumor activity 
by MCSPxDR5 was enhanced after secondary cross-linking of its IgG domain by either 
an artificial cross-linker or by Fc receptors present on myeloid immune effector cells. 
Importantly, MCSPxDR5 potently induced apoptosis in primary patient-derived melano-
ma cells that was further enhanced after secondary cross-linking of its human IgG1 Fc 
domain. Taken together, we present a melanoma-directed DR5 agonistic bispecific anti-
body in which high-affinity binding to MCSP results in melanoma cell-localized activation 
of pro-apoptotic DR5 signaling. This novel antibody-based approach may provide a new 
avenue to unlock the therapeutic potential of DR5-targeted cancer therapy, in particular 
for targeted treatment of melanoma and other MCSP-expressing malignancies. 
Introduction
Malignant melanoma is the most lethal type of skin cancer and its incidence continues 
to increase at an alarming rate.1 When diagnosed at an early stage, localized malignant 
melanoma can be cured by radical removal of the lesion, resulting in excellent survival 
rates. However, once progressed to the metastatic stage, melanoma is extremely dif-
ficult to cure.2 Currently, ipilimumab (CTLA4 blockade), BRAF inhibitors (vemurafenib 
and dabrafenib) and high-dose IL-2 are used as first line agents for stage IV melanoma. 
Newly emerging treatment options include antibodies that target the PD-1/PD-L1 check-
point axis (e.g. nivolumab), oncolytic viruses, adoptive T cell transfer and dendritic cell 
vaccines.3 
In this respect, Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) appears 
to be a promising anticancer agent as it induces apoptosis in a wide range of refractory 
malignancies including melanoma.4 TRAIL is an immune effector protein that induces 
apoptosis in virus-infected cells and cancer cells by activating death receptor-4 (DR4) 
and/or death receptor-5 (DR5) without deleterious activity towards DR4/DR5-express-
ing normal cells.5 Consequently, DR4/DR5 agonists have been regarded as promising 
anticancer agents. Indeed, treatment with “first-generation” DR4/DR5-targeted ther-
apeutics, such as recombinant human soluble TRAIL (rhTRAIL) and agonistic DR4/DR5 
antibodies was well tolerated, but had disappointing clinical efficacy.4 For instance, in 
a phase I dose-escalation study in patients with relapsed or refractory carcinoma, the 
DR5-agonistic antibody tigatuzumab only induced stable disease in selected patients.6 
Similarly, in a phase II trial in non-small cell lung cancer patients, combined treatment 
with rhTRAIL and chemotherapy had no added benefit compared to chemotherapy treat-
ment alone.7 
However, advances in the understanding of death receptor signaling revealed that 
first-generation DR4/DR5 agonists do not fully exploit the unique signaling character-
istics of TRAIL receptor-mediated cancer cell death.4,8 Specifically, DR4 and DR5 have 
distinct cross-linking requirements for the induction of apoptosis. DR4 is activated upon 
binding of rhTRAIL (or conventional DR4 antibodies), whereas apoptotic DR5 signaling 
requires membrane-bound TRAIL or secondarily cross-linked rhTRAIL.8,9 Indeed, to gain 
therapeutic activity, agonistic DR5 antibodies such as tigatuzumab appear to require 
cross-linking by Fc-receptors as present on myeloid effector cells.10-12 Further, rhTRAIL 
and conventional agonistic DR4/5 antibodies have no tumor-selective binding activity, 
since TRAIL receptors are ubiquitously expressed on normal tissue.13 Consequently, a 
massive target antigen sink formed by DR5 expressed on normal cells may hamper the 
efficacy of agonistic anti-DR5 antibodies.
To overcome these limitations, we engineered a recombinant bispecific antibody, desig-
nated MCSPxDR5, with high binding affinity for Melanoma-associated Chondroitin Sulfate 
Proteoglycan (MCSP) and potent agonistic activity towards DR5, complemented with a 
human IgG1 Fc domain. MCSP is highly overexpressed on the cell surface of over 90% of 
cutaneous and uveal melanomas and is a well-established target for melanoma immu-











cyte lineage.14-15 MCSPxDR5 was designed to selectively bind with high affinity to tumor 
cell surface-expressed MCSP and concomitantly trigger localized activation of apoptosis 
by DR5 cross-linking.
Material and Methods
Antibodies and reagents 
mAb 9.2.27, a high-affinity murine IgG2a antibody directed against an extracellular epi-
tope on MCSP was purchased from Abcam. Anti-DR5 antibody DJR2-4 was purchased 
from Enzo Life Sciences. Recombinant TRAILR2:Fc protein was from ALEXIS. Goat-an-
ti-human IgG (Southern Biotech); goat anti-human IgG-PE (Santa Cruz biotechnolo-
gy); mouse anti-human IgG-488 and mouse anti-human IgG-647 (ImmunoTools,) and 
FITC-conjugated goat anti-mouse (Invitrogen) were used for flow cytometry. BRAF inhib-
itor vemurafenib (APExBio) and caspase inhibitor zVAD-fmk (Calbiochem) were dissolved 
at 10 mM in DMSO. Histone deacetylase inhibitor valproic acid (VPA) (Sigma-Aldrich) was 
dissolved at 2.5 mM in DMSO. The proteasome inhibitor Bortozomib (Millennium Phar-
maceuticals) was dissolved at 10 mM in DMSO; Vybrant DiD cell-labeling reagent (Invi-
trogen); Easy-Titer Human (gamma chain) kit (Thermo Scientific), were used according 
to the manufacturer’s recommendations.
Cell lines 
Human cell lines A375M, MM-RU, SK-MEL-28 (MCSPpos cutaneous melanomas); DLD-
1, HCT 116 (colorectal adenocarcinomas) and Jurkat (T-ALL leukemia) were purchased 
from American Tissue Culture Collection (ATCC, Rockville, MD). Human MCSPpos uveal 
melanoma cell line OCM3 was kindly provided by Prof. G.P.M. Luyten, Department of 
Ophthalmology, LUMC, Leiden, Netherlands. The MCSPneg human melanoma parental cell 
line M14 and the MCSPpos transfectant cell line M14.MCSP were kindly provided by Prof. 
James McCarthy, University of Minnesota, Minneapolis, USA. Cell line HEK293.CD64 sta-
bly expressing human CD64 (high-affinity IgG Fc-receptor) was generated by transfect-
ing parental HEK293 cells with pCMV/hygroCD64 (Sino Biological Inc). HEK293.CD64 
cells were cultured in DMEM plus 10% dialyzed fetal calf serum (dFCS), supplemented 
with 500 μg/ml Hygromycin B (Life technologies). Human cells were cultured in either 
RPMI 1640 or DMEM culture medium with 10% FCS at 37°C in a humidified 5% CO2 at-
mosphere. Cells lines were authenticated by commercial Short Tandem Repeat analysis 
and routinely tested for mycoplasma infection.
Primary patient-derived melanoma cells and primary human hepatocytes (PHH) 
Tumor samples were collected during conventional surgical resection procedure after in-
formed consent. Tumor samples were minced and cultured in RPMI 1640 supplemented 
with 10% FCS and allowed to adhere to culture flasks. Non-adherent cells were discarded 
and phenotyping of remaining adherent cells was performed by flow cytometry using 
antibodies directed against CD14, DR5 and MCSP, respectively. Primary patient-derived 
melanoma cells used in this study were CD14 negative, DR5 and MCSP positive and were 
used before passage 4.
Cryopreserved human hepatocytes were purchased from Tebu-bio bv. Hepatocytes were 
cultured in a 48 well plate to a density of 2.5x104 cells per well before use. 
Isolation of white blood cells  and lymphocytes 
White blood cells (WBCs) were obtained from venous blood from healthy volunteers after 
informed written consent. Briefly, blood was diluted ten times in cold isotonic ammonium 
chloride lysis buffer and incubated at 4°C for 10-15 min until red blood cells had lysed. 
Leukocytes were harvested by centrifugation (1000g, 10 min), washed with PBS and 
re-suspended in RPMI 1640/10% FCS. 
Peripheral blood lymphocytes (PBLs) were obtained from venous blood of healthy vol-
unteers after informed written consent using standard density gradient centrifugation 
(Lymphoprep). 
Analysis of cell surface expression of DR5 and MCSP 
Cell surface expression levels of DR5 and MCSP were assessed by flow cytometry. In 
short, cells were harvested and washed with PBS and re-suspended at 1×105 cells in 200 
μl fresh culture medium containing anti-DR5 mAb (DJR2-4) or mAb 9.2.27 according to 
the manufacturer’s recommendations. Specific binding of these antibodies was detected 
using secondary conjugated antibodies (FITC-conjugated for DR5 staining and APC-con-
jugated for MCSP staining). All antibody incubations were carried out for 45 min at 0°C 
followed by 3 washes with PBS.
Construction of MCSPxDR5
Antibody fragment scFvMCSP was constructed using published VH and VL sequence data 
of mAb 9.2.27 by applying standard antibody engineering technologies. Similarly, scF-
vDR5 was constructed using published VH and VL sequence data of agonistic anti-DR5 
antibody tigatuzumab. For construction and production of MCSPxDR5 we used eukaryotic 
expression plasmid pEE14-bsAb, which is equipped with an enhanced CMV promoter to 
drive recombinant protein expression and an N-terminal leader peptide for excretion 
of MCSPxDR5 protein in the culture medium. The pEE14-bsAb contains 3 consecutive 
multiple cloning sites (MCS#1, MCS#2 and MCS#3, respectively). MCS#1 and MCS#2 
are interspersed by a 22 amino acid flexible linker derived from a CH1 domain. MCS#1 
was used for directional and in-frame insertion of the scFvDR5 encoding DNA fragment. 
MCS#2 was used for directional and in-frame insertion of the scFvMCSP encoding DNA 
fragment. MCS#3 of pEE14-bsAb was used for in-frame insertion of DNA fragments 
encoding either a human IgG1 or IgG4 domain. Of note, hinge regions and flexible 
spacers were inserted between the different antigen recognizing parts of the bispecific 
antibody (bsAb) to allow each part of the molecule to function independently. More-
over, the codon usage of the various protein encoding DNA sequences mentioned above 
were optimized for expression in human (HEK) and hamster (CHO) production cell lines 
and were ordered from a certified gene synthesis services (Genscript). This procedure 












Production of MCSPxDR5 in CHO cells 
Plasmids pEE14-MCSPxDR5-IgG1 and pEE14-MCSPxDR5-IgG4 were stably transfected in 
CHO production cells using the FuGene-HD reagent (Promega), after which clones with 
amplified recombinant protein production (10 μg/ml and 7 μg/ml for MCSPxDR5-IgG1 
and MCSPxDR5-IgG4, respectively) were selected by the glutamine synthetase selection 
method as described previously.16 
Concentrations of MCSPxDR5 and MCSPxDR5-IgG4 were determined using the Human 
Easy-Titer kit (Thermo Scientific) according the manufacturer’s recommendations. 
MCSP-selective binding of MCSPxDR5 
MCSP-selective binding of MCSPxDR5 was assessed by flow cytometry using CHO.MCSP 
cells and MCSP-negative parental CHO cells. In short, cells were incubated with MC-
SPxDR5 (1 µg/ml) in the presence or absence of an excess amount of the competing 
parental anti-MCSP antibody mAb 9.2.27 (10 µg/ml). Detection of cell surface-bound 
MCSPxDR5 was analyzed by flow cytometry using anti-human IgG1-PE. 
MCSP-directed induction of apoptosis by MCSPxDR5 
A panel of MCSPpos and MCSPneg tumor cell lines was treated with MCSPxDR5. Briefly, 
tumor cells were seeded in 48-well plates at a concentration of 2x104 cells/well and 
treated with MCSPxDR5 (1 µg/ml) overnight, after which apoptosis was assessed using 
Annexin-V staining according to manufacturer’s instructions (Immunotools). Briefly, cells 
were washed once with cold binding buffer (140 mmol/L NaCl, 2.5mmol/L CaCl2 and 10 
mmol/L HEPES, pH 7.4) and resuspended in binding buffer containing Annexin-V-FITC. 
After incubation for 10-15 min at 4°C, apoptosis was assessed by flow cytometry. Alter-
natively, tumor cells were treated with MCSPxDR5 (2.5 µg/ml) on ice for 40 min, after 
which unbound MCSPxDR5 was removed by washing twice with cold PBS. After overnight 
incubation, apoptosis was assessed using Annexin-V staining. Finally, where indicated, 
tumor cell lines were treated with MCSPxDR5 for 24-72h, after which cell viability was 
assessed using an MTS-based calorimetric assay (CellTiter 96 AQueous One Solution 
Cell Proliferation, Promega) at 490 nM using a Victor V3 multi-label plate counter (Per-
kin Elmer). Absorbance of maximum death  (treatment with 70% ethanol for 15 min) 
was subtracted from all values, after which cell viability was calculated as percentage of 
medium control.
To determine toxicity of MCSPxDR5 to normal cells, human hepatocytes, lymphocytes 
and HUVECs were treated with MCSPxDR5 (2.5 µg/ml) overnight, after which apoptosis 
was assessed using Annexin-V staining.
Assessment of synergy between MCSPxDR5 and clinical antitumor drugs
MCSPpos/DR5pos melanoma cell lines (A375M, MM-RU and OCM-3) were treated with MC-
SPxDR5 (0.25 μg/ml) in the presence or absence of proteasome inhibitor velcade (1 
nM), HDAC inhibitor VPA (2.5 μM) or BRAF-inhibitor vemurafenib (10 μM). After 18h, 
apoptosis was assessed using Annexin-V staining. Briefly, cells were washed once with 
cold binding buffer (140 mmol/L NaCl, 2.5mmol/L CaCl2 and 10 mmol/L HEPES, pH 7.4) 
and resuspended in binding buffer containing Annexin-V-FITC. After incubation for 10-15 
min at 4°C, apoptosis was assesed by flow cytometry. Synergy was determined using the 
cooperativity index (CI), in which the sum of apoptosis induced by single-agent treat-
ment is divided by apoptosis induced by combination-treatment. When CI<1, treatment 
was termed synergistic.
Colony forming assay 
In short, a single-cell suspension of tumor cells was prepared in 0.6% low gelling tem-
perature (LGT) agarose dissolved in pre-warmed complete medium (RPMI 1640 with 20 
% FCS). Tumor cells (1.0x104 cells per well) were placed in 24-well plates containing a 
bottom layer of solidified 4% LGT agarose in complete medium. Once the tumor cell-con-
taining agarose top layer had solidified, a final 0.5 ml of complete medium was added. In 
this assay, MCSPpos melanoma cells A375M, SK-MEL-28, MM-RU and HT1080 were treat-
ed with MCSPxDR5 (final concentration up to 250 ng/ml) for 14 days, after which colony 
formation was evaluated by light microscopy. In control experiments, identical treatment 
was performed in the presence of an excess amount of TRAIL-R2-Fc (5 µg/ml) or the 
pan-caspase inhibitor zVAD-fmk (10 μM). Colony forming assays were performed in 
quadruplicates. The number and size of colonies were quantified using image processing 
software (ImageJ). The percentage of colony formation was calculated according to the 
formula: percentage of colonies formed = (number of colonies in experimental condition) 
/ (number of colonies in medium control) x 100%. 
siRNA-mediated knockdown of DR5 expression
SK-MEL-28 cells were pre-seeded at a concentration of 1x105 cells/well in 12-wells plates, 
24h before treatment with either DR5-selective siRNA or scrambled siRNA according to 
manufacturer’s recommendations (DharmaFECT 2 transfection reagent (Thermo Scien-
tific)). siRNA knockdown DR5 protein expression was evaluated after 72h by flow cytom-
etry using anti-DR5 antibodies. Antibody incubations were carried out for 45 min at 0°C 
and were followed by 3 washes with PBS. Subsequently, DR5-silenced SK-MEL-28 cells 
were seeded and subjected to treatment as indicated. 
Assessment of  MCSPxDR5 antitumor activity upon cross-linking 
The following assays were used to assess whether MCSP-directed pro-apoptotic activi-
ty of MCSPxDR5 towards cancer cell lines and primary patient-derived melanoma cells 
could be further enhanced by secondary cross-linking of its IgG1 Fc domain. 
Artificial cross-linking: In short, cancer cells were seeded at 3x104/well in 96-well 
micro-culture plates and subsequently treated with increasing doses of MCSPxDR5 in the 
presence or absence of an Fc cross-linker (0.5 µg/ml of goat-anti-human IgG), hereafter 
indicated as CL. Apoptosis and cell viability were evaluated after 24h and 72h, respec-
tively. To investigate whether the observed apoptotic activity of MCSPxDR5 was depen-
dent on DR5 signaling, MM-RU cells (3x104/well) were co-treated with MCSPxDR5 and CL 
in the presence or absence of recombinant TRAILR2-Fc (5 µg/ml) or pan-caspase inhibi-











we used MCSPpos SK-MEL-28 melanoma cells in which DR5 expression was knocked-down 
using DR5-specific siRNA silencing technology as described previously.17 Subsequently, 
DR5-silenced SK-MEL-28 cells and wt SK-MEL28 cells were treated with MCSPxDR5 (1 
µg/ml) or anti-TRAILR2 monoclonal antibody HGT-ETR2 (1 µg/ml), after which apoptosis 
was assessed using Annexin-V staining.
Cell-based cross-linking: To mimic cell-based Fc cross-linking of MCSPxDR5, we used 
HEK293.CD64 cells ectopically expressing human CD64, also known as the high-affinity 
IgG receptor FcγRI. In short, DiD-labeled MM-RU cells were co-cultured with HEK293.
CD64 cells at a cellular ratio of 5:1 in the presence or absence of MCSPxDR5 (250 ng/
ml). After 24h, apoptosis in DiD-labeled MM-RU cells was evaluated. Analogously, vari-
ous effector cells (PBLs, leukocytes (WBCs) or NK cells) were used as natural cell-based 
Fc cross-linkers18 of MCSPxDR5. In short, DiD-labeled MM-RU target cells were treated 
with MCSPxDR5 in the presence of various ratios of myeloid effector cells (E:T cell ratios 
were 20:1, 5:1 and 20:1 for PBLs, WBCs and NK cells, respectively). To discriminate 
ADCC from DR5-cross-linking antitumor activity we used MCSPxDR5-IgG4, a human 
IgG4-isotype variant of MCSPxDR5 that has only marginal ADCC activity.19 
Statistical analysis 
The results reported in this study are mean values ± standard deviation of the mean of 
at least three independent experiments. Statistical analysis was performed by one-way 
ANOVA followed by Tukey-Kramer post-test or by two-sided unpaired Student’s t-test. 
p<0.05 was defined as a statistically significant difference.
Results
MCSPxDR5 has MCSP-directed pro-apoptotic activity
BsAb MCSPxDR5 (Fig. 1A) was designed to bind to MCSP on cancer cells and subse-
quently induce apoptosis in targeted cancer cells by local ligation of DR5. In line with 
this, flow cytometric analysis showed that MCSPxDR5 strongly bound to MCSPpos/DR5pos 
SK-MEL-28 melanoma cells (Fig. 1B), but not to MCSPneg/DR5pos DLD-1 carcinoma cells 
(Fig. 1C). Binding of MCSPxDR5 to SK-MEL-28 cells was blocked by co-incubation with 
excess amounts of epitope-competing anti-MCSP mAb 9.9.27 (Fig. 1B), indicating that 
MCSPxDR5 indeed selectively binds to cell surface-expressed MCSP. Correspondingly, 
treatment of tumor cells incubated with MCSPxDR5 for 40 min at 4°C, after which any 
unbound antibody was removed by washing, selectively induced apoptosis in a panel of 
MCSPpos/DR5pos melanoma cells, but not in MCSPneg/DR5pos HCT116 carcinoma cells (Fig. 
1D). Treatment in the continued presence of MCSPxDR5 (no washing) induced apopto-
sis in both MCSPpos/DR5pos and MCSPneg/DR5pos cancer cells (Fig. 1E), albeit in the latter 
cancer cells at much lower levels. Moreover, MCSPxDR5 treatment was associated with 
reduced tumor cell viability in MCSPpos/DR5pos MM-RU, SK-MEL-28 and OCM3 cells, but 
not in MCSPpos/DR5neg DLD-1 cells (Fig. 1F). 
MCSP-selective pro-apoptotic activity of MCSPxDR5 was also evaluated using primary 
patient-derived melanoma cells that expressed MCSP and DR5 (Fig. 1G). These primary 
tumor cells were sensitive to MCSPxDR5 treatment, with an >40% increase in apoptosis 
compared to medium control (Fig. 1H). Thus, MCSPxDR5 selectively binds to MCSP and 
has MCSP-directed pro-apoptotic activity towards MCSPpos/DR5pos cancer cell lines and 
primary patient-derived melanoma cells.
Figure 1: MCSP-directed apoptotic ac-
tivity of MCSPxDR5 toward melanoma 
cells. A) Schematic representation of 
bispecific antibody MCSPxDR5. B) Bind-
ing of MCSPxDR5 to SK-MEL-28 cells in 
the presence of absence of MCSP block-
ing antibody (10 µg/ml) was analyzed 
by flow cytometry. C) Binding of MC-
SPxDR5 to DLD-1 cells as in B in the 
presence or absence of MCSP blocking 
antibody (10 µg/ml) or DR5 blocking 
antibody (10 µg/ml). D) Cell lines were 
incubated with MCSPxDR5 (2.5 µg/ml) 














































































































































































with excess cold phosphate buffered saline. Subsequently, cells were incubated for 18h at 37°C, after 
which apoptosis was measured by flow cytometry using Annexin-V/PI staining. E) Both MCSPpos and 
MCSPneg cancer cells were treated with or without MCSPxDR5 (1 µg/ml) for 18h, after which apoptosis 
was assessed using Annexin-V staining F) Cells were treated as in E for 72h, after which cell viability 
was determined by MTS. G) Representative histogram of MCSP and DR5 expression of a primary 
patient-derived melanoma cells. H) Patient-derived melanoma cells were treated with MCSPxDR5 (1 
µg/ml) or left untreated for 24h, after which apoptosis was analyzed by flow cytometry with Annex-
in-V staining. Statistical analysis was performed using two-sided unpaired Student t test (D-F) or the 











MCSPxDR5 inhibits of colony formation of MCSPpos/DR5pos cancer cells 
Next, the effect of MCSPxDR5 on anchorage–independent growth of MCSPpos melanoma 
was evaluated using a soft agar colony forming assay. Treatment with MCSPxDR5 for 14 
days led to a significant reduction in colony number in MCSPpos melanoma cell lines (Fig. 
2A). Further, as illustrated for A375M, residual colonies after MCSPxDR5 treatment were 
reduced in size by >90% (Fig. 2B). This MCSPxDR5-mediated effect was completely 
blocked by either co-treatment with recombinant anti-TRAILR2-Fc or by pan-caspase 
inhibitor zVADfmk, indicating that the inhibitory effect of MCSPXDR5 on colony formation 
is caspase-mediated and dependent on DR5 (Fig. 2C). Of note, MCSPxDR5 also reduced 
colony number of MCSPpos/DR5pos HT1080 sarcoma cells by ~90%, whereas control 
non-targeted anti-DR5 antibody HGS-ETR2 only reduced colony number by ~50% (Fig. 
2D). Taken together, MCSPxDR5 selectively inhibits colony forming capacity of MCSPpos/
DR5pos cancer cells.
Efficacy of MCSPxDR5 is enhanced by cross-linking of its Fc domain 
MCSPxDR5 was designed to trigger apoptosis through MCSP-directed cross-linking of 
DR5. Since the antitumor activity of tigatuzumab appears to requires cross-linking of 
its IgG1 Fc domain through binding to FcγRs on immune effector cells.10,12 Therefore, 
cross-linking of tumor cell-bound MCSPxDR5 via its IgG domain may further augment its 
pro-apoptotic activity. 
To investigate this in more detail, we exploited MCSPneg/DR5pos Jurkat cells as indicator 
cells for effective DR5 cross-linking. Treatment of Jurkat cells with MCSPxDR5 alone did 
not induce apoptosis. However, in the presence of a human IgG cross-linking reagent, 
MCSPxDR5 strongly induced apoptosis in Jurkat cell up to almost 100%, with apoptotic 
activity of MCSPxDR5 already apparent at doses as low as 5 ng/ml (Fig. 3A). Similarly, 
secondary cross-linking of MCSPxDR5 enhanced its pro-apoptotic antitumor activity in 
a panel of MCSPpos/DR5pos melanoma cell lines (Fig. 3B and 3C). Furthermore, second-
ary cross-linking of MCSPxDR5 also increased the level of apoptosis induced in primary 
patient-derived melanoma cells, with a mean increase in apoptosis from 48% to 70% 
(Fig. 3D). Although the apoptotic activity of MCSPxDR5 was enhanced by cross-linking, 
its activity was still abrogated by co-treatment with recombinant DR5-Fc or pan-caspase 
inhibitor zVADfmk (Fig. 3E). Moreover, siRNA-mediated DR5 silencing in A375M cells 
significantly decreased DR5 expression (Fig. 3F) and strongly reduced the apoptotic 
activity of both MCSPxDR5 and the DR5-agonistic antibody HGS-ETR2 (Fig. 3G). Thus, 
Fc-mediated cross-linking augments the pro-apoptotic antitumor activity of MCSPxDR5 
through enhanced DR5 signaling. 
Efficacy of MCSPXDR5 is augmented by FcR-mediated cross-linking
Next, the effect of Fc cross-linking of MCSPxDR5 by surface expressed Fc receptors was 
evaluated using HEK293.CD64 cells ectopically expressing the high-affinity Fc receptor 
CD64. HEK293 cells are resistant to TRAIL receptor-mediated apoptosis and lack intrinsic 
cytolytic activity (data not shown). Treatment of mixed cultures of MM-RU target cells 
and parental HEK293 cells with an increasing dose of MCSPxDR5 only induced apopto-
sis in ~30% of MM-RU cells. However, in mixed cultures of MM-RU with HEK293.CD64, 
MCSPxDR5 treatment resulted in >70% apoptosis (Fig. 4A). To further confirm this cel-
lular FcR-mediated cross-linking effect and exclude contributions of antibody-dependent 
cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) to MC-
SPxDR5 activity, experiments were performed with isotype variant MCSPXDR5-IgG4, 
containing the human IgG4 Fc domain that is known to be largely devoid of ADCC and 
CDC activity.19 Treatment of MM-RU/HEK293.CD64 mixed cultures with MCSPxDR5-IgG4 
induced up to 60% apoptosis, similar to MCSPxDR5-IgG1 treatment (Fig. 4B). 
Importantly, Fc receptor cross-linking also induced MCSP-independent DR5-mediated 
activation in MCSPneg/DR5pos M14 melanoma cells (Fig. 4C). However, Fc receptor-medi-
ated cross-linking on MCSPpos cells was abrogated when treatment was performed in the 
presence of MCSP-competing mAb 9.9.27 (Fig. 4D). In mixed culture experiments with 
freshly isolated PBLs, MCSPxDR5 dose-dependently reduced the viability of MM-RU cells 
to down to ~40% (Fig. 4E). Moreover, treatment with an increasing dose of MCSPxDR5 
reduced MM-RU cell viability down to ~20% in the presence of leukocytes (Fig. 4F). 
Similarly, MCSPxDR5 significantly enhanced NK cell-mediated killing of MCSPpos/DR5pos 
A375M cells, but not of MCSPneg/DR5pos DLD1 cells (Fig. 4G). Thus, the MCSP-direct-
ed pro-apoptotic activity of MCSPxDR5 is further augmented by FcR-mediated cellular 
cross-linking and is able to induce ADCC through interaction with Fc receptor-expressing 
immune effector cells.
medium MCSPxDR5


























































































































Figure 2: MCSPxDR5 inhibits colony formation of melanoma cells. 
A) MCSPpos/DR5pos cell lines were treated with MCSPxDR5 (250 ng/
ml) or left untreated in colony-forming assays for 14 days, after 
which  the number of colonies was determined by counting three 
fields of view per condition. Number of colonies was represented as 
percentage of colonies compared to medium control. B) Representa-
tive light microscopic images of colony size of A375M cells in medium 
control versus MCSPxDR5-treated conditions in colony-forming assay 
and dose-response curve of colony size upon MCSPxDR5 treatment. 
C) MCSPpos/DR5pos A375M cells were treated with MCSPxDR5 (50 ng/
ml) in the presence or absence of pan-caspase inhibitor zVADfmk (5 
µM) or recombinant TRAILR2-Fc (5 µg/ml) for 14 days, after which 
the number of colonies was determined. D) MCSPpos/DR5pos HT1080 
cells were treated with MCSPxDR5, MCSP:sTRAIL or HSG-ETR2 (250 
ng/ml) or left untreated in colony-forming agar assays for 14 days, 
after which  the number of colonies was determined. Statistical anal-
ysis was performed using two-sided unpaired Student t test. *P < 












Figure 3: Cross-linking of its Fc domain enhances antitumor activity of MCSPxDR5. A) MCSPneg/
DR5pos Jurkat cells were treated with MCSPxDR5 in the presence or absence of goat-anti-human 
IgG (cross-linker [CL]; 0.5 mg/ml). Apoptosis was measured after 18h by flow cytometry using 
Annexin-V. B) MCSPneg/DR5pos melanoma cell lines were treated with MCSPxDR5 (250 ng/ml) in the 
presence or absence of CL for 18h, after which apoptosis was measured by flow cytometry using 
Annexin-V. C) MCSPneg/DR5pos melanoma MM-RU cells were treated with an increasing dose of MCSPx-
DR5 in the presence or absence of CL for 72h, after which cell viability was determined by MTS assay. 
D) Primary patient-derived melanoma cells were co-treated with MCSPxDR5 (0.25 mg/ml) and CL. 
Apoptosis was measured after 18h. E) MM-RU cells were treated with MCSPxDR5 in the presence or 
absence of pan-caspase inhibitor (zVAD-fmk, 5 µM) or recombinant human DR5:Fc (5 µg/ml) for 18h, 
after which apoptosis was evaluated by flow cytometry using Annexin-V/PI staining. F) RNA silencing 
was used to selectively knock down DR5 expression in SK-MEL-28 cells, which was confirmed by flow 
cytometry using an anti-DR5 mAb. G) SK-MEL-28 cells were treated with either CL alone, MCSPxDR5 
plus CL, or DR5 agonistic antibody HGS-ETR2 for 18h, after which apoptosis was evaluated by flow 
cytometry using Annexin V/PI staining.
Figure 4: FcR-mediated cross-linking augments MCSPxDR5 effi-
cacy. A) Pre-seeded MM-RU cells were co-cultured with parental 
HEK293 cells or HEK293.CD64 cells and treated with an increasing 
dose of MCSPxDR5. Apoptosis in MM-RU cells was assessed by 
flow cytometry using Annexin-V/PI. B) Pre-seeded MM-RU cells 
were co-cultured with parental HEK293 cells or HEk293.CD64 cells 
and subsequently treated with either medium only, MCSPxDR5 (50 
ng/ml), or its IgG4 isotype variant MCSPxDR5-4 for 24h. Apopto-
sis in melanoma cells was assessed by flow cytometry using An-
nexin-V/PI. C) Pre-seeded M14 cells (MCSPneg/DR5pos) were co-cultured with parental HEK293 cells 
or HEK293.CD64 cells and subsequently treated with either medium only or MCSPxDR5 (50 ng/ml). 
Apoptosis in melanoma cells was assessed by flow cytometry using Annexin-V/PI. D) (DiD)-labeled 
A375M cells were treated with either culture medium or MCSPxDR5 (1.5 µg/ml) in the presence or 
absence of anti-MCSP mAb 9.9.27. Unbound antibodies were removed by repeated washing steps. 
Subsequently, parental HEK293 cells or HEK293.CD64 cells were added, after which apoptosis was 
assessed in DID-labeled cells by flow cytometry using Annexin V/PI staining. E) Peripheral blood 
lymphocytes (E) were added to pre-seeded MM-RU target cells (T) at an E:T ratio of 20:1 and treated 
with an increasing dose of MCSPxDR5 for 48h. Subsequently, the non-adherent immune cells were 
carefully removed, and the cell viability of MM-RU cells was assessed by MTS assay. F) As in E, WBCs 
(E) were added to pre-seeded MM-RU cells (T) at an E:T ratio of 5:1. G) Pre-seeded MM-RU cells (T) 
were co-cultured with NK cells of healthy donors (E) at E:T ratio of 20:1 in the presence or absence 
of MCSPxDR5 (250 ng/ml) for 6h after which cell viability of MM-RU cells was assessed by MTS assay. 
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MCSPxDR5 shows no or limited toxicity toward normal cells
Treatment of DR5-expressing normal primary human hepatocytes and immortal human 
hepatocytes (IHH) with MCSPxDR5 induced no or minimal apoptosis (Fig. 5A). Moreover, 
treatment of HUVECs and normal lymphocytes with MCSPxDR5 (2.5 µg/ml) did not in-
duce apoptosis (Fig. 5B). This indicates that MCSPxDR5 has selective tumoricidal activity 
with no or only limited toxicity towards normal cells. This is in line with a previous phase 
I clinical study that showed that tigatuzumab was well-tolerated with dose-limiting tox-
icity (DLT) reached and no drug-related grade 3 or 4 hepatic or hematological toxicity 
observed.20 
Anticancer drugs synergize with anticancer activity of MCSPxDR5 
Melanoma-relevant drugs (bortezomib, valproic acid and vemurafenib) were evaluated 
for their ability to synergize the antitumor activity of MCSPxDR5. Co-treatment of MC-
SPpos/DR5pos melanoma cells with MCSPxDR5 and proteasome inhibitor velcade triggered 
synergistic induction of apoptosis in A375M cells and MM-RU cells but not in OCM-3 cells 
(Fig. 6A). MCSPxDR5-mediated apoptosis showed strong synergy with HDAC inhibitor 
VPA in A375M cells, as apoptosis increased up to 60% compared to 20% for single treat-
ment with either MCSPxDR5 or VPA alone. A synergistic treatment effect with VPA was 
also observed in MM-RU and SK-MEL-28 cells (Fig. 6B). Interestingly, we found that ve-
murafenib not only enhanced MCSPxDR5-mediated apoptosis in V600-mutant cell lines 
OCM-3 and SK-MEL-28, but also induced apoptosis up to 60% in V600-wt melanoma cell 
line MM-RU compared to single treatment with MCSPxDR5 (Fig. 6C). 
Discussion
Recombinant TRAIL formulations (e.g. dulanermin) and agonistic anti-DR4/5 antibodies 
(e.g. conatumumab and tigatuzumab) have been extensively evaluated in pre-clinical 
models and in a number of clinical studies.6-7,21 Results from early-stage clinical studies 
indicated that both recombinant TRAIL and agonistic anti-DR antibodies are well toler-
ated in patients with various cancers. However, the therapeutic efficacy of current DR 
agonists is rather disappointing. This appears to be related to the fact that these agonists 
indiscriminately interact with DRs that are broadly present on normal cells,13,20,22 thereby 
precluding sufficient accumulation of such agonists in malignant lesions. Moreover, cur-
rent DR agonists have limited capacity to activate pro-apoptotic DR5 signaling in cancer 
cells in the absence of secondary cross-linking.12
To overcome these limitations, we developed a novel bispecific antibody-based approach 
that promotes melanoma-directed pro-apoptotic activation of DR5. Hereto, we engi-
neered bispecific antibody MCSPxDR5 that combines high binding affinity for the mela-
noma-associated antigen MCSP with potent agonistic activity towards DR5. The mode-
of-action of MCSPxDR5 involves high-affinity binding to tumor cell surface-expressed 
MCSP with concomitant localized enhanced cross-linking of DR5. The antitumor activity 
of tumor-bound MCSPxDR5 was further enhanced by secondary cross-linking of its hu-
man IgG Fc domain by either an artificial cross-linker or by Fc receptors on myeloid 
immune effector cells. Moreover, various melanoma-relevant drugs (bortezomib, valproic 
acid and vemurafenib) synergistically enhanced the antitumor activity of MCSPxDR5. Im-
portantly, MCSPxDR5 potently induced apoptosis in primary patient-derived melanoma 
cells, which was further enhanced after secondary cross-linking of its IgG1 Fc domain.
The anti-DR5 antibody fragment we used in bsAb MCSPxDR5 is derived from the agonis-
tic DR5 antibody tigatuzumab. The in vivo therapeutic activity of tigatuzumab appears 
to fully rely on cross-linking of its Fc domain that may occur after binding to FcγRs as 
expressed on myeloid effector cells.10-12 In contrast, selective binding of MCSPxDR5 to 
MCSP already triggered effective activation of membrane DR5 in melanoma cells, in-
dicating that on MCSPpos target cells MCSPxDR5 can at least partially circumvent the 
need for FcR-mediated cross-linking. Importantly, the antitumor activity of MCSPxDR5 
could be further enhanced by FcR-expressing immune effector cells, via FcR-mediated 
cross-linking as well as by induction of ADCC. 
Figure 5: MCSPxDR5 has limited toxicity towards normal cells. A) Binding of MCSPxDR5 to primary 
human hepatocytes and immortal human hepatocytes (IHH) was assessed by flow cytometry. B) 
Normal human cells were treated with MCSPxDR5 (1 µg/ml) for 18h, after which apoptosis was de-










































Figure 6: MCSPxDR5 shows synergy with anticancer drugs A) Pre-seeded melanoma cells were 
co-treated with MCSPxDR5 (0.25 µg/ml) and velcade (2.5 µM) for 24h. B) Pre-seeded melanoma 
cells were co-treated with MCSPxDR5 (0.25 µg/ml) and VPA (2 µM) for 24h. C) Pre-seeded melanoma 
cells were co-treated with MCSPxDR5 (1 µg/ml) and vemurafenib (10 µM) for 24h. In A-C, apoptosis 





















































































Recently, a similar DR5-targeted bispecific antibody, RG7386, targeting the fibroblast-as-
sociated protein (FAP) on cancer-associated fibroblasts was described.23 RG7386 induced 
apoptosis in FAP-positive cells and, when combined with irinotecan or doxorubicin, in-
duced tumor regression in patient-derived xenograft models.23 Our in vitro data largely 
corroborates these observations, indicating a common mode-of-action for RG7386 and 
MCSPxDR5.
MCSP is expressed in 90% of melanoma lesions15 and other malignancies, e.g. sarcomas 
and gliomas.24-25. MCSP overexpression plays a significant role in melanoma progres-
sion by influencing tumor cell adhesion/spreading, migration, invasion, and metastasis. 
It has been reported that binding of mAb 9.2.27 to MCSP already in its own right can 
partially inhibit various oncogenic features of MCSP expression.26 Indeed, we previously 
reported on a MCSP-targeting TRAIL fusion protein that not only induced MCSP-directed 
TRAIL-mediated apoptosis in melanoma cells, but also inhibited MCSP-mediated tum-
origenic signaling.27 The MCSP-directed antibody fragment used in bsAb MCSPxDR5 is 
derived from mAb 9.2.27. Although not formally studied here, it is tentative to speculate 
that bsAb MCSPxDR5 may have retained the potential to (partially) inhibited MCSP-tu-
morigenic signaling that may add to or even synergize with its pro-apoptotic anticancer 
activity. 
Co-treatment of agonistic anti-DR5 antibodies or soluble TRAIL with various chemother-
apeutics or (experimental) small inhibitory molecules has been evaluated in order to 
mutually augment their antitumor activities towards various forms of cancer, including 
carcinoma, breast cancer, lung cancer and metastatic melanoma.21,28-30 Here, we found 
that co-treatment of HDAC inhibitor VPA synergistically enhanced the pro-apoptotic an-
ticancer activity of MCSP in MCSPpos/DR5pos melanoma cells. This synergy is likely attrib-
utable to the fact that HDAC inhibitors are known to down-regulate c-FLIP and thereby 
increase sensitivity to treatment of DR5-based agonists.31 Interestingly, we found that 
BRAFV600E inhibitor vemurafenib enhanced MCSPxDR5-induced apoptosis in both wild-
type and V600E-mutant melanoma cells. This non-specific synergy with vemurafenib and 
TRAIL was also published by others32 but the underlying mechanism remains unclear. 
Our current data indicates that MCSPxDR5 has potent MCSP-directed pro-apoptotic ac-
tivity towards MCSPpos/DR5pos melanoma cells with essentially no or minimal toxicity to-
wards various normal cells. However, more in-depth in vivo studies are needed to es-
tablish whether this will ultimately also translate in a safe toxicity profile when applied 
in melanoma patients.
Taken together, we present a novel bispecific antibody-based approach that promotes 
melanoma-directed pro-apoptotic activation of DR5. This novel approach may be of value 
for the targeted treatment of melanoma and other MCSP-expressing malignancies. 
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Antibodies that block PD-L1/PD-1 immune checkpoints restore the activity of function-
ally-impaired antitumor T cells. These antibodies show unprecedented clinical benefit in 
various advanced cancers, particularly in melanoma. However, only a subset of cancer 
patients responds to current PD-L1/PD-1-blocking strategies, highlighting the need for 
further advancements in PD-L1/PD-1-based immunotherapy. Here, we report on a nov-
el approach designed to combine PD-L1 checkpoint inhibition with the tumor-selective 
induction of apoptosis by TNF-related Apoptosis Inducing Ligand (TRAIL). In brief, a 
new bi-functional fusion protein, designated anti-PD-L1:TRAIL, was constructed com-
prising a PD-L1 blocking antibody fragment genetically fused to the extracellular domain 
of the pro-apoptotic tumoricidal protein TRAIL. Treatment of PD-L1-expressing cancer 
cells with anti-PD-L1:TRAIL induced PD-L1-directed TRAIL-mediated cancer cell death. 
Treatment of T cells with anti-PD-L1:TRAIL augmented T cell activation, as evidenced 
by increased proliferation, secretion of IFN-γ and enhanced killing of cancer cell lines 
and primary patient-derived cancer cells in mixed T cell/cancer cell culture experiments. 
Of note, elevated levels of IFN-γ further up-regulated PD-L1 on cancer cells and si-
multaneously sensitized cancer cells to TRAIL-mediated apoptosis by anti-PD-L1:TRAIL. 
Additionally, anti-PD-L1:TRAIL converted immunosuppressive PD-L1-expressing myeloid 
cells into pro-apoptotic effector cells that triggered TRAIL-mediated cancer cell death. 
In conclusion, combining PD-L1 checkpoint inhibition with TRAIL-mediated induction of 
apoptosis using anti-PD-L1:TRAIL yields promising multi-fold and mutually reinforcing 
anticancer activity that may be exploited to enhance the efficacy of therapeutic PD-L1/
PD-1 checkpoint inhibition.
Introduction
Programmed Death Ligand 1 (PD-L1) and its cognate receptor PD-1 represent an im-
mune checkpoint of great interest for cancer immunotherapy. Antibodies that block PD-
L1/PD-1 interaction restore the anticancer activity of functionally impaired tumor infil-
trating lymphocytes (TILs), specifically cytotoxic T cells. Treatment with these antibodies 
has transformed the landscape of cancer immunotherapy, yielding long-term remission 
and cure in a subset of advanced stage melanoma patients.1, 2
The PD-L1/PD-1 immune checkpoint normally ensures timely shut-down of immune re-
sponses to prevent collateral damage or autoimmunity (reviewed in 3). In brief, PD-L1 
expression is upregulated on antigen-presenting cells during inflammation by locally pro-
duced IFN-γ and is expressed by myeloid suppressor cells.4-6 Simultaneously, expression 
of PD-1 increases on activated T cells7, which upon interaction with PD-L1 dampens the 
cytolytic activity of T cells4. Interestingly, activated T cells not only express PD-1, but 
upon activation also upregulate PD-L1.8, 9 Antibody-mediated cross-linking of PD-L1 on 
T cells triggers co-stimulatory signaling and ultimately leads to induction of apoptosis10, 
indicative of an immunoregulatory role for PD-L1 on T cells. 
Various cancer types upregulate PD-L1 expression either constitutively via oncogenic 
signaling pathways or in response to IFN-γ produced in the tumor environment.11, 12 
Consequently, antitumor T cells are inhibited via PD-L1/PD-1 interaction, which allows 
cancer cells to evade the immune system even in highly immunogenic malignancies such 
as melanoma.12, 13 Hence, the expression of PD-L1 on cancer cells often correlates with 
unfavorable prognosis.14, 15 Although PD-1 and PD-L1-blocking antibodies have triggered 
breakthrough curative anticancer immunity, most notably in advanced melanoma,1, 2 the 
benefit of these antibodies is still restricted to a minority of cancer patients. 
To expand the clinical effects of immune checkpoint therapy, various combinatorial ap-
proaches have been attempted in order to identify opportunities for synergistic activi-
ty. For instance, treatment with PD-1-blocking antibody nivolumab was combined with 
CTLA-4 antibody ipilimumab, which significantly enhanced response rates in melanoma 
patients.16 Similarly, combination of PD-1/PD-L1 blockade with induction of cytotoxic 
cancer cell death by radiotherapy proved more effective and enhanced activation of an-
ticancer immunity.17, 18 These selected examples highlight that more efficacious PD-L1/
PD-1 targeted therapy can be achieved by rational design of combinatorial therapeutic 
approaches.
In this respect, we and others have previously reported on a class of bi-functional fusion 
proteins that comprise an scFv antibody fragment genetically fused to the tumoricid-
al protein tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) (re-
viewed in 19). TRAIL is a homotrimeric death-inducing ligand of the TNF superfamily 
with well-documented tumor-selective pro-apoptotic activity that has been proven safe 
in clinical trials (reviewed in 20). Antibody fragment-mediated delivery of soluble TRAIL 
optimizes its target cell-selective accretion and, moreover, triggers enhanced TRAIL-re-
ceptor mediated apoptosis in targeted cancer cells.21, 22 Importantly, use of an scFv anti-











tional tumoricidal activity, e.g. by inhibition of EGFR-mitogenic signaling23 or by blocking 
tumor-expressed CD47 and thereby augmenting neutrophil-mediated phagocytosis of 
cancer cells24. Furthermore, scFv-mediated display of TRAIL on the surface of T cells or 
granulocytes augments the cytolytic activity of these immune effector cells.25, 26
Based on this bi-functional TRAIL-based fusion protein format, we constructed and 
pre-clinically evaluated an anti-PD-L1:TRAIL fusion protein comprised of a PD-L1 block-
ing antibody fragment genetically fused to human soluble TRAIL. This anti-PD-L1:TRAIL 
fusion protein was designed to combine PD-L1 checkpoint inhibition with simultaneous 
TRAIL-mediated activation of cancer cell death.
Materials & methods 
Antibodies, Reagents, Inhibitors
The following antibodies were used in this study; anti-CD279-PE (PD-1, clone MIH4, 
eBioscience), anti-CD274-APC (PD-L1, clone 29E.2A3, BioLegend), anti-CD83-PE (clone 
HB15e, eBioscience), anti-CD206-PE (clone 19.2, eBioscience), anti-CD3-PerCP-Cy-
anine5.5 (clone OKT-3, eBioscience), anti-TRAIL/TNFSF10-PE (clone 75402, R&D sys-
tems), NG2-FITC (anti-MCSP, clone LHM2, Santa Cruz Biotechnology), polyclonal Goat-
anti-Human-PE (SouthernBiotech), Goat-anti-Mouse IgG (H+L) Secondary Antibody 
(Alexa Fluor 488 conjugate, Thermo Scientific) and anti-CD4-APC (clone MEM-241), 
anti-CD8-FITC (clone HIT8a), anti-CD56-PE (clone B-A19), anti-CD14-FITC (clone MEM-
15), anti-CD11b-FITC (clone MEM-174), anti-HLA-DR-PE (clone MEM-12), anti-CD86-
FITC (clone BU63), Mouse IgG2b-APC, Annexin-V-FITC (all Immunotools). Recombi-
nant human IFN-γ, GM-CSF, M-CSF, IL-4, IL-10, TGF-β1, anti-CD3 (clone UCHT-1) and 
anti-IFN-γ (clone B27) were purchased from ImmunoTools. LPS (Lipopolysaccharides 
from E. coli 0111:B4) was purchased from Sigma-Aldrich. Recombinant human PD-1:Fc 
was purchased from R&D systems. Pan-caspase inhibitor z-VAD-fmk, TRAILR1 (clone 
DJR1) and TRAILR2 (clone DJR2-4) antibodies were purchased from Enzo Life Sciences. 
TRAIL-neutralizing mAb 2E5 was purchased from Life Technologies. Recombinant CMV 
protein pp65 was purchased from Miltenyi Biotec. A PD-L1 neutralizing murine antibody 
was purchased from BPS Bioscience. 
Cell Lines 
DLD-1, HCT-116, SK-MEL-28, A2058 and CHO-K1, NCI-H1975, ES-2, MDA-MB-231 were 
obtained from the American Type Culture Collection (ATCC). TRAIL-resistant cell line 
HCT-116.cFLIPs was kindly provided by Prof. dr. Harald Wajant (University of Würzburg, 
Würzburg, Germany). All cell lines were cultured in RPMI-1640 or DMEM (Lonza) sup-
plemented with 10% fetal calf serum (FCS, Thermo Scientific). DLD-1.PD-L1 cells were 
generated by transfection of parental DLD-1 cells with eukaryotic expression plasmid pC-
MV6-PD-L1 using Fugene-HD (Promega). Stable transfectants were generated using Hy-
gromycin B selection (Life technologies). All cells were cultured at 37°C, in a humidified 
5% CO2 atmosphere. Cell numbers were quantified using a cell counter (Sysmex). For 
experiments, tumor cells were cultured in 48-wells plates at a density of 2x104 cells/well. 
For up-regulation of PD-L1, cells were pre-treated for 24 hours with 20 ng/ml IFN-γ. 
PD-L1 expression was analyzed with an Accuri C6 flow cytometer (BD Biosciences) using 
PD-L1-APC antibody or appropriate isotype control. Relative PD-L1 expression levels 
are listed in Supplementary Table 1. TRAIL receptor expression was determined by flow 
cytometry using TRAILR1 and TRAILR2 antibodies with secondary Goat-anti-Mouse-488 
conjugate staining. Relative TRAIL receptor expression levels are listed in Supplemen-
tary Table 2.
Primary patient-derived melanoma cells and Tumor Infiltrating Lymphocytes
Fresh melanoma and appendix carcinoma tissue was collected during surgical resection 
after informed consent (local approval nr. METc2012/330). Tissue was minced and cul-
tured in RPMI 1640 with 10% FCS. Adherent cell phenotype was analyzed by flow cytom-
etry using fluorescently labeled CD14, PD-L1 and MCSP antibodies. Primary patient-de-
rived melanoma cells used in this study were CD14-negative and MCSP-positive and 
were used before passage 4. For generation of Tumor Infiltrating Lymphocytes (TILs), 
minced tissue fragments were cultured in RPMI 1640 with 10% FCS supplemented with 
50 IU/ml IL-2 (Proleukin, Novartis). TIL phenotype was analyzed by flow cytometry for 
CD3, CD4, CD8 and CD56.
Production of TRAIL fusion proteins
Anti-PD-L1:TRAIL was constructed by insertion of an anti-PD-L1 mAb 3G10-derived 
scFv into Sfi1 and Not1 restriction sites into the previously described plasmid pEE14-
scFv:TRAIL.27 Briefly, CHO-K1 cells were transfected with eukaryotic expression plasmid 
pEE14scFv:sTRAIL using the Fugene-HD reagent (Promega) and stable transfectants 
were generated by the glutamine synthetase selection method. Stable transfectants 
were cultured at 37°C in serum-free CHO-S SFM II suspension medium (Gibco, Life 
Technologies) for up to 7 days after which supernatant was harvested (1,500g, 10 min) 
and stored at −20°C until further use. Fusion protein concentration in culture superna-
tant was determined by TRAIL ELISA (Abcam). Anti-EpCAM:TRAIL and anti-MCSP:TRAIL 
were described before.22, 27
PD-L1 specific binding of anti-PD-L1:TRAIL
Tumor cells were incubated with anti-PD-L1:TRAIL (1 µg/ml) for 1 hour at 4˚C, washed 
twice with PBS (1000g, 5 min), stained with anti-TRAIL-PE for 30 minutes at 4˚C, washed 
twice with PBS, and analyzed for binding by flow cytometry. Where indicated tumor cells 
were pre-incubated with excess (10 µg/ml) PD-L1 blocking mAb. 
PD-1/PD-L1 blocking by anti-PD-L1:TRAIL  
DLD-1 and DLD-1.PD-L1 cells were pre-incubated with indicated concentrations of anti-
PD-L1:TRAIL for 1 hour at 0ºC, after which cells were washed twice (1000g, 5 min) and 
incubated with 4 μg/ml PD-1:Fc for 1 hour at 0ºC. Subsequently, cells were washed twice 
(1000g, 5 min) and stained with Goat-anti-Human-PE for 30 min at 0˚C and washed 












Tumor cells were treated with anti-PD-L1:TRAIL or anti-EpCAM:TRAIL and, where indi-
cated, in the presence of PD-L1 blocking mAb (10 µg/ml), pan-caspase inhibitor z-VAD-
FMK (10 µM) or TRAIL-neutralizing mAb 2E5 (1 µg/ml). After 18 hours, apoptosis was 
assessed by flow cytometry using Annexin-V staining according to manufacturer’s pro-
tocol (Immunotools). Where indicated, cells were co-treated with 1 μg/ml cycloheximide 
(CHX, Sigma-Aldrich).
Spheroid assay
DLD-1, DLD-1.PD-L1 or NCI-H1975 cells (1-5x103 cells/well) were seeded in low adher-
ence 96-well plates (Costar) in DMEM supplemented with MITO+ Serum Extender (Corn-
ing). Cells were treated with anti-PD-L1:TRAIL, anti-EpCAM:TRAIL or anti-MCSP:TRAIL 
as indicated. After 72 hours, cell viability was determined using MTS (CellTiter 96 AQue-
ous One Solution Cell Proliferation, Promega) at 490 nM using a Victor V3 multi-label 
plate counter (Perkin Elmer). Absorbance of the maximum death control (treatment with 
70% ethanol for 15 min) was subtracted from all values, after which cell viability was 
calculated as percentage of medium control. Light microscopy images were acquired at 
10x magnification using the EVOS XL core cell imaging system (Life Technologies) and 
colony number was counted manually in three separate fields-of-view per condition in 
triplicates. Pre-formed spheroids of DLD-1 and DLD-1.PD-L1 cells were generated by 96 
hours culture in low adherence flasks (Costar), after which spheroids were transferred to 
low adherence plates for experiments.
PBMC stimulation assays
Peripheral blood mononuclear cells (PBMCs) were obtained from venous blood of healthy 
volunteers after informed written consent using standard density gradient centrifugation 
(Lymphoprep). PBMCs (1.25x105/well) were cultured in a 48-well plate in the presence of 
0.5 μg/ml agonistic CD3 mAb (UCHT-1) and indicated concentrations anti-PD-L1:TRAIL, 
anti-EpCAM:TRAIL or PD-L1 mAb. After 72 hours, total cell number was quantified using 
an automated cell counter (Sysmex) and culture supernatants were stored at -20°C. 
IFN-γ levels in culture supernatant were determined by IFN-γ ELISA (eBioscience). 
Where indicated, freshly isolated PBMCs were labeled with carboxyfluorescein succinim-
idyl ester (CFSE) (CellTrace CFSE Cell Proliferation Kit, Invitrogen), and after 72 hours of 
respective treatment the cell proliferation was analyzed by flow cytometry within the live 
PBMCs (defined by FSC/SSC gating).
For CMV specific responses, freshly isolated PBMCs from CMV negative and positive do-
nors were cultured in 96-well plates (1.5x105/well) in the presence of CMV pp65 accord-
ing to manufacturer’s instructions (Miltenyi Biotec). After 96 hours, culture supernatants 
were stored at -20°C and secreted IFN-γ was determined by IFN-γ ELISA. 
Antitumor reactivity assay
Tumor cells were labeled with DiD (Vybrant Cell-Labeling Solution, LifeTechnologies). 
Subsequently, 2x104 tumor cells were co-cultured with freshly isolated PBMCs or CD3+ 
T cells (98% purity, using the human Pan T Cell Isolation Kit (Miltenyi Biotec)) in the 
presence of 0.5 μg/ml agonistic CD3 mAb (UCHT-1) or CD3/CD28 beads (Dynabeads Hu-
man T-Activator CD3/CD28, Thermo Fischer) at a bead-to-cell ratio of 1:10, respectively. 
Mixed cultures were further treated with 0.5 μg/ml anti-PD-L1:TRAIL, anti-EpCAM:TRAIL 
or PD-L1 mAb. After 48 hours, loss of mitochondrial membrane potential (∆ψ) in DiD 
labeled tumor cells was analyzed by DiOC6 staining (Eugene) as previously described.27 
After harvesting, PBMCs were stained with fluorescent CD4 and CD8 antibodies where-
upon the number of CD4+ and CD8+ T cells within the PBMC gate was analyzed by flow 
cytometry. 
Alternatively, 5x104 DLD-1 cells were pre-seeded 24 hours before addition of freshly iso-
lated PBMCs. Tumor cells were mixed with PBMCs at indicated E:T ratio’s and co-treated 
with 50 ng/ml BIS-1 (anti-EpCAM:anti-CD3 bispecific antibody previously described in28) 
and 0.5 μg/ml anti-PD-L1:TRAIL or anti-MCSP:TRAIL. After 24 hours, non-adherent cells 
were carefully washed away and cell viability was determined using MTS as described 
above.
Patient-derived melanoma and appendix carcinoma cells were co-cultured with autol-
ogous TILs in E:T ratio of 2:1. After 48 hours, apoptosis was assessed by Annexin-V 
staining and IFN-γ levels in culture supernatant were determined by ELISA.
Isolation and generation of myeloid-derived cell types
Monocytes: PBMCs were subjected to magnetic-activated cell sorting (MACS) with anti-
CD14-beads and MS columns (Miltenyi Biotec). Macrophages: monocytes (1x106/ml) 
were treated with 50 ng/ml M-CSF for 6 days, yielding M0 macrophages. M0 macro-
phages were subsequently stimulated with 50 ng/ml LPS and 20 ng/ml IFN-γ to gener-
ate M1 macrophages or 20 ng/ml IL-4, IL-10 and TGF-β1 to generate M2 macrophages. 
Macrophage phenotype was confirmed by flow cytometric analysis of CD14, CD206 and 
PD-L1, as described before.29 Dendritic cells: immature DCs (iDCs) were generated by 
treatment of monocytes (3x106/ml) with 500 U/ml GM-CSF and 1000 U/ml IL-4 for 7 
days. Mature DCs (mDCs) were generated by treatment of iDCs with 1 μg/ml LPS for 3 
days. DC phenotype was confirmed by flow cytometric analysis of PD-L1, CD83, CD14, 
HLA-DR and CD86. 
For mixed culture experiments, myeloid cell types were mixed with 2.5x103 DLD-1 cells 
(at E:T ratio 4:1) with the indicated concentrations of anti-PD-L1:TRAIL in presence or 
absence of PD-L1 mAb. After 18 hours, DLD-1 cells were analyzed for apoptosis by flow 
cytometric analysis of Annexin-V staining. DLD-1 cells were separately analyzed by ex-
cluding CD14+ (monocytes and macrophages) or CD11b+ (DCs) cells.
Statistical analysis
Statistical analysis was performed by two-way ANOVA followed by Tukey-Kramer post-
test, one-way ANOVA followed by Tukey-Kramer post-test, Wilcoxon matched pairs test 
or two-sided unpaired Student t test as indicated using Prism software. P<0.05 was de-













anti-PD-L1:TRAIL induces PD-L1 restricted TRAIL-mediated apoptosis in can-
cer cells 
The anti-PD-L1:TRAIL fusion protein was designed to bind to PD-L1 on cancer cells 
and subsequently trigger TRAIL-mediated apoptosis by activating agonistic TRAIL-re-
ceptors. In line with this, anti-PD-L1:TRAIL strongly and dose-dependently bound to 
carcinoma cell line DLD-1.PD-L1 that ectopically overexpress PD-L1 (Fig. 1A). In con-
trast, anti-PD-L1:TRAIL did not bind to parental DLD-1 cells (Fig. 1B and Suppl. Fig. 
1A). Binding of anti-PD-L1:TRAIL to DLD-1.PD-L1 was abrogated by co-incubation with 
molar excess of epitope-competing anti-PD-L1 monoclonal antibody (Fig. 1A). Treat-
ment of DLD-1.PD-L1 with anti-PD-L1:TRAIL triggered dose-dependent TRAIL-mediated 
apoptosis, whereas similar treatment of DLD-1 cells did not trigger apoptosis (Fig. 1C). 
Thus, anti-PD-L1:TRAIL triggers cell death specifically after binding to cell surface-ex-
pressed PD-L1. Of note, treatment of DLD1.PD-L1 with PD-L1-blocking antibody alone 
and anti-EpCAM:TRAIL alone induced ~20% and 45% apoptosis, respectively (Fig. 1D). 
Combined treatment with PD-L1-blocking antibody and anti-EpCAM:TRAIL additively 
enhanced apoptosis to ~65% (Fig. 1D). However, treatment with anti-PD-L1:TRAIL at 
the same concentration induced up to 90% apoptosis (Fig. 1D). The apoptotic activity 
of anti-PD-L1:TRAIL was abrogated when cells were treated in the presence of excess 
epitope-competing PD-L1 monoclonal antibody (Fig. 1E). Further, apoptotic activity was 
TRAIL-mediated since TRAIL-neutralizing monoclonal antibody or total caspase-inhibitor 
z-VAD-fmk blocked apoptosis induction in DLD-1.PD-L1 (Fig. 1E). Of note, DLD-1 and 
DLD.PD-L1 are equally sensitive to TRAIL-mediated apoptosis since control EpCAM-tar-
geted anti-EpCAM:TRAIL, that binds equally well to both cell lines (data not shown), 
induced apoptosis to a similar extent in both cell lines (Fig. 1D). In contrast, a control 
non-targeted fusion protein, anti-MCSP:TRAIL, only minimally induces apoptosis in ei-
ther cell line (Fig. 1E). In a small panel of cancer cell lines that naturally express PD-
L1 (Suppl. Table 1), treatment with anti-PD-L1:TRAIL also induced apoptosis (Fig. 1F). 
Anti-PD-L1:TRAIL treatment further abrogated spheroid formation in DLD-1.PD-L1, but 
not DLD-1 cells (Fig. 1G-H), and strongly reduced viability of established spheroids (Fig. 
1I). In spheroid forming assays, anti-PD-L1:TRAIL also significantly reduced cell viability 
of NCI-H1975 cells that endogenously express PD-L1 (Suppl. Fig 1B-C). Thus, apoptotic 
activity of anti-PD-L1:TRAIL is dependent on PD-L1 specific binding to target cells and 
subsequent induction of TRAIL-mediated apoptosis.
anti-PD-L1:TRAIL blocks PD-1/PD-L1 interaction and enhances T cell activation
Since TRAIL is a naturally occurring homotrimer the anti-PD-L1:TRAIL fusion protein 
contains three PD-L1 blocking scFvs, which should allow for effective inhibition of PD-L1/
PD-1 interaction. Indeed, anti-PD-L1:TRAIL dose-dependently inhibited binding of recom-
binant PD-1:Fc to DLD-1.PD-L1 cells, whereas similar treatment with anti-EpCAM:TRAIL 
did not affect PD-1:Fc binding (Fig. 2A). In line with the PD-L1/PD-1 blocking effect of 
anti-PD-L1:TRAIL, treatment of peripheral blood mononuclear cells (PBMCs) with anti-
PD-L1:TRAIL and an agonistic CD3 mAb increased proliferation and cell number 2-fold 
Figure 1: anti-PD-L1:TRAIL induces PD-L1-restricted TRAIL-mediated apoptosis in cancer cells. A) 
Binding of anti-PD-L1:TRAIL to DLD-1.PD-L1 cells in the presence or absence of excess PD-L1 block-
ing antibody (10 µg/ml) was analyzed by flow cytometry. B) DLD-1.PD-L1 or DLD-1 cells were incu-
bated with an increasing dose of anti-PD-L1:TRAIL and binding was assessed by flow cytometry. C) 
DLD-1.PD-L1 or DLD-1 cells were treated with an increasing dose of anti-PD-L1:TRAIL for 18 hours, 
after which apoptosis was measured by flow cytometry using Annexin-V staining. D) DLD-1.PD-L1 or 
DLD-1 cells were treated with anti-PD-L1:TRAIL (250 ng/ml), anti-EpCAM:TRAIL (250 ng/ml) or PD-
L1 antibody (1 µg/ml). Apoptosis was assessed by Annexin-V staining after 18 hours. E) DLD-1.PD-L1 
or DLD-1 cells were treated with anti-PD-L1:TRAIL (250 ng/ml) in the presence or absence of PD-L1 
blocking antibody (10 µg/ml), TRAIL-neutralizing mAb (1 µg/ml) or total caspase inhibitor z-VAD-fmk 
(10 µM). DLD-1.PD-L1 or DLD-1 cells were also treated with anti-MCSP:TRAIL(250 ng/ml). Apoptosis 
was assessed by Annexin-V staining after 18 hours. F) PD-L1-expressing cell lines were co-treated 
with cycloheximine (CHX, 1 µg/ml) and anti-PD-L1:TRAIL (1 µg/ml). Apoptosis was determined by 
Annexin-V staining after 18 hours. G) Representative light microscopy images of spheroid size of 
DLD-1.PD-L1 cells or DLD-1 cells in medium control versus anti-PD-L1:TRAIL-treated conditions after 
72 hours. H) Spheroid formation of DLD-1.PD-L1 or DLD-1 cells was assessed in the presence or 
absence of 100 ng/ml anti-PD-L1:TRAIL, anti-MCSP:TRAIL or anti-EpCAM:TRAIL. Number of spheroid 
colonies was determined after 72 hours by counting three fields-of-view per condition in triplicates. 
I) Established spheroids of DLD-1.PD-L1 cells or DLD-1 cells were treated with 500 ng/ml anti-PD-
L1:TRAIL, anti-MCSP:TRAIL or anti-EpCAM:TRAIL. Cell viability was determined by MTS after 72 
hours. All graphs represent mean±SD. Statistical analysis was performed using two-way ANOVA (*p 






























































































































































































































































compared to treatment with the agonistic CD3 mAb alone (Fig. 2B, C). Furthermore, an-
ti-PD-L1:TRAIL dose-dependently increased secretion of IFN-γ (Fig. 2D), to a level sim-
ilar to that induced by a monoclonal antagonistic anti-PD-L1 antibody (Fig. 2E). This T 
cell stimulatory effect of anti-PD-L1:TRAIL was also detected in mixed cultures of PBMCs 
with DLD-1 cells (Suppl. Fig. 1D). Importantly, co-treatment with anti-EpCAM:TRAIL did 
not increase T cell proliferation or T cell number compared to CD3 activation alone (Fig. 
2B, C). To subsequently investigate pro-inflammatory activity of anti-PD-L1:TRAIL in an 
antigen-specific reaction, a model system using Cytomegalovirus (CMV)-specific T cells 
was used. To this end, PBMCs from CMVpos and CMVneg donors were loaded with CMV pro-
tein pp65 in combination with anti-PD-L1:TRAIL or anti-EpCAM:TRAIL. Loading of PBMCs 
with pp65 in the presence of anti-PD-L1:TRAIL significantly increased IFN-γ secretion by 
CMVpos donor cells (Fig. 2F), whereas no effect on IFN-γ secretion was detected in T cells 
from CMVneg donors. 
Importantly, anti-EpCAM:TRAIL only minimally induces IFN-γ secretion (Suppl. Fig. 1E). 
Taken together, anti-PD-L1:TRAIL potentiates T cell proliferation and IFN-γ production 
via blockade of PD-1/PD-L1 interaction.
PD-L1:TRAIL enhances anticancer T cell activity 
Next, we analyzed whether enhanced T cell activation by anti-PD-L1:TRAIL could aug-
ment anticancer T cell activity. In mixed cultures of A2058 melanoma cells and PBMCs, 
treatment with CD3 agonist at sub-optimal doses triggered apoptosis in ~30% of cancer 
cells, whereas treatment with anti-PD-L1:TRAIL alone did not induce apoptosis (Fig. 3A). 
However, combination treatment with CD3 agonist and anti-PD-L1:TRAIL synergistically 
enhanced apoptosis in A2058 to over 60% (Fig. 3A). Further, co-treatment with anti-PD-
L1:TRAIL also significantly increases IFN-γ secretion (Suppl. Fig. 1F). Correspondingly, 
in these mixed culture experiments the expression of PD-L1 on A2058 increased 3-fold 
(Suppl. Fig. 1G), whereas PD-1 expression on T cells increased 6-fold (Suppl. Fig. 1H). 
Importantly, treatment of activated T cells with PD-L1:TRAIL did not induce apoptosis 
in T cells (Suppl. Fig. 1I).  Anti-PD-L1:TRAIL also significantly increased production of 
IFN-γ in mixed culture experiments with primary melanoma patient-derived TILs and 
autologous melanoma cells (Fig. 3B), to a level similar to that induced by anti-PD-L1 
blocking antibody. PD-L1:TRAIL treatment of autologous primary cancer/TIL mixed cul-
ture experiments also increased apoptotic cell death in autologous cancer cells, both 
in melanoma and appendix carcinoma cells (Fig. 3C). The enhanced cytotoxicity of PB-
MCs upon CD3 agonist and anti-PD-L1:TRAIL treatment was blocked to medium levels 
by co-incubation with TRAIL-neutralizing antibody (2E5) (Fig. 3D) and was, therefore, 
dependent on TRAIL/TRAIL-receptor interaction. Correspondingly, anti-PD-L1:TRAIL in-
duced apoptosis in mixed cultures of HCT-116 and PBMCs, but not in TRAIL resistant 
HCT-116.cFLIPs (Suppl. Fig. 1J), demonstrating that cell death upon anti-PD-L1:TRAIL 
treatment is TRAIL-mediated. 
Of note, treatment with anti-EpCAM:TRAIL, PD-L1 blocking antibody or a combination did 
not significantly enhance the cytotoxic activity of PBMCs towards A2058 cells (Fig. 3A, D) 
nor did it increase the number of T cells (Fig. 3E). In these mixed cultures, the number of 
T-cells significantly increased upon anti-PD-L1:TRAIL treatment (Fig. 3E). Furthermore, 
in mixed cultures of A2058 and isolated CD3+ T-cells, only anti-PD-L1:TRAIL treatment 
synergistically enhances apoptosis in A2058 to >80% (Fig. 3F) and significantly increas-
es IFN-γ secretion (Fig. 3G). Thus, anti-PD-L1:TRAIL augments cytolytic activity of T 
cells in mixed culture experiments with T cells and tumor cells.
To mimic antigen-specific T cell activation, DLD-1 cancer cells were treated with T cell 
retargeting bispecific antibody (bsAb) anti-EpCAM:anti-CD3 (28). This bsAb retargets T 
cells to EpCAM-positive cancer cells and, in mixed cultures of DLD-1 and PBMCs, triggered 
cell death in an E:T ratio-dependent manner (Fig. 3H). Importantly, co-treatment with 
anti-EpCAM:anti-CD3 and anti-PD-L1:TRAIL significantly increased apoptotic elimination 
of DLD-1 cells leading to ~80% loss in cell viability after 24h of treatment at an E:T ratio 
of 5:1. (Fig. 3H). In contrast, control fusion protein anti-MCSP:TRAIL did not potentiate 
the cytotoxic effect of anti-EpCAM:anti-CD3 retargeted T cells (Fig.3H). In these mixed 
Figure 2: anti-PD-L1:TRAIL blocks the PD-1/PD-L1 interaction and enhances T cell activation. A) 
Binding of PD-1:Fc (4 µg/ml) to DLD-1.PD-L1 cells in the presence of an increasing dose of an-
ti-PD:L1:TRAIL or anti-EpCAM-TRAIL was analyzed by flow cytometry. B) Representative histograms 
of CFSE-labeled PBMCs co-treated with agonistic CD3 mAb (0.5 µg/ml) and 500 ng/ml anti-PD-
L1:TRAIL or anti-EpCAM:TRAIL. After 72 hours, cell proliferation was analyzed by flow cytometry. 
C) PBMCs were treated with 500 ng/ml anti-PD-L1:TRAIL or anti-EpCAM:TRAIL in the presence of 
agonistic CD3 mAb (0.5 μg/ml). After 72 hours, cell number was quantified using an automated cell 
counter. D) PBMCs were co-treated with agonistic CD3 mAb (0.5 μg/ml) and an increasing dose of 
anti-PD-L1:TRAIL or anti-EpCAM:TRAIL. After 72 hours, IFN-γ levels in culture supernatant were 
determined by ELISA. E) PBMCs were co-treated with agonistic CD3 mAb (0.5 μg/ml) and 500 ng/ml 
anti-PDL1:TRAIL, anti-EPCAM:TRAIL or mAb PD-L1 for 72 hours. IFN-γ levels in culture supernatant 
were determined by ELISA. F) PBMCs from CMV-positive or CMV-negative donors and were treated 
with 500 ng/ml anti-PD-L1:TRAIL in the presence of CMV protein pp65 for 96 hours. IFN-γ levels 
in culture supernatant were determined by ELISA. All graphs represent mean±SD. Statistical anal-
ysis was performed using unpaired two-sided Student t test (C),  two-way ANOVA (D) or Wilcoxon 


















































































































































































Figure 3: PD-L1:TRAIL enhances anticancer T cell activity. A) DiD-la-
beled A2058 cells were co-cultured with PBMCs at E:T ratio 5:1. Where 
indicated, cells were co-treated with 500 ng/ml anti-PD-L1:TRAIL or 
anti-EpCAM:TRAIL, in the presence or absence of agonistic CD3 mAb 
(0.5 μg/ml). After 48 hours, apoptosis in DiD-positive cells was deter-
mined by flow cytometry using DiOC6 staining B) Autologous primary 
patient-derived melanoma cells and TILs were co-cultured at E:T ratio 
2:1 and treated with 1 μg/ml anti-PD-L1:TRAIL, anti-EpCAM:TRAIL or 
4 μg/ml mAb PD-L1 for 48 hours. IFN-γ levels in culture supernatant 
were determined by ELISA. C) Primary patient-derived melanoma and 
appendix carcinoma cells were co-cultured with autologous TILs at E:T 
ratio 2:1 and treated with 1 μg/ml anti-PD-L1:TRAIL for 48 hours, after 
which apoptosis was assessed by Annexin-V staining. D) DiD-labeled 
A2058 cells were co-cultured with PBMCs at E:T ratio 5:1 in the presence 
of agonistic CD3 mAb (0.5 μg/ml). Cells were co-treated with 500 ng/ml anti-PD-L1:TRAIL or anti-Ep-
CAM:TRAIL, where indicated cells were co-treated with TRAIL-neutralizing antibody (1 ug/ml). After 
48 hours, apoptosis in DiD-positive cells was determined by flow cytometry using DiOC6 staining. 
E) In mixed cultures of PBMCs and A2058 as described in D, the PBMC population was stained with 
fluorescent CD4 and CD8 antibodies whereupon the number of CD4+ and CD8+ T cells within the PBMC 
gate was analyzed by flow cytometry. F) DiD-labeled A2058 cells were co-cultured with isolated CD3+ 
T-cells at E:T ratio 5:1 in the presence of CD3/CD28 beads at a bead-to-cell ratio of 1:10. Cells were 
co-treated with 500 ng/ml anti-PD-L1:TRAIL or anti-EpCAM:TRAIL and after 48 hours, apoptosis in 
DiD-positive cells was determined by flow cytometry using DiOC6 staining. G) IFN-γ levels in culture 
supernatant of F were determined by ELISA. H) DLD-1 cells were pre-seeded 24 hours before PBMCs 
were added at indicated E:T ratios in the presence of anti-EpCAM:anti-CD3 (50 ng/ml) with or with-
out 500 ng/ml anti-PD-L1:TRAIL or anti-MCSP-TRAIL. Cell viability was determined by MTS after 24 
hours. I) IFN-γ levels in culture supernatant of H were determined by ELISA. All graphs represent 
mean±SD. Statistical analysis was performed using two-way ANOVA (A), one-way ANOVA (D) or un-
paired two-sided Student t test (B, F) (* p < 0.05, **p < 0.01, *** p < 0.001, n.s. not significant).
Figure 4: IFN-γ upregulates PD-L1 expression and sensitizes cancer cells to TRAIL-mediated apop-
tosis. A) Primary patient-derived melanoma cells were treated with or without 20 ng/ml IFN-γ for 
24 hours after which PD-L1 expression was analyzed by flow cytometry. B) 7 cancer cell lines and 9 
primary patient-derived melanoma cell cultures were treated with or without 20 ng/ml IFN-γ for 24 
hours after which PD-L1 expression was analyzed by flow cytometry. Fold increase was calculated 
compared to non-treated cells. C)  IFN-γ pre-treated or non-treated DLD-1 cells were incubated with 
an increasing dose of anti-EpCAM:TRAIL for 18 hours, after which apoptosis was assessed by flow 
cytometry using Annexin-V staining. D) IFN-γ pre-treated or non-treated A2058 cells were incubated 
with an increasing dose of anti-PD-L1:TRAIL. Apoptosis was assessed by Annexin-V staining after 
18 hours. E) IFN-γ pre-treated or non-treated A2058 cells were incubated with 500 ng/ml anti-PD-
L1:TRAIL in the presence or absence of PD-L1 blocking mAb (10 µg/ml). Apoptosis was determined 
by Annexin-V staining after 18 hours. F) A small panel of cancer cell lines were pre-treated with or 
without IFN-γ (20 ng/ml), followed by treatment of anti-PD-L1:TRAIL (500 ng/ml) for additional 18 
hours. Apoptosis was determined by Annexin-V staining. G) IFN-γ pre-treated primary patient-de-
rived melanoma cultures were treated with 1 μg/ml anti-PD-L1:TRAIL or anti-EpCAM:TRAIL for 48 
hours. Apoptosis was determined using Annexin-V. H) DLD-1 cells were treated with or without 20 
ng/ml IFN-γ in the presence or absence of 8 µg/ml IFN-y neutralizing mAb. After 24 hours, PD-L1 
expression was analyzed by flow cytometry. I) DLD-1 cells were pre-treated with or without 20 ng/
ml IFN-γ in the presence or absence of 8 µg/ml IFN-γ neutralizing mAb. After 24 hours, cells were 
treated with anti-PD-L1:TRAIL (250 ng/ml) in the presence or absence of PD-L1 blocking mAb (10 
µg/ml), anti-EpCAM:TRAIL (250 ng/ml) or mAb PD-L1 (1 μg/ml). All graphs represent mean±SD. 
Statistical analysis was performed using two-way ANOVA (F) or Wilcoxon matched pairs test (G) (* p 
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cultures, IFN-γ production increased upon co-treatment with anti-EpCAM:anti-CD3 and 
anti-PD-L1:TRAIL when compared to co-treatment with anti-MCSP:TRAIL (Fig. 3I).
IFN-γ enhances PD-L1 expression and sensitizes cancer cells to TRAIL-mediat-
ed apoptosis 
IFN-γ up-regulates PD-L1 expression on cancer cells,11 a finding confirmed here in 
a panel of 7 cancer cell lines and 9 primary patient-derived melanoma cell cultures 
(Fig. 4A, B). Since pro-apoptotic activity of anti-PD-L1:TRAIL is dependent on PD-L1 
specific binding to cells, this upregulation of PD-L1 may sensitize cancer cells to an-
ti-PD-L1:TRAIL-mediated killing. Further, IFN-γ is known to sensitize cancer cells to 
TRAIL-mediated apoptosis, e.g. through down-regulation of cFLIP.30, 31 Correspondingly, 
apoptotic activity of control fusion protein anti-EpCAM:TRAIL on DLD-1 cells was in-
creased by IFN-γ pre-treatment (Fig. 4C). This effect was due to TRAIL sensitization and 
not due to EpCAM upregulation as IFN-γ does not affect EpCAM expression.32 Thus, IFN-γ 
both upregulates PD-L1 and sensitizes cancer cells to TRAIL, which may augment anti-
PD-L1:TRAIL activity. In line with the above, pre-treatment of A2058 cells with IFN-γ 
dose-dependently sensitized A2058 cells to anti-PD-L1:TRAIL-mediated apoptosis (Fig. 
4D), as well as a further panel of 5 cancer cell lines (Fig. 4F) and 11 primary melanoma 
cell cultures (Fig. 4G). This apoptotic activity of anti-PD-L1:TRAIL was still abrogated by 
co-treatment with excess PD-L1 blocking antibody (Fig. 4E). Additionally, co-treatment 
with IFN-γ neutralizing antibody inhibited IFN-γ  mediated PD-L1 upregulation on DLD-1 
cells (Fig. 4H) and abrogated anti-PD-L1:TRAIL-mediated apoptosis (Fig. 4I). Thus, the 
apoptotic activity of anti-PD-L1:TRAIL is enhanced by IFN-γ, likely due to both upregu-
lation of PD-L1 expression on cancer cells and simultaneous sensitization of cancer cells 
to TRAIL-mediated apoptotic signaling. 
Anti-PD-L1:TRAIL converts PD-L1 expressing myeloid cells into pro-apoptotic 
tumoricidal effector cells
Within the tumor micro-environment, various types of infiltrated myeloid cells, such 
as M2 macrophages and DCs, are known to express PD-L1 and to suppress antitumor 
immunity.33, 34 On these cells, PD-L1 expression is further elevated by tumor localized 
IFN-γ.4, 5 Previously, we demonstrated that direct arming of myeloid effector cells using 
a TRAIL fusion protein that binds to CLL-1 on granulocytes, enhanced the pro-apoptotic 
activity of such myeloid cells.26 To assess whether potentiation of myeloid effector cell 
activity might also contribute to anti-PD-L1:TRAIL activity, we generated various my-
eloid effector cell populations, i.e. monocytes, M0, M1 and M2 macrophages, immature 
DCs (iDCs) and mature DCs (mDCs). All of these effector cells expressed PD-L1 to a 
varying degree, with monocytes having lowest and mDCs having the highest expres-
sion (Fig. 5A). Further, M1 macrophages had higher PD-L1 expression compared to the 
immunosuppressive M2 macrophages, a finding in line with an earlier report.29 PD-L1 
expression was upregulated by IFN-γ pre-treatment, as illustrated for monocytes (Fig. 
5B). In subsequent mixed culture experiments of monocytes and DLD-1 target cells, 
such IFN-γ pre-treated monocytes alone did not significantly induce apoptosis in DLD1 
cells (Fig. 5C). However, treatment with anti-PD-L1:TRAIL dose-dependently increased 
apoptosis in DLD-1 cells (Fig. 5C). This increase was blocked by co-treatment with mo-
lar excess of PD-L1 blocking mAb (Fig. 5D). Similarly, M0, M1 or M2 macrophages and 
immature or mature DCs alone minimally induced apoptosis of DLD-1 cells in mixed 
culture experiments (Fig. 5E, F). However, addition of anti-PD-L1:TRAIL to these mixed 
cultured significantly triggered apoptosis in DLD-1 cells (Fig. 5E, F), with e.g. an >50% 
increase in apoptosis in DLD-1 cells in mDC mixed culture experiments (Fig. 5F). In all 
mixed culture experiments, PD-L1 blocking mAb strongly inhibited the apoptotic activity 
of anti-PD-L1:TRAIL (Fig. 5D-F). Of note, background apoptosis in DLD-1 cells was re-
duced from ~20 to ~10% in the presence of M2 macrophages, a finding in line with their 
pro-tumorigenic role (Fig. 5E). Further, although M1 macrophages express higher levels 
of PD-L1 (Fig. 5A) and were intrinsically more cytolytic (Fig. 5E), the potentiating effect 
of anti-PD-L1:TRAIL was most pronounced for M2 macrophages, with a 4-fold increase in 
apoptosis with M2 vs. a 3-fold increase with M1 macrophages (Suppl. Fig. 1K). 
Figure 5: Anti-PD-L1:TRAIL converts PD-L1 expressing myeloid cells into pro-apoptotic tumoricidal 
effector cells. A) PD-L1 expression levels of monocytes, M0, M1, M2 macrophages, immature and 
mature DCs were determined by flow cytometry. Isotype control MFI was subtracted from original 
MFI. B) Monocytes were treated with or without 20 ng/ml IFN-γ for 24h after which PD-L1 expression 
was analyzed by flow cytometry. C) Monocytes were pre-treated with or without 20 ng/ml IFN-γ for 
24 hours, washed twice with PBS after which DLD-1 cells were added at E:T ratio 4:1 in the presence 
of an increasing dose of anti-PD-L1:TRAIL. After 18 hours, apoptosis was assessed by Annexin-V 
staining. D) As in C with 500 ng/ml anti-PD-L1:TRAIL with or without PD-L1 blocking mAb (10 µg/
ml). E) M0, M1 or M2 macrophages were co-cultured with DLD-1 cells at E:T ratio 4:1 in the presence 
of 500 ng/ml anti-PD-L1:TRAIL with or without PD-L1 blocking mAb (10 µg/ml). After 18 hours, apop-
tosis was assessed by Annexin-V staining. F) Immature or mature DCs were co-cultured with DLD-1 
cells at E:T ratio 4:1 in the presence of 500 ng/ml anti-PD-L1:TRAIL with or without PD-L1 blocking 
mAb (10 µg/ml). After 18 hours, apoptosis was assessed by Annexin-V staining. All graphs represent 
mean±SD. Statistical analysis was performed using two-way ANOVA (* p < 0.05, **p < 0.01, *** p 




































































































































Taken together, these data demonstrate that anti-PD-L1:TRAIL binds to PD-L1 on my-
eloid cells, whereupon these normally immunosuppressive cells trigger TRAIL-mediated 
apoptotic cell death in cancer cells.
Discussion
Here, we describe a new PD-L1/PD-1 checkpoint inhibitor approach that combines PD-
L1 checkpoint blockade with targeted delivery of the pro-apoptotic tumoricidal protein 
TRAIL. Fusion protein anti-PD-L1:TRAIL has a multi-fold therapeutic effect, depicted in 
Fig. 6, comprised of 1. induction of TRAIL-mediated cancer cell death after binding to 
tumor-expressed PD-L1, 2. reactivation of antitumor T-cells by blocking of PD-L1/PD-1 
interaction, 3. converting suppressive monocytes/macrophages/DCs into pro-apoptotic 
effector cells that trigger TRAIL-mediated cancer cell death and 4. enhancement of IFN-γ 
production by immune effector cells, leading to simultaneous PD-L1 upregulation and 
sensitization of cancer cells to TRAIL.
Blockade of the PD-L1/PD-1 axis by anti-PD-L1:TRAIL enhanced T cell activation, prolif-
eration and IFN-γ production, an effect similar to that reported for anti-PD-L1 monoclonal 
antibodies,35 and triggered TRAIL-mediated apoptosis in cancer cells. TRAIL has strong 
pro-apoptotic activity towards various cancers in the absence of deleterious activity to-
wards normal cells.36 Clinical evaluation of first-generation recombinant human TRAIL 
(rhTRAIL, brand name “dulanermin”) and TRAIL receptor antibodies typically yielded low 
to absent toxicity towards normal cells and tissues (reviewed in37), with a maximum tol-
erable dose (MTD) not being reached for dulanermin.38 Of note, dulanermin did not have 
toxicity towards immune cells in these studies.37, 38 Thus, the use of TRAIL as additional 
effector domain is anticipated to have no or only minimal side-effects when combined 
with PD-L1 blockade strategies. In line with this, we did not detect any negative effects 
of the TRAIL domain of PD-L1:TRAIL on T cells, with no increase in apoptosis in activated 
T cells. A recent study did report suppression in T cell activation and proliferation when 
T-cells were co-stimulated with recombinant TRAIL and CD3/CD28 antibodies.39 Howev-
er, this suppressive effect was only observed at a concentration of recombinant TRAIL of 
50 μg/ml, which is ~50 fold higher than the highest concentration of 1 ug/ml typically 
used in literature and by us here for PD-L1:TRAIL. 
Of note, early clinical trials in various types of malignancies yielded only limited clin-
ical benefit for dulanermin with stable disease being the best-reported activity.38, 40, 41 
However, it has become evident that first generation TRAIL receptor-agonists do not 
optimally exploit the unique apoptotic signaling characteristics of the various TRAIL re-
ceptors (reviewed in42-44). Most notably, apoptotic signaling via TRAIL-R2, one of the two 
agonistic TRAIL receptors, is not efficiently achieved by soluble homotrimeric rhTRAIL, 
as TRAIL-R2 requires binding of membrane-bound TRAIL or secondarily cross-linked 
rhTRAIL.21, 45, 46 Since TRAIL-R2 is often highly expressed on cancer cells it forms an 
important target for TRAIL-based therapy. Importantly, we and others have previously 
shown that tumor-directed scFv:TRAIL fusion proteins effectively activate TRAIL-R2 on 
targeted cancer cells only. In this process high affinity and tumor-selective binding via 
its scFv domain converts a soluble and essentially inactive scFv:TRAIL fusion protein into 
membrane-bound TRAIL with highly potent agonistic activity towards both TRAIL-R1 and 
TRAIL-R2.21, 47, 48 Thus, anti-PD-L1:TRAIL has combined and mutuallyreinforcing PD-L1-
blocking and TRAILR agonistic activities within one therapeutic anticancer fusionprotein, 
which outperforms combined treatment with PD-L1-blocking antibody and TRAIL.
Importantly, in mixed culture experiments using primary patient-derived melanoma cells 
and autologous TILs, treatment with anti-PD-L1:TRAIL enhanced IFN-γ production and 
augmented TIL-mediated cancer cell apoptosis. Additionally, when T cells were redirected 
to carcinoma cells using an anti-EpCAM:anti-CD3 bispecific antibody, anti-PD-L1:TRAIL 
synergistically enhanced their pro-apoptotic antitumor activity. A similar potentiating 
effect of PD-L1 blockade has been previously reported for T cell retargeting BiTEs that 
target CEA or CD33.49, 50 This suggests that anti-PD-L1:TRAIL may be exploited to aug-
ment tumor-specific activity of T cells. In line with this, anti-PD-L1:TRAIL also increased 
IFN-γ secretion in a model antigen-specific reaction where T-cells from CMV-positive 
donors were stimulated with CMV protein pp65.
Figure 6: Proposed mechanism of action for anti-PD-L1:TRAIL. anti-PD-L1:TRAIL induces TRAIL-me-
diated cancer cell death after binding to tumor-expressed PD-L1 (1) or after binding to PD-L1 on 
myeloid effector cells (2), restores proliferation and antitumor activity of T cells by blocking PD-L1/
PD-1 interaction (3) and enhances IFN-γ production of T cells, leading to simultaneous PD-L1 upreg-


















































Tumor cells that do not constitutively express PD-L1 can rapidly upregulate PD-L1 when 
the tumor micro-environment is infiltrated by T cells. As previously reported, this up-
regulation is likely due to IFN-γ generated by T cells upon tumor cell recognition and 
attempted elimination.12 In the context of anti-PD-L1:TRAIL, this IFN-γ production may 
contribute to its antitumor efficacy as IFN-γ not only sensitizes cancer cells to TRAIL 
but also upregulates PD-L1 expression.11, 30, 31 Thus, anti-PD-L1:TRAIL may trigger a 
feed-forward loop of increasing IFN-γ, increasing PD-L1 expression and increasing TRAIL 
sensitivity.
In the tumor microenvironment, various myeloid cells such as macrophages and DCs, 
also express PD-L1 and hereby can suppress antitumor immunity.33, 34 The presence of 
these suppressive cell types correlated with disease progression and reduced survival 
in HCC and breast cancer patients.6, 51 Here, we showed that anti-PD-L1:TRAIL can arm 
PD-L1-expressing monocytes, DCs and macrophages with TRAIL, turning these suppres-
sive cell types into pro-apoptotic effector cells whilst simultaneously blocking potential 
PD-L1-mediated immunosuppressive effects. The obvious promise of this arming strate-
gy is illustrated by reports where PD-L1 blockade alone significantly improved the in vivo 
antitumor activity of T cells treated with suppressive DCs or monocytes.6, 33
Interestingly, based on the known receptor interactions of PD-1 ligands (reviewed in3), 
PD-1 antibodies may have distinct biological activities from PD-L1 antibodies and their 
activities may not be redundant, depending on the dominant interaction for a particular 
cancer. In this respect, simultaneous blockade of PD-1 and PD-L1 maximized cytolytic 
T cell activity of tumor-directed bispecific T cell engaging antibodies.49. These findings 
suggest that combining anti-PD-L1:TRAIL with PD-1 blocking antibodies may further 
optimize checkpoint inhibitor-based therapy. 
In conclusion, fusion protein anti-PD-L1:TRAIL has promising multi-fold and mutually re-
inforcing therapeutic effects comprised of PD-L1 checkpoint blockade and simultaneous 
induction of TRAIL-mediated apoptosis. This new fusion protein may provide possibilities 
to enhance the efficacy of therapeutic PD-L1/PD-1 checkpoint inhibition alone or in com-
bination with other immunotherapeutic strategies.
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Supplementary Figure 1: A) Binding of anti-PD-L1:TRAIL to DLD-1 cells was analyzed by flow 
cytometry. B) Spheroid formation of DLD-1.PD-L1 or DLD-1 cells was assessed in the presence or 
absence of 100 ng/ml anti-PD-L1:TRAIL, anti- MCSP:TRAIL or anti-Ep-CAM:TRAIL. Cell viability was 
determined by MTS after 72 hours. C) Spheroid formation of NCI-H1975 cells was assessed in the 
presence or absence of 1 μg/ml anti-PD-L1:TRAIL or anti-EpCAM:TRAIL. Cell viability was deter-
mined by MTS after 72 hours. D) DLD-1 cells were co-cultured with PBMCs at E:T ratio 5:1 in the 
presence of agonistic CD3 mAb (0.5 μg/ml) and an increasing dose of anti-PD-L1:TRAIL or anti-Ep-
CAM:TRAIL. After 72 hours, IFN-γ levels in culture supernatant were determined by ELISA. E) PBMCs 
from CMV-positive or CMV-negative donors were treated with 500 ng/ml anti-EpCAM:TRAIL in the 
presence of CMV protein pp65 for 96 hours. IFN-γ levels in culture supernatant were determined by 
ELISA. F) A2058 cells were co-cultured with PBMCs at E:T ratio 5:1 and treated with 500 ng/ml anti-
PD-L1:TRAIL or anti-EpCAM:TRAIL as indicated, in the presence of agonistic CD3 mAb (0.5 μg/ml). 
Where indicated, cells were co-treated with TRAIL-neutralizing antibody (1 ug/ml). After 48 hours, 
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C D IFN-γ levels in culture supernatant were determined by ELISA. G) A2058 cells were co-cultured with 
PBMCs at E:T ratio 5:1 in the presence or abscence of agonistic CD3 mAb (0.5 μg/ml).After 48 hours, 
PD-L1 expression on A2058 cells was measured by flow cytometry. H) As in G, PD-1 expression on 
PBMCs was measured by flow cytometry. Fold increase was calculated compared to medium control. 
I) A2058 cells were co-cultured with isolated CD3+ cells at E:T ratio 5:1. Cells were co-treated with 
500 ng/ml anti-PD-L1:TRAIL in the presence of CD3/CD28 beads. After 48 hours, loss of mitochon-
drial membrane potential (MMP) in T cells was measured by flow cytometry. J) As in F, HCT-116.wt 
or TRAIL resistantHCT-116.cFLIPs cells were co-cultured with PBMCs at E:T ratio 2.5:1 and loss of 
mitochondrial potential was assesed after 48 hours. K) M0, M1 or M2 macrophages were co-cultured 
with DLD-1 cells at E:T ratio 4:1 in the presence of 500 ng/ml anti-PD-L1:TRAIL with or without PD-
L1 blocking mAb (10 μg/ml). After 18 hours, apoptosis was assessed by Annexin-V staining. Fold 
increase was calculatedcompared to medium control. All graphs represent mean ±SD. Statistical 
analysis was performed using Wilcoxon matched pairs test (E), unpaired two-sided Student t test (F) 
or ANOVA (K). (* p < 0.05, **p < 0.01, *** p < 0.001, n.s. not significant)









Melanoma 1 +++ 6
Melanoma 2 +++ 1
Melanoma 3 ++++ 2
Melanoma 4 ++ 1.5
Melanoma 5 + 2
Melanoma 6 +++ 2
Melanoma 7 + 2
Melanoma 8 + 3
Melanoma 9 + 1
Melanoma 10 + 4
Appendix Carcinoma ++++ 2
Supplementary Table 1: PD-L1 expression levels of all cell lines and primary samples used in this 
study were determined by flow cytometry using PD-L1-APC antibody with appropriate isotype con-
trol. Relative expression levels were calculated by subtracting isotype control MFI from original MFI. 
(Relative expression index: MFI <20.000 = +, 20.000 <MFI> 50.000 = ++, 50.00 <MFI> 100.000 
= +++, MFI >100.000 = ++++). Cells were also pre-treated with or with-out 20 ng/ml IFN-γ for 24 
hours, after which PD-L1 expression was determined using flow cytometry. Fold increase was calcu-
lated compared to non-treated cells (nd=not determined).
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Melanoma 1 50.984 47.653
Melanoma 2 11.678 501.374
Melanoma 3 117.701 10.992
Melanoma 4 109.621 180.582
Melanoma 5 64.969 191.333
Melanoma 6 76.436 49.606
Melanoma 7 356.732 71.917
Supplementary Table 2: TRAIL receptor expression levels of cell lines and primary samples used 
in this study. Tumor cells were incubated with 1 ug/ml TRAILR1 or TRAILR2 antibody for 1 hour at 
4˚C, washed twice with PBS (1000g, 5 min), stained with Goat-anti-Mouse conjugate for 30 minutes 
at 4˚C, washed twice with PBS, after which TRAIL receptor expression was subsequently analyzed by 
flow cytometry. Relative expression levels were calculated by subtracting conjugate control MFI from 












Purpose: PD-1/PD-L1-blocking antibodies can restore the antitumor activity of func-
tionally-impaired antigen-experienced CD8+ T-cells and have provided significant clinical 
benefit in selected cancer patients with advanced stage disease. However, current PD-1/
PD-L1-blocking antibodies lack intrinsic tumor selectivity and may indiscriminately re-
activate all T-cells, including silenced autoreactive T-cells. The latter is evidenced by the 
frequent occurrence of severe autoimmune-related adverse events in patients receiving 
these antibodies. Here, we report on a novel bispecific antibody (bsAb), designated bsAb 
PD-L1xEGFR, which selectively directs PD-L1 blockade to EGFR-overexpressing cancer 
cells.
Experimental Design: We constructed bsAb PD-L1xEGFR (human IgG1) in which a 
PD-L1-blocking scFv antibody fragment is genetically fused to an EGFR-blocking scFv. 
EGFR-selective binding and blocking of PD-1/PD-L1 interaction by bsAb PD-L1xEGFR was 
assessed using EGFR-positive versus EGFR-negative cancer cell lines. The ability of bsAb 
PD-L1xEGFR to promote the antitumor activity of antigen-experienced CD8+ T-cells was 
assessed by co-culturing CMV-pp65 specific effector T-cells with HLA-matched target 
tumor cells ectopically expressing CMV-pp65 protein.
Results: Our pre-clinical data demonstrate that treatment with bsAb PD-L1xEGFR se-
lectively directs PD-L1 blockade to EGFR-overexpressing cancer cells. In this process, 
bsAb PD-L1xEGFR augmented the capacity of T cells to proliferate, secrete IFN-γ and 
selectively kill EGFR-overexpressing target cells, while simultaneously blocking onco-
genic EGFR signaling. Finally, EGFR-directed blockade of PD-L1 promoted the activity of 
antigen-experienced CMV-specific CD8+ T cells. 
Conclusions: EGFR-directed PD-1/PD-L1 immune checkpoint inhibition can be achieved 
by applying bsAb PD-L1xEGFR. In this process, bsAb PD-L1xEGFR has multi-fold mutu-
ally reinforcing activities that promote CD8+ T-cells to selectively eliminate EGFR-over-
expressing cancer cells. BsAb PD-L1xEGFR may be of clinical importance for enhancing 
selectivity, efficacy and safety of PD-1/PD-L1 checkpoint inhibition approaches in EG-
FR-overexpressing malignancies.
Introduction
Interaction between Programmed Death-1 receptor (PD-1) and PD ligand 1 (PD-L1) in-
hibits proliferation and cytokine production by antigen-experienced CD8+ T cells and 
serves to prevent collateral damage and autoimmunity.1 Cancer cells can misuse this im-
mune checkpoint in order to escape from elimination by anticancer CD8+ T cells.2 Cancer 
cells may constitutively express PD-L1 due to aberrant oncogenic signals or upregulate 
PD-L1 in an adaptive response to IFN-γ released by anticancer CD8+ T cells in the tumor 
microenvironment.2, 3 Expression of PD-L1 on cancer cells is associated with reduced 
survival and unfavorable prognosis in selected cancer types, including melanoma, lung 
cancer and renal cancer.4-6
Blocking the interaction between PD-L1 on tumor cells and PD-1 on effector T cells using 
antagonistic antibodies is a promising therapeutic approach and produced durable an-
titumor responses in multiple cancer types. Particularly, nivolumab and pembrolizumab 
yielded long-term remissions in advanced stage melanoma7-9 and non-small-cell lung 
carcinoma (NSCLC)10, 11. However, PD-1 and PD-L1 are also broadly expressed on normal 
cells which may reduce the efficacy of PD-1/PD-L1 blocking antibodies. Consequently, 
treatment with PD-1/PD-L1 blocking antibodies can have severe autoimmune-related 
side effects in the skin, gastrointestinal tract, liver and lungs as observed for nivolumab.7, 
12
To improve the clinical activity, various combinations of immune checkpoint-blocking an-
tibodies have been evaluated, including combining the PD-1-blocking antibody nivolum-
ab with the cytotoxic T lymphocyte antigen-4 (CTLA-4)-blocking antibody ipilimumab. 
This combination significantly enhanced response rates in melanoma patients, but is also 
associated with a higher incidence of toxicities than single antibody therapy.12
Recently, we proposed a novel approach to safely improve the efficacy of immune check-
point blockade using a recombinant fusion protein, designated anti-PD-L1:TRAIL, in 
which a PD-L1-blocking scFv antibody fragment is fused to a soluble form of the tu-
mor-selective pro-apoptotic death ligand TRAIL. In vitro evaluation demonstrated that 
anti-PD-L1:TRAIL not only enhanced the anticancer activity of T cells, but also selectively 
induced TRAIL-mediated apoptosis of PD-L1-positive cancer cells.13
Here, we describe a novel bispecific antibody (bsAb)-based approach that allows for 
more selectively directing PD-1/PD-L1 blockade to cancer cells. For this purpose, we 
produced recombinant bsAb PD-L1xEGFR that was designed to have both blocking activ-
ity for PD-L1 and high-affinity binding activity for the epidermal growth factor receptor 
(EGFR). EGFR is a well-established tumor target antigen that is overexpressed by vari-
ous malignancies in which it correlates with poor prognosis.14, 15 Aberrant EGFR signaling 
plays crucial roles in the pathogenesis of cancer by initiating the early stages of tumor 
development, sustaining tumor growth, promoting infiltration, and mediating resistance 
to therapy (reviewed in16). Several EGFR-targeted strategies that inhibit oncogenic EGFR 
signaling are FDA-approved (reviewed in17), including antibody cetuximab. Of note: 
cetuximab (IgG1) not only inhibits downstream signaling of EGFR18 but also activates 











Taken together these notions prompted us to devise and pre-clinically evaluate a nov-
el bispecific antibody-based approach to achieve EGFR-directed PD-1/PD-L1 immune 
checkpoint inhibition. To this end, we constructed recombinant bispecific antibody (bsAb) 
PD-L1xEGFR that comprises a PD-L1-blocking scFv antibody fragment fused in tandem to 
an EGFR-directed scFv and a human IgG1 Fc domain. 
Materials and methods
Antibodies and reagents
Goat anti-human Ig-PE (Southern Biotech), anti-PD-L1-APC (clone 29E.2A3, BioLegend), 
anti-EGFR-FITC (clone 528, Santa Cruz Biotechnology), anti-CD137-PE (clone 4B4, eBio-
science), anti-CD107a-APC (clone H4A3, BD Pharmingen), anti-IFN-γ-PerCP-Cyanine5.5 
(clone 4S.B3, eBioscience), anti-CD3-PerCP-Cyanine5.5 (clone OKT-3, eBioscience), and 
anti-CD8-FITC, APC (clone HIT8a), anti-CD56-PE (clone B-A19), anti-CD14-FITC, PE 
(clone MEM-15), anti-CD25-FITC, APC (clone MEM-181), anti-HLA-DR-FITC, PE (clone 
MEM-12), mouse IgG1-FITC, PE, Mouse IgG2b-APC, Annexin-V-FITC (all from Immu-
notools). Recombinant human IFN-γ, TNF-α, PGE2, GM-CSF, IL-1β, IL-4, IL-6, IL12 and 
anti-CD3 mAb (clone UCHT-1) were purchased from Immunotools. PD-L1-blocking mAb 
was purchased from BPS Bioscience. Anti-EGFR mAb 425 was purchased from Merck. 
Cetuximab was obtained from the Department of Hospital Pharmacy, UMCG, The Neth-
erlands. Secretion of cytokines by T-cells was measured using appropriate ELISA kits 
(IFN-γ from eBioscience and granzyme B from Mabtech) according to the manufacturer’s 
recommendations.
Cell Lines and transfectants 
Cell lines A431, FaDu, H292, OVCAR3, HT1080, DLD-1, LNCaP, A2058, A375m, A2780, 
CHO-K1 and Jurkat cells were obtained from the American Type Culture Collection 
(ATCC). Cells were cultured in RPMI-1640 or DMEM (Lonza), supplemented with 10% 
fetal calf serum (FCS, Thermo Scientific), CHO-K1 cells were cultured in GMEM (First 
Link) supplemented with 5% dialyzed FBS (Sigma Aldrich) at 37°C in a humidified 5% 
CO2 atmosphere. Cell surface expression of PD-L1 and EGFR were analyzed by flow cy-
tometry using anti-PD-L1-APC and anti-EGFR-FITC antibodies. 
CHO.PD-L1 cells stably expressing human PD-L1 were generated by lipofection (Fu-
gene-HD, Promega) with plasmid pCMV6-PD-L1 (Origene). A431.pp65 cells stably ex-
pressing CMV pp65 protein were generated by lipofection with plasmid pCMV6-pp65 
(Origene). A2058-EpCAM cells stably expressing EpCAM-YFP were generated by lipo-
fection with plasmid pEpCAM-YFP-N1 (kindly provided by Dr. Olivier Gires, Munich, Ger-
many). Clones with stable expression of the indicated transgenes were selected using 
culture media supplemented with the appropriate antibiotic. 
Construction of bsAb PD-L1xEGFR
Recombinant antibody fragments encoding scFvPD-L1 and scFvEGFR were generated by 
commercial gene synthesis service (Genscript) using published VH and VL sequence data 
of PD-L1-blocking antibody 3G10 and EGFR-directed antibody mAb 425, respectively. For 
construction and production of bsAb PD-L1xEGFR we used eukaryotic expression plasmid 
pEE14-bsAb,20 which contains 3 consecutive multiple cloning sites (MCS). MCS#1 and 
MCS#2 are interspersed by a 22 amino acid flexible linker derived from a CH1 domain. 
MCS#1, MCS#2 and MCS#3 were used for directional and in-frame insertion of DNA 
fragments encoding scFvPD-L1, scFvEGFR, and human IgG1, respectively, yielding plas-
mid pEE14-PD-L1xEGFR. Analogously, we constructed pEE14-PD-L1xMock by replacing 
scFvEGFR by scFv4-4-20 that is directed against fluorescein. 
Eukaryotic production of bsAb PD-L1xEGFR 
BsAb PD-L1xEGFR and bsAb PD-L1xMock were produced using the Expi293 expression 
system according to manufacturer’s recommendations (ThermoFisher). Briefly, Expi293 
production cells were transfected with plasmid pEE14-PD-L1xEGFR or pEE14-PD-L1x-
Mock and cultured in suspension for 7 days on a shaker platform (125 rpm) at 37°C, 8% 
CO2. Next, conditioned culture supernatant was harvested and cleared by centrifugation 
(1,500g, 10 min), after which bsAb PD-L1xEGFR and bsAb PD-L1xMock were purified 
using an HiTrap protein A HP column connected to ÄKTA Start chromatography system 
(GE Healthcare Life Sciences).
Assessment of EGFR-specific binding by bsAb PD-L1xEGFR
EGFR-specific binding of bsAb PD-L1xEGFR was assessed by flow cytometry using EG-
FR-positive cancer cells (A431, FaDu, OVCAR3, HT1080, DLD1, LNCaP) versus EGFR-neg-
ative cancer cells (A2058, A375m, A2780, Jurkat). In short, cancer cells were incubated 
with bsAb PD-L1xEGFR (0.01-10 µg/ml, 45 min at 4°C), washed 3 times with PBS, and 
then incubated with a PE-conjugated anti-human mAb (45 min at 4°C).
Assessment of functional affinity of bsAb PD-L1xEGFR 
Functional affinity (the accumulated strength of affinities for PD-L1 and EGFR) of bsAb 
PD-L1xEGFR was assessed using a competitive binding assay. In short, PD-L1+/EGFR+ 
A431 cells were pre-incubated (or not) with excess amounts of mAb 425 (50 µg/ml) 
for 15 min at  4°C, after which bsAb PD-L1xEGFR or bsAb PD-L1xMock was added in a 
concentration range from 0.01 to 50 µg/ml. After 1h, an APC-labeled PD-L1-blocking 
antibody (8 µg/ml) was added and allowed to compete for PD-L1 binding for 30 min. 
Competitive binding of anti-PD-L1-APC to A431 cells was quantified by flow cytometry. 
Bioassay for PD-1/PD-L1 blockade 
Blockade of PD-1/PD-L1 interaction was assessed using the PD-1/PD-L1 Blockade Bio-
assay (Promega). This assay uses two engineered cell lines; Jurkat-PD1-NFAT-luc T cells 
expressing both PD-1 and NFAT-inducible luciferase and CHO-PD-L1-CD3 cells express-
ing both PD-L1 and a membrane-linked agonistic anti-CD3 antibody. When co-cultured, 
PD-1/PD-L1 interaction between both cell types inhibits TCR signaling and NFAT-medi-
ated luciferase activity in Jurkat-PD1-NFAT-luc indicator T cells. Addition of a PD-1/PD-
L1 blocking antibody results in TCR signaling and subsequent NFAT-mediated luciferase 











Bioassay for EGFR-directed PD-1/PD-L1 blockade by bsAb PD-L1xEGFR
The capacity of bsAb PD-L1xEGFR for EGFR-directed PD-1/PD-L1 blockade was assessed 
using a modified assay in which CHO-PD-L1-CD3 cells were replaced by A431 cells (EG-
FRpos/EpCAMpos/PD-L1pos) pretreated with a suboptimal amount of bsAb BIS-1; an Ep-
CAM-directed CD3-agonistic bispecific antibody21. The latter results in the decoration of 
A431 cells with BIS-1 and that endows them with capacity for anti-CD3-mediated TCR 
triggering of Jurkat-PD1-NFAT-luc indicator T cells. In short, Jurkat-PD1-NFAT-luc T cells 
were mixed with CHO-PD-L1-CD3 cells or BIS-1-pretreated A431 cells at a cell ratio of 5 
to 1 and then cultured for 18h in the presence of bsAb PD-L1xEGFR, bsAb PD-L1xMock 
or appropriate control antibodies. Subsequently, Bio-Glo reagent was added after which 
bioluminescence was quantified using a Victor V3 multilabel plate reader (Perkin Elmer).
Assessment of T cell stimulation by bsAb PD-L1xEGFR
PBMCs were obtained from healthy volunteers after informed consent using standard 
density gradient centrifugation (Lymphoprep) and labeled with carboxyfluorescein suc-
cinimidyl ester (CFSE) (CellTracel Proliferation Kit, Invitrogen). CFSE-labeled PBMCs 
were cultured in a 96-wells plate at a density of 1x105 cells/well and stimulated with 
agonistic anti-CD3 mAb UCHT-1 (0.5 µg/ml). BsAb PD-L1xEGFR, bsAb PD-L1xMock or 
appropriate control antibodies were added to the wells (5 µg/ml) and T cell proliferation 
was measured at day 5 by analysis of CFSE dilution by flow cytometry.
Assessment of T cell activation by bsAb PD-L1xEGFR in MLR assay
The capacity of bsAb PD-L1xEGFR to promote activation of T cells was assessed in a 
mixed lymphocyte reaction (MLR). To this end, monocytes were isolated from PBMCs by 
adherence to culture flasks followed by culturing in X-VIVO-15 medium (Lonza), sup-
plemented with 2% human serum (HS; PAA laboratories), IL-4 (500 U/ml) and GM-CSF 
(800 U/ml). After 3 days, MoDCs were matured by continuing culturing for an additional 
24h in the presence of IL-1ß (5 µg/ml), IL-6 (15 µg/ml), TNF-α (20 µg/ml), and PGE2 
(2.5 mg/ml), essentially as described before (Hobo, 2012). For the MLR, freshly isolated 
PBMCs were labeled with CFSE, resuspended in RPMI + 10% HS at 2x106 cells/ml and 
then stimulated with allogeneic MoDC in a final volume of 200µl/well using round-bottom 
96-well plates (Corning Costar) at T cell to DC cell ratio of 10 to 1. Next, bsAb PD-L1xE-
GFR, bsAb PD-L1xMock, or appropriate control antibodies were added to the wells (5 µg/
ml). After 5 days of co-culturing, spend culture medium was collected and assayed for 
cytokine secretion. Subsequently, induction of T cell proliferation was evaluated by CFSE 
dilution analysis using flow cytometry. 
Assessment of inhibition of cancer cell proliferation by bsAb PD-L1xEGFR
Cancer cells were pre-cultured in 48-wells plates in RPMI-1640 (or DMEM) containing 
10% FBS for 6h at a density of 8.000 cells/well, followed by addition of bsAb PD-L1x-
EGFR, bsAb PD-L1xMock or appropriate control antibodies (each 5 µg/ml).  After 5 d, 
cancer cell proliferation was determined in a MTS-based colorimetric assay (CellTiter 
96, Promega) using a Victor V3 multi-label plate counter (Perkin Elmer) at 490 nM. 
Absorbance data for maximum cell death were obtained by control treatment with 70% 
ethanol for 15 min. 
Assessment of promotion oncolytic activity of BIS-1-redirected T cells by bsAb 
PD-L1xEGFR
T cells were sorted from PBMC by MACS using the human Pan T cell isolation kit accord-
ing to manufacturer’s protocol (Miltenyi Biotec). Sorted T cells were incubated with bsAb 
BIS-1 (75 ng/ml) and then added to A431, FaDu or A2058.EpCAM cells in a 2 to 1 cell 
ratio, in the presence or absence of bsAb PD-L1xEGFR, bsAb PD-L1xMock, or appropriate 
control antibodies (5 µg/ml). At day 3, apoptosis induction in cancer cells (Annexin-V) 
and CD25 expression on T cells were evaluated by flow cytometry. 
Assessment of activation of antigen-experienced T cells bsAb PD-L1xEGFR
We assessed whether bsAb PD-L1xEGFR could promote the cytotoxicity of CMV-specif-
ic CD8+ T-cells towards HLA-matched EGFR+ A431.pp65 versus wild type A431 target 
cells. To this end, A431.pp65 or A431 cells were incubated with bsAb PD-L1xEGFR, bsAb 
PD-L1xMock or appropriate control antibodies (5 µg/ml), washed to remove unbound 
antibody and then cultured in 48-wells plates at a density of 3x104 cells/well. Freshly 
isolated PBMCs from a CMV-positive donor were then mixed with cancer cells at cell 
ratio of 20 to 1. At day 4, the PBMCs were restimulated with A431 or A431.pp65 cells 
treated (or not) with the indicated antibodies. At day 7, 40% of PBMCs were removed, 
restimulated for 1h with fresh A431 or A431.pp65 cancer cells, followed by incubation 
for 16h in the presence of monensin (eBioscience) and anti-CD107a (BD Pharmigen). 
Subsequently, T-cells were stained with fluorescently-labeled anti-CD3 and anti-CD8 an-
tibodies after which intracellular IFN-γ production was evaluated by flow cytometry us-
ing the FIX&PERM® kit (NordicMubi) and anti-IFN-γ antibody labeled with PerCp.Cy5.5 
(eBioscience). At day 8, the remaining PBMCs were harvested and analyzed for CD3, 
CD8, HLA-DR, CD25 and CD137 expression by flow cytometry. The corresponding spend 
culture supernatants were assayed for cytokine production.
Assessment of NK cell-mediated ADCC by bsAb PD-L1xEGFR
NK cells were sorted from PBMCs using the MagnisortTM Negative Selection kit according 
to manufacturer’s instructions (eBioscience). Sorted NK cells were stimulated for 24h 
with IL-12 (10 ng/ml) at a density of 1x106 cells/ml in RPMI-1640/10% FBS as described 
previously.33 NK cells were washed with PBS and then mixed with cancer cells at indicat-
ed E to T ratio’s and treated with bsAb PD-L1xEGFR, bsAb PD-L1xMock or appropriate 
control antibodies (5 µg/ml). After 18h of treatment, apoptosis was assessed by flow 
cytometry using Annexin-V staining. 
Alternatively, LNCaP cells were treated with PBMCs at E to T ratio of 5 to 1 and then 
treated with bsAb PD-L1xEGFR or indicated control antibodies (5 µg/ml). After 48h, AD-













Statistical analysis was performed by one-way ANOVA followed by Bonferroni post-hoc 
test, as indicated using Prism software. P<0.05 was defined as a statistically significant 
difference. Where indicated * = P<0.05; ** = P<0.01; *** = P<0.001.
Results
Eukaryotic production of bsAb PD-L1xEGFR 
BsAb PD-L1xEGFR was constructed as a so-called bispecific (scFv)4-IgG1
22, a class of 
symmetric tetravalent bispecific human IgG1 molecules (Suppl. Fig. 1A), produced in 
human HEK293 cells and purified by protein A column chromatography.
BsAb PD-L1xEGFR selectively and simultaneously binds to PD-L1 and EGFR 
In flow cytometric analysis, bsAb PD-L1xEGFR dose-dependently bound to CHO.PD-L1 
cells and not to CHO cells (Fig. 1A). Similarly, bsAb PD-L1xEGFR showed potent binding 
to EGFR-expressing A431 cells, whereas bsAb PD-L1xMock only minimally bound to A431 
cells (Fig. 1B). Binding levels of bsAb PD-L1xEGFR to a panel of EGFR+PD-L1+ cell lines 
closely correlated with respective expression levels of EGFR (Fig. 1C and Suppl. Fig. 1B). 
In contrast, relative low binding of bsAb PD-L1xEGFR was detected to EGFR-PD-L1+ cell 
lines (Fig. 1C). Furthermore, the binding of bsAb PD-L1xEGFR to A431 cells was strongly 
inhibited in the presence of excess amounts of parental anti-EGFR mAb 425, whereas 
presence of excess amounts of a PD-L1-blocking antibody only partly inhibited binding. 
Importantly, binding of bsAb PD-L1xEGFR to A431 cells was fully abrogated only in the 
combined presence of excess amounts of a clinically-used PD-L1-blocking antibody and 
mAb 425 (Fig. 1D), indicating that bsAb PD-L1xEGFR selectively and simultaneously 
binds to PD-L1 and EGFR. 
Enhanced functional affinity of bsAb PD-L1xEGFR towards PD-L1+/EGFR+ can-
cer cells
Functional affinity (avidity) of bsAb PD-L1xEGFR was assessed in a competitive binding 
assay. The data indicated that bsAb PD-L1xEGFR strongly outperformed bsAb PD-L1x-
Mock in preventing the binding of a conventional PD-L1-blocking antibody to PD-L1+/
EGFR+ A431 cancer cells, with a calculated IC that was at least 100 times lower. The 
competitive binding capacity of bsAb PD-L1xEGFR for A431 cells was reduced to that of 
bsAb PD-L1xMock when incubation was performed in the presence of an excess amount 
of anti-EGFR mAb 425 (Fig. 1E). Together, this indicated that bsAb PD-L1xEGFR has 
strongly enhanced avidity towards PD-L1+/EGFR+ A431 cells compared to bsAb PD-L1x-
Mock. 
Figure 1: BsAb PD-L1xEGFR selectively and simultaneously binds to PD-L1 and EGFR. A) CHO.PD-
L1 or parental CHO cells were incubated with an increasing dose of bsAb PD-L1xEGFR and binding 
was analyzed by flow cytometry. B) EGFR-positive A431 cells were incubated with an increasing 
dose of bsAb PD-L1xEGFR or PD-L1xMock and binding was analyzed by flow cytometry. C) Binding 
of bsAb PD-L1xEGFR or PD-L1xMock to EGFR+/PD-L1+ and EGFR-/PD-L1+ cell lines was analyzed by 
flow cytometry. D) Binding of bsAb PD-L1xEGFR (1 µg/ml) to A431 cells in the presence or absence 
of excess mAb PD-L1 and/or EGFR blocking mAb 425 was analyzed by flow cytometry. E) Binding of 
PD-L1-APC to A431 cells in the presence of an increasing dose (0.01-50 µg/ml) of bsAb PD-L1xEGFR 
or PD-L1xMock was analyzed by flow cytometry. Where indicated, A431 cells were pre-treated with 
excess EGFR-blocking mAb 425 (50 µg/ml) or isotype control IgG2a 15 min before addition of bsAb 
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BsAb PD-L1xEGFR and bsAb PD-L1xMock have comparable PD-1/PD-L1 block-
ing activity
The capacity of bsAb PD-L1xEGFR and bsAb PD-L1xMock to inhibit PD-1/PD-L1 inter-
action was evaluated using a commercially available PD-1/PD-L1 blockade bioassay. In 
this assay, both bsAb PD-L1xEGFR and bsAb PD-L1xMock showed similar capacity to 
dose-dependently release the PD-1/PD-L1 mediated block on TCR signaling in the Jurkat 
indicator T cells which resulted in prominent induction of luciferase activity (Fig. 2A). 
In the same assay, equimolar amounts of a clinically used high-affinity PD-L1-blocking 
antibody appeared to be more potent in blocking PD-1/PD-L1 interaction compared to 
bsAbs PD-L1xEGFR and PD-L1xMock, whereas an isotype-matched control antibody of 
irrelevant specificity did not block PD-1/PD-L1 interaction.
BsAb PD-L1xEGFR blocks PD1/PD-L1 interaction in an EGFR-directed manner
Next, we investigated whether EGFR-directed binding by bsAb PD-L1xEGFR also en-
hanced its capacity to block PD-1/PD-L1 interaction. To this end, we modified the stan-
dard PD-1/PD-L1 blockade bioassay by replacing CHO-PD-L1-CD3 cells by EGFR- and 
PD-L1-expressing A431 cells that were artificially equipped with anti-CD3 agonistic ac-
tivity. Similar as observed in the standard PD-1/PD-L1 blockade bioassay, co-culturing of 
anti-CD3-equipped A431 cells with Jurkat indicator T cells resulted in minimal luciferase 
activity. In the modified assay, bsAb PD-L1xEGFR and a clinically used PD-L1 antibody 
showed comparable capacity for dose-dependent inhibition of PD-1/PD-L1 interaction as 
was evident from the comparable increase in luciferase activity (Fig. 2B). Importantly, 
PD-1/PD-L1 blocking activity of both bsAb PD-L1xMock and isotype-matched control an-
tibody was not enhanced (Fig. 2B). Taken together, the data indicated that bsAb PD-L1x-
EGFR blocks PD1/PD-L1 interaction in an EGFR-directed manner. 
BsAb PD-L1xEGFR and bsAb PD-L1xMock promote activity of T cells
Next, the capacity of bsAb PD-L1xEGFR and bsAb PD-L1xMock to activate suboptimal 
CD3-stimulated T cells was evaluated. The results indicated that bsAb PD-L1xEGFR and 
bsAb PD-L1xMock have comparable capacity to promote proliferation (Fig. 2C) and IFN-γ 
secretion (Fig. 2D) by suboptimal CD3-activated T cells. Similar treatment with agonistic 
anti-CD3 antibody alone or combined with anti-EGFR antibody cetuximab did not signifi-
cantly enhance proliferation or IFN-γ secretion by T cells. Similarly, in a MLR of CFSE-la-
beled PBMCs and DCs, bsAb PD-L1xEGFR and bsAb PD-L1xMock showed comparable 
capacity to promote T cell proliferation (Fig. 2E and F) and IFN-γ production (Fig. 2G) 
Figure 2: BsAb PD-L1xEGFR blocks the PD-1/PD-L1 interaction A) Blockade of the PD-1/PD-L1 in-
teraction was analyzed using the commercially available PD-1/PD-L1 Blockade Bioassay (Promega). 
Briefly, mixed cultures of CHO-K1.PD-L1 cells and Jurkat.PD-1 cells were treated with an increasing 
dose (0.01-10 µg/ml) of bsAb PD-L1xEGFR, PD-L1xMock, human anti-PD-L1 mAb or isotype control. 
NFAT-RE-mediated luciferase activity was quantified using a plate reader and expressed as fold in-
crease compared to medium control. B) Similar to A, mixed cultures of EGFR-positive A431 cells and 
Jurkat.PD-1 cells were treated with an increasing dose (0.01-10 µg/ml) of indicated antibodies in the 
presence of 75 µg/ml BIS-1.





























































human anti-PD-L1 Figure 2 (continued): BsAb PD-L1xEGFR blocks the PD-1/PD-L1 interaction and promotes T cell 
activation. C) CFSE-labeled PBMCs were treated with agonistic CD3 mAb (0.5 µg/ml) in combination 
with bsAb PD-L1xEGFR, bsAb PD-L1xMock or cetuximab (5 µg/ml). After 5 days, cell proliferation 
was analyzed by flow cytometry. %proliferation in medium control was subtracted. D) IFN-γ levels in 
culture supernatant of C were determined by ELISA. E) Representative histograms of CFSE-labeled 
PBMCs co-treated with allogenic DCs and bsAb PD-L1xEGFR or bsAb PD-L1xMock. F) CFSE-labeled 
PBMCs were co-treated with allogenic DCs and bsAb PD-L1xEGFR, bsAb PD-L1xMock or anti-PD-L1. 
After 5 days, cell proliferation was analyzed by flow cytometry. G) IFN-γ levels in culture supernatant 


























































































































































































that outperformed a human anti-PD-L1 antibody. Taken together, both bsAb PD-L1xEGFR 
and bsAb PD-L1xMock promote proliferation and IFN-γ secretion by T cells that is most 
likely due to their capacity to block PD-1/PD-L1 interaction.
BsAb PD-L1xEGFR promotes cytotoxic activity of BIS-1-redirected T cells
To evaluate whether bsAb PD-L1xEGFR promoted cytotoxic activity, T cells were redirect-
ed to EpCAM expressing cancer cells using a suboptimal amount of BIS-1 (an EpCAM-di-
rected CD3-agonistic bispecific antibody.21 BIS-1-redirected T cells triggered apoptosis in 
EpCAM+/EGFR+ DLD-1 and DLD-1.PD-L1 colon cancer cells in an E to T ratio-dependent 
manner (Fig. 3A and B). However, apoptosis induction was significantly enhanced in 
DLD-1.PD-L1 cells, but not in DLD-1 cells, when the same experiment was performed in 
the continued presence of bsAb PD-L1xEGFR (Fig. 3A and B). Similarly, BIS-1-treated 
T cells induced moderate levels of apoptosis in EpCAM+/EGFR+ FaDu cells or A431 cells 
(~20% and ~15%, respectively; Fig. 3C and D) that was significantly enhanced when 
treatment was performed in the continued presence of bsAb PD-L1xEGFR (up to 60% 
in FaDu cells, up to 50% in A431 cells, respectively; Fig. 3C and D). BsAb PD-L1xEG-
FR-enhanced oncolytic activity of T cells was accompanied by a 2-fold increase in IFN-γ 
production (Fig. 3E) and significantly enhanced expression of activation marker CD25 
(Suppl. Fig. 1C). Treatment of FaDu or A431 with bsAb PD-L1xEGFR alone showed mini-
mal apoptosis induction (Fig. 3C and D), whereas treatment with mAb 425 alone resulted 
in moderate apoptosis induction up to 35%. The latter is likely the result of the capacity 
of mAb 425 to block oncogenic EGFR-signaling in cancer cells.
BsAb PD-L1xEGFR promotes cytotoxic activity of BIS-1-redirected T cells in an 
EGFR-directed manner
To evaluate whether bsAb PD-L1xEGFR promoted cytotoxic activity in an EGFR-directed 
manner, incubation with the indicated PD-L1-blocking agents was limited to only 1h, af-
ter which unbound antibodies were removed by washing. Under these conditions, treat-
ment with bsAb PD-L1xEGFR almost completely eradicated the cancer cell monolayer 
while control antibodies had a minimal effect (Fig. 3F). Indeed, the data indicated that 
bsAb PD-L1xEGFR (and not bsAb PD-L1xEGFR or PD-L1 blocking mAb) promoted the 
pro-apoptotic activity BIS-1-redirected T cells towards EGFR-positive cancer cells (A431 
and FaDu, 50% and 80% apoptosis, respectively; Fig. 3G). Importantly, neither bsAb 
PD-L1xEGFR nor bsAb PD-L1xEGFR promoted cytotoxic activity of T cells towards EG-
FR-negative A2058.EpCAM cells (Suppl. Fig. 1D). BsAb PD-L1xEGFR-enhanced oncolytic 
activity of T cells was accompanied by a 3-fold increase in CD25 expression (Fig. 3H). 
Taken together, bsAb PD-L1xEGFR appears to specifically enhance the anticancer activity 










































































































































































































































Figure 3: BsAb PD-L1xEGFR promotes cytotoxic activity of BIS-1-redirected T cells A) DLD1.PD-L1 
or B) DLD1 cells were pre-seeded 24h before PBMCs were added at indicated effector to target (E:T) 
ratio’s. Cells were co-treated in the presence of BIS-1 (100 ng/ml) with or without 5 µg/ml bsAb 
PD-L1xEGFR. After 72h, apoptosis was determined by flow cytometry using Annexin-V staining. 
C) A431 cells were pre-seeded 6h before T-cells were added at E:T ratio 2:1 in the presence of 
BIS-1 (75 µg/ml) and 5 µg/ml bsAb PD-L1xEGFR, anti-PD-L1, bsAb PD-L1xMock, mAb 425 or iso-
type control as indicated. After 72h, apoptosis was determined by flow cytometry using Annexin-V 
staining. D) FaDu cells were treated as described in D. E) IFN-γ levels in culture supernatant of C 
were determined by ELISA. IFN-γ levels for isotype control treatment were subtracted. F) Before 
pre-seeding, FaDu cells were loaded with bsAb PD-L1xEGFR or control antibodies as indicated. After 
6h, T-cells were added at E:T ratio 2:1 in the presence of BIS-1 (75 ng/ml). After 72h, T cells were 
carefully washed away and microscopic images of the FaDu monolayer were taken. G) In mixed cul-
tures with FaDu cells and A431 cells as described in F, apoptosis was determined by flow cytometry 
using Annexin-V staining. H) In mixed cultures with FaDu cells as described in F, expression of T cell 
activation marker CD25 was analyzed by flow cytometry. Mean fluorescence intensity (MFI) of BIS-1 
treatment alone was subtracted. All graphs represent mean ± SD. Statistical analysis in C and D was 












BsAb PD-L1xEGFR enhances cytotoxicity of antigen-experienced T cells
Next we assessed whether bsAb PD-L1xEGFR could promote the cytotoxicity of CMV-spe-
cific CD8+ T-cells towards HLA-matched EGFR+ A431.pp65 cells, that express CMV pp65 
protein, versus wild type A431 target cells. CMV-specific CD8+ T cells showed enhanced 
cytotoxicity towards A431.pp65 (and not towards A431 cells) that were briefly pretreat-
ed with bsAb PD-L1xEGFR. Enhancement of the activity of CMV-specific T cells by bsAb 
PD-L1xEGFR was accompanied by an increased expression of activation markers CD25, 
HLA-DR, CD137 and CD107a compared to treatment with control antibodies (Fig. 4A 
to D). Of note, expression of CD137 is restricted to T cells recently activated through 
TCR-mediated signaling and as such identified specific activation of CMV-specific CD8+ T 
cells by bsAb PD-L1xEGFR towards A431.pp65 cells. Similarly, upregulation of degran-
ulation marker CD107a indicated a concomitantly increased cytotoxic activity (Aktas 
2009). These results were in line with the observed increase in secretion of IFN-γ and 
granzyme B by CD8+ T cells that were co-cultured with bsAb PD-L1xEGFR-pretreated 
A431.pp65 (Fig. 4E and F). Taken together, these results indicate that bsAb PD-L1xEG-
FR increases activity of antigen-experienced CD8+ T cells by blocking PD-1/PD-L1 in an 
EGFR-directed manner. 
BsAb PD-L1xEGFR blocks oncogenic EGFR-signaling
EGFR-blocking antibodies mAb 425 and cetuximab can inhibit oncogenic signaling by 
EGFR. Therefore, the capacity of bsAb PD-L1xEGFR to inhibit cancer cell proliferation 
of EGFR-expressing cancer cells was investigated. Indeed, both bsAb PD-L1xEGFR and 
cetuximab inhibited cell growth of FaDu and H292 cells, whereas bsAb PD-L1xMock and 
isotype control antibody had no effect (Fig. 5A to C). These results indicate that bsAb 
PD-L1xEGFR inhibits EGFR-mediated oncogenic signaling in cancer cells with an efficacy 
comparable to that of cetuximab. 
Figure 4: BsAb PD-L1xEGFR enhances cytotoxicity of antigen-experienced T cells A) A431 or A431.
pp65 cells were incubated with bsAb PD-L1xEGFR or control antibodies as indicated and unbound 
antibody was washed away before pre-seeding. After 6h, T-cells from CMV-positive donors were 
added at effector to target (E:T) ratio 20:1. After 8 days, CD25 expression within CD8+ T cells was 
analyzed by flow cytometry. Additionally, B) HLA-DR, C) CD137, D) CD107a expression, and E) 
intracellular IFN-γ within CD8+ T cells was analyzed by flow cytometry. F) Granzyme B levels within 
culture supernatants of treatment conditions described in A were determined by ELISA. All graphs 
































































































































































































































































Figure 5: BsAb PD-L1xEGFR blocks oncogenic EGFR-signaling and induces NK-cell mediated ADCC 
A) Representative light microscopy images of FaDu cells after 120h treatment with 5 µg/ml bsAb 
PD-L1xEGFR, bsAb PD-L1xMock, cetuximab or isotype control as indicated. B) Cell viability of FaDu 
cells as treated in A was determined by MTS and expressed as percentage of medium control. C) 
Cell viability of H292 cells as treated in A was determined by MTS. D) FaDu cells were mixed with 
IL-12 pre-treated NK cells in indicated effector to target (E:T) ratio’s in the presence of 5 µg/ml bsAb 
PD-L1xEGFR or control antibodies as indicated. After 24h, apoptosis was determined by flow cytom-
etry using Annexin-V staining. E) FaDu cells were co-cultured with IL-12 pretreated NK cells at E:T 
ratio 2:1 as described in D. F) LNCaP cells were mixed with PBMCs in E:T ratio 5:1 in the presence 
of 5 µg/ml bsAb PD-L1xEGFR or control antibodies as indicated. After 48h, apoptosis was determined 
by flow cytometry using Annexin-V staining. All graphs represent mean ± SD. Statistical analysis in B 
and C was performed using One-way ANOVA followed by a Bonferroni post-hoc test. (*p < 0.05, **p 









































































































































































































BsAb PD-L1xEGFR induces NK cell-mediated ADCC
We investigated whether the human IgG1 domain of bsAb PD-L1xEGFR allowed for induc-
ing NK cell-mediated ADCC towards EGFR-expressing cancer cells. Indeed, NK cell-me-
diated ADCC towards FaDu and LNCaP cancer cells was enhanced by bsAb PD-L1xEGFR 
or cetuximab, but not by bsAb PD-L1xMock or murine mAb 425 (Fig. 5D to F). Taken 
together, these data indicated that bsAb PD-L1xEGFR can induce NK cell-mediated ADCC 
towards EGFR-expressing cancer cells. 
Discussion
PD-1/PD-L1-blocking antibodies can restore the anticancer activity of functionally-im-
paired antigen-experienced CD8+ T cells and showed significant clinical efficacy in dif-
ficult-to-treat advanced stage malignant diseases.8, 10 However, the benefits of current 
PD-1/PD-L1 checkpoint inhibition appear to be limited to only a selected group of cancer 
patients and is accompanied by the occurrence of sometimes severe and irreversible au-
toimmune-related adverse events.7, 11, 23 This may be explained by the fact that current 
PD-1- and PD-L1-blocking antibodies lack intrinsic tumor-directed binding selectivity, 
whereas PD-1/PD-L1 checkpoint interactions are likely to be widespread in the human 
body and thus not restricted to the tumor microenvironment. This lack of tumor-selective 
binding reduces sufficient accretion of PD-1/PD-L1-blocking antibodies in the tumor mi-
croenvironment, particularly when local immune checkpoint expression is relatively low. 
Moreover, PD-1/PD-L1-blocking antibodies indiscriminately reactivate all T cells, in-
cluding silenced yet potentially highly deleterious autoreactive T cells. In this respect, 
PD-L1-blocking antibodies generally show less severe side effects than PD-1-blocking 
antibodies, with e.g. 14% drug-related grade 3-4 adverse events reported for a PD-1-
blocking antibody versus 9% for a PD-L1-blocking antibody.7, 24 Moreover, no drug-re-
lated pneumonitis was observed in patients treated with the PD-L1-blocking antibody. 
In line with this, 3-5% grade 3 but no grade 4 adverse events or treatment-related 
deaths were observed in patients treated with PD-L1-blocking antibodies avelumab or 
MEDI4736.25, 26 However, PD-L1 is constitutively expressed on various non-immune cells 
such as vascular endothelium, and endothelial and Kupffer cells in the liver.1, 27 Moreover, 
PD-L1 expression is upregulated by many cell types in response to IFN-γ secretion during 
inflammatory responses.2, 3 Therefore, we reasoned that generation of a PD-L1-blocking 
antibody format with enhanced tumor-selective binding capacity would have more favor-
able therapeutic characteristics. In this respect, bispecific antibodies may provide prom-
ising possibilities to enhance efficacy and selectivity of therapeutic immune checkpoint 
inhibition as they can be designed to simultaneously target cancer cells with high affinity 
and have PD-1/PD-L1 blocking activity.
Here, to the best of our knowledge, we report for the first time on a bispecific antibody 
(bsAb)-based approach that selectively directs PD-L1 blockade to EGFR-overexpressing 
cancer cells. EGFR is a well-established target for antibody-based therapy as it is overex-
pressed by various cancers in which it is involved in oncogenic proliferation and survival 
signaling. EGFR-specific antibodies, like cetuximab, are in clinical practice in oncology 
in which their anticancer action comes from their ability to inhibit EGFR-signaling and 
induce ADCC. 
We constructed bsAb PD-L1xEGFR in the so-called bispecific (scFv)4-IgG1 format, a class 
of symmetric tetravalent bispecific IgGs in which each of the two arms of the molecule 
contains two scFv antibody fragments that are linked in tandem and possess differ-
ent binding specificities.22 The functional affinity, also known as avidity, of a tetravalent 
bs(scFv)4-IgG1 is significantly enhanced compared to bivalent monospecific antibodies 
due to the combined effect of up to 4 individually participating binding affinities. Using 
various detailed preclinical assays we demonstrated that bsAb PD-L1xEGFR has multiple 
mutually reinforcing anticancer activities not available in any of the current conventional 
PD-L1-blocking antibodies. Our data demonstrated that bsAb PD-L1xEGFR (see Fig. 6): 
simultaneously binds to both PD-L1 and EGFR resulting in an enhanced avidity towards 
PD-L1+/EGFR+ cancer cells; blocked PD1/PDL-1 interaction, but less potently then a clini-
cally used PD-L1-blocking antibody; blocked PD-1/PD-L1 interaction in an EGFR-directed 
manner with enhanced avidity; promoted anticancer activity of both BIS-redirected and 
antigen-experienced T cells in an EGFR-directed manner; blocked oncogenic EGFR-sig-
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Figure 6: Proposed mechanism of action for bsAb PD-L1xEGFR. A) Tetravalent bsAb PD-L1xEG-
FR comprises EGFR-blocking and PD-L1-blocking antibody fragments (scFv) and a human IgG1 Fc 
domain. B) BsAb PD-L1xEGFR binds to both PD-L1 and EGFR on the cancer cell surface. C) BsAb 
PD-L1xEGFR blocks EGFR-mediated growth signaling and enhances NK-cell mediated antigen-depen-
dent cellular phagocytosis (ADCC) via its IgG1 domain. D) BsAb PD-L1xEGFR enhances the antitumor 











We expect that these unique features of bsAb PD-L1xEGFR may prove to be of clinical im-
portance for enhancing tumor selectivity, efficacy and safety of PD-1/PD-L1 checkpoint 
inhibition approaches in EGFR-overexpressing malignancies. 
Of particular relevance is the fact that bsAb PD-L1xEGFR enhanced activation of an-
tigen-experienced T-cells in an EGFR-directed manner. In particular, pre-treatment of 
CMV-pp65 transfected EGFR-positive cancer cells with bsAb PD-L1xEGFR, followed by 
removing unbound antibody, potently promoted the oncolytic activity of HLA-matched 
CMV-specific CD8+ T cells, corroborated by an increased expression of CD137, CD107a 
and IFN-γ production. Previously, it was reported that PD-L1 blocking antibody avelumab 
has similar in vitro capacity to enhance activation of antigen-experienced T-cells directed 
against CMV, EBV, Flu or tetanus28, yet obviously not in a tumor-directed manner.
Our data indicated that treatment of EGFR-expressing HNC and NSCLC cell lines with 
bsAb PD-L1xEGFR alone inhibited oncogenic EGFR-signaling with similar efficacy as EG-
FR-targeted antibody cetuximab, as was evident from a comparable reduction in cancer 
cell viability. These results indicated that bsAb PD-L1xEGFR has the combined capacity 
to block both PD-L1 and EGFR signaling. Recently, a link between EGFR-signaling and 
upregulation of PD-L1 expression was discovered in HNC and NSCLC.29-32 Therefore, the 
simultaneous blockade of EGFR-mediated oncogenic signaling and PD-1/PD-L1 interac-
tion by bsAb PD-L1xEGFR may be of therapeutic interest. 
Furthermore, its fully functional human IgG1 domain endowed bsAb PD-L1xEGFR with 
the potential therapeutic capacity to promote NK cell-mediated ADCC in EGFR-express-
ing cancer cells. This is in line with recent reports stating that NK cell-mediated ADCC is 
induced by PD-L1 mAb avelumab (human IgG1)33, 34 and as such enhanced its anticancer 
activity. Typically, PD-1/PD-L1-blocking antibodies are engineered to be of the human 
IgG4 isotype11,24,35 or to contain an engineered IgG domain with reduced ADCC activity to 
avoid elimination of PD-1/PD-L1 expressing immune cells.36, 37 Nevertheless, avelumab 
showed a toxicity profile comparable to ADCC-null PD-L1-blocking antibodies25, 38, 39 with 
only low levels of avelumab-mediated lysis of PBMCs in vitro.28, 33 Since bsAb PD-L1xE-
GFR selectively targets EGFR-positive cancer cells, we expect that IgG1-mediated ADCC 
will enhance the efficacy of bsAb PD-L1xEGFR with minor deleterious effects towards 
immune effector cells. 
In conclusion, our results demonstrate that bsAb PD-L1xEGFR has multiple mutually 
reinforcing anticancer activities not available in any of the current conventional PD-L1-
blocking antibodies. Clinical development of this novel approach appears warrented.
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Supplementary Figure 1: A) BsAb PD-L1xEGFR was constructed as a so-called double-variable 
domain (DVD)-IgG1, a class of symmetric tetravalent bispecific IgGs, and contains EGFR-blocking 
and PD-L1-blocking antibody fragments (scFv) and a human IgG1 Fc domain. B) EGFR-expression 
and binding of 1 µg/ml bsAb PD-L1xEGFR to EGFR-positive cell lines was assessed by flow cytometry. 
C) A431 cells were pre-seeded 6 h before T-cells were added at effector to target (E:T) ratio 2:1 in 
the presence of BIS-1 (75 µg/ml) and 5 µg/ml bsAb PD-L1xEGFR, anti-PD-L1, bsAb PD-L1xMock, 
mAb 425 or isotype control as indicated. After 72 h, expression of T cell activation marker CD25 was 
analyzed by flow cytometry. D) A2058.EpCAM cells were loaded with 5 µg/ml bsAb PD-L1xEGFR, 
anti-PD-L1, bsAb PD-L1xMock, mAb 425 or isotype control as indicated and pre-seeded 6 h before 
T-cells were added at E:T ratio 2:1 in the presence of BIS-1 (75 µg/ml). After 72 h, apoptosis was 
determined by flow cytometry using Annexin-V staining. All graphs represent mean ± SD. Statistical 
analysis in C was performed using One-way ANOVA followed by a Bonferroni post-hoc test. (*p < 





















































































































As outlined in Chapter 2, antibody-based cancer therapy has come of age with more 
than 20 antibodies currently approved and many more in clinical development.1 How-
ever, many of the currently available antibodies are directed against antigens that are 
overexpressed rather than exclusively present on cancer cells. This lack of authentic 
tumor-selectivity may explain the observed limitations in clinical efficacy and the some-
times dose-limiting on-target/off-tumor side-effects. A large body of research is ongo-
ing to leverage the specificity of antibodies towards improved cancer-selective therapy. 
Hereto, antibodies or antibody-derivatives can be equipped with cytotoxic or immuno-
modulatory domains, such as explored for the cytokine TRAIL in Chapter 4. 
Alternatively, recombinant antibodies can be engineered to have specificity for two (or 
even more) tumor-associated target antigens, as explored in Chapter 5. The rapid ad-
vances in antibody engineering have increased the number of available molecular for-
mats, providing tools to rationally design antibody-based drugs with multiple specificities 
and/or effector functions. Of note, suitable targets for antibody-based cancer immuno-
therapy are not limited to tumor antigens, as its efficacy may also be significantly en-
hanced by targeted blocking or activation of selected antigens on immune cells.
In Chapter 3, we describe a novel antibody-based approach to improve the efficacy 
of TRAIL-R2 agonistic antibodies. In brief, we constructed bispecific antibody (bsAb) 
MCSPxDR5, a bispecific tetravalent antibody that comprises a scFv antibody fragment 
derived from tigatuzumab, a clinically evaluated agonistic antibody targeting TRAIL-R2 
(DR5), a high-affinity scFv antibody fragment targeting the melanoma-associated chon-
droitin sulfate proteoglycan (MCSP), and a human IgG1 Fc domain. BsAb MCSPxDR5 
induced potent MCSP-restricted TRAIL-R2-mediated apoptosis in a panel of melanoma 
cell lines and primary patient-derived melanoma cells. BsAb MCSPxDR5 also inhibited 
colony formation of melanoma cells more efficiently than an agonistic anti-DR5 antibody, 
suggesting a synergistic effect of combined apoptosis induction via DR5 and simultane-
ous blockade of MSCP-mediated proliferative signaling by bsAb MCSPxDR5. Importantly, 
cross-linking of its Fc domain using either artificial cross-linker or Fc receptor positive 
immune effector cells significantly enhanced its anticancer activity. BsAb MCSPxDR5 also 
enhanced the anticancer efficacy of NK cells via Fc-mediated induction of antibody-de-
pendent cellular cytotoxicity (ADCC). Taken together, bsAb MCSPxDR5 has promising 
MCSP- and DR5-restricted anticancer activity, which warrants further development for 
the treatment of melanoma and other MCSP-positive malignancies.
In Chapter 4, we describe a novel checkpoint inhibition strategy that combines re-
activation of anticancer immunity via blockade of the PD-1/PD-L1 interaction with si-
multaneous induction of TRAIL-mediated apoptosis. Hereto, we constructed anti-PD-
L1:TRAIL, a bi-functional TRAIL fusion protein that comprises a PD-L1 blocking scFv 
antibody fragment genetically fused to soluble TRAIL. Fusion protein anti-PD-L1:TRAIL 
selectively induced apoptosis in PD-L1-positive cancer cell lines and primary patient-de-
rived melanoma cells. At the same time, anti-PD-L1:TRAIL enhanced anticancer activity 
and IFN-γ production of T cells via blockade of the PD-1/PD-L1 interaction. Since IFN-γ 
increases PD-L1 expression and sensitizes cancer cells to TRAIL-mediated apoptosis, 
anti-PD-L1:TRAIL may trigger a feed-forward loop of increasing IFN-γ, increasing PD-L1 
expression and increasing TRAIL sensitivity. In line with this, IFN-γ enhanced the efficacy 
of anti-PD-L1:TRAIL-mediated apoptosis in cell lines and in primary patient-derived mel-
anoma cells. Additionally, anti-PD-L1:TRAIL was able to convert potentially immunosup-
pressive PD-L1-expressing immune cells into TRAIL-displaying effector cells that induce 
TRAIL-mediated apoptosis in cancer cells. In conclusion, fusion protein anti-PD-L1:TRAIL 
shows promising multi-fold and mutually reinforcing anticancer activity that may pro-
vide possibilities to enhance the efficacy of therapeutic PD-1/PD-L1 inhibition alone or in 
combinatorial strategies.
In Chapter 5, we describe a novel bispecific antibody-based strategy for tumor-selec-
tive blockade of PD-1/PD-L1 that may increase efficacy and safety of immune check-
point inhibition. Hereto, we constructed recombinant bsAb PD-L1xEGFR that comprises 
a PD-L1-blocking scFv antibody fragment, an epidermal growth factor receptor (EG-
FR)-targeted scFv antibody fragment, and a human IgG1 Fc domain. BsAb PD-L1xE-
GFR was designed to selectively block the PD-1/PD-L1 interaction in an EGFR-directed 
fashion. BsAb PD-L1xEGFR inhibited the PD-1/PD-L1 interaction on EGFR-positive cells 
with similar efficacy as a conventional PD-L1-blocking antibody. Importantly, our data 
showed that treatment of EGFR and PD-L1-positive cancer cells with bsAb PD-L1xEGFR 
resulted in EGFR-directed blocking of PD-L1, which resulted in both enhanced anticancer 
activity and IFN-γ production of T cells. Additionally, bsAb PD-L1xEGFR enhanced NK 
cell-mediated ADCC towards cancer cells via its human IgG1 Fc domain and reduced 
the viability of EGFR-positive cancer cells by blocking oncogenic EGFR-signaling. Indeed, 
bsAb PD-L1xEGFR selectively enhanced the anticancer activity of T cells towards EG-
FR-positive cells and as such outperformed a PD-L1-blocking antibody that is in clinical 
use. In conclusion, the promising multi-fold EGFR-restricted anticancer activity of bsAb 
PD-L1xEGFR may provide possibilities to improve clinical efficacy and reduce side effects 
compared to conventional PD-1/PD-L1 antibodies. 
Future perspectives
Antibody-based blockade of immune checkpoint molecules such as CTLA-4 and PD-1/PD-
L1 has emerged as a promising strategy to improve anticancer immune responses.2 In 
particular, antibodies that block the PD-1/PD-L1 checkpoint have triggered unprecedent-
ed curative anticancer immunity, most notably in advanced melanoma.3, 4 However, since 
PD-1 and PD-L1 are broadly expressed on normal tissues, antibodies blocking the PD-1/
PD-L1 interaction are not inherently tumor-selective. This can result in severe autoim-
mune-related side effects in the skin, gastrointestinal tract, liver and lungs as observed 
for PD-1 blocking antibodies nivolumab and lambrolizumab.4-6 Additionally, despite their 
unprecedented response rates, only a subset of patients responds to single treatment 
with currently available PD-1 and PD-L1 blocking antibodies.3, 4 Hence, there is a clear 
rationale to improve the efficacy of PD-1/PD-L1 blocking immunotherapy.
Based on our results in Chapter 4-5, we speculate that bsAb PD-L1xEGFR and fusion 
protein anti-PD-L1:TRAIL may be able to enhance therapeutic efficacy and reduce side 











that bsAb PD-L1xEGFR selectively delivers PD-L1 blockade to EGFR-positive target cells 
(Chapter 5). We expect that EGFR-directed blockade of the PD-1/PD-L1 checkpoint will 
result in less on-target/off-tumor side effects compared to currently available PD-1/
PD-L1-blocking antibodies. Moreover, we showed that bsAb PD-L1xEGFR has additional 
anticancer activities, including blockade of pro-tumorigenic EGFR-signaling and induc-
tion of Fc-mediated ADCC. The multi-fold modes-of-action of bsAb PD-L1xEGFR may be 
responsible for its potent anticancer activity that appears to outperform a clinically used 
conventional PD-L1-blocking antibody. 
Alternatively, the efficacy of PD-1/PD-L1 targeted therapy may be enhanced using fu-
sion proteins that combine PD-1/PD-L1 blockade with a tumor-selective immune effec-
tor molecule such as TNF-related Apoptosis Inducing Ligand (TRAIL). In Chapter 4, 
we showed that TRAIL fusion protein anti-PD-L1:TRAIL efficiently combines reactivation 
of anticancer immunity via blockade of the PD-1/PD-L1 interaction with simultaneous 
induction of TRAIL-mediated apoptosis in cancer cells. The multi-fold and mutually re-
inforcing anticancer activities of anti-PD-L1:TRAIL appeared superior to the anticancer 
activity of conventional PD-L1-blocking antibodies. We therefore speculate that anti-PD-
L1:TRAIL may be of use in PD-1/PD-L1-blocking immunotherapy for obtaining clinical 
efficacy at reduced dosages, thereby limiting side effects. 
Reduction of the on-target/off-tumor side effects observed for current PD-1/PD-L1 block-
ing antibodies is particularly relevant in combinatorial regimes with other immunothera-
peutic strategies, such as adoptive transfer of autologous tumor-infiltrating lymphocytes 
(TILs) or T cells that have been genetically engineered to express a chimeric antigen 
receptor (CAR), as discussed later. 
Adoptive transfer of autologous TILs can induce durable MHC-restricted responses in 
patients with metastatic melanoma.7 Such TILs are harvested after surgical resection, 
expanded and tested for appropriate anticancer activity and then re-infused into the 
same patient. However, such TILs are characterized by expression of PD-1,8 implicat-
ing that their anticancer may be hampered by PD-1/PD-L1 interaction in the tumor 
microenvironment. This forms a rationale to combine adoptive transfer of autologous 
TILs with PD-1/PD-L1-blocking immunotherapy. In line with this, TILs from mice that 
were pretreated with a PD-L1-blocking antibody showed enhanced anticancer efficacy 
after adoptive transfer.9 We speculate that combining adoptive transfer of TILs with tu-
mor-selective blockade of PD-1/PD-L1 interaction (e.g. using a melanoma-directed PD-
L1-blocking bsAb) may result in enhanced efficacy and possibly a more favorable safety 
profile compared to combinations with conventional PD-1/PD-L1-blocking antibodies.
CAR T cells are generated by transfection of peripheral blood T cells from a patient with 
a CAR construct that comprises an extracellular scFv domain, a transmembrane domain, 
and one or more intracellular co-stimulatory domains.10 As a result, CAR T cells are redi-
rected to cancer cells irrespective of their endogenous TCR specificity in a MHC-non-re-
stricted manner. Upon binding to the tumor-associated target antigen, CAR T cells are 
engaged to proliferate and kill the targeted tumor cells. Thus, CAR T cells harness the 
capacity of both antibody-mediated target antigen recognition and selective delivery of 
the full cytotoxic T cell armament. However, CAR T cells are typically directed against 
tumor-associated antigens that are overexpressed on cancer cells, but that may also be 
expressed at lower levels on normal tissues. Consequently, CAR T cell treatment often 
shows deleterious on-target/off-tumor activity towards normal cells that express these 
target antigens.11 Moreover, in mouse models with established tumors, it was identified 
that several tumor-related factors may limit the clinical activity of CAR T cells,12, 13 in-
cluding PD-1/PD-L1 interaction in the tumor microenvironment. Of note, co-treatment of 
CAR T cells with conventional PD-1/PD-L1 blocking antibodies is likely to further enhance 
on-target/off-tumor side effects. Based on our results in Chapter 4-5, we speculate that 
combinatorial regimes with PD-L1xEGFR or anti-PD-L1:TRAIL and CAR T cells may be of 
use to enhance therapeutic efficacy while reducing side effects and as such may outper-
form combinations with conventional PD-1/PD-L1- blocking antibodies. 
Of note, several strategies have been applied to reduce on-target/off-tumor side effects 
of CAR T cells. These include incorporation of ‘ON-switches’ for suicide genes that allow 
for controlled shut-down of CAR T cells14, 15 and dual specificity CARs that redirect T cells 
to two different tumor antigens.16, 17 
Recently, the use of so-called synthetic Notch (synNotch) receptors has been described. 
Using this approach, T cells can be engineered to only express the CAR in the tumor 
environment.18 Binding of the synNotch receptor to its corresponding target antigen ex-
pressed by cancer cells induces cleavage of its intracellular domain, thereby releasing a 
transcription factor that initiates transcription of the CAR. Thus, such T cells only express 
the CAR after initial synNotch recognition at the tumor site. Other potential applications 
of the synNotch system included targeted therapeutic delivery of the apoptosis-inducing 
ligand TRAIL and release of therapeutic antibodies,19 including αPD1, αCTLA4, and bispe-
cific T-cell engagers (BiTE, see later). We hypothesize that the therapeutic potential and 
safety of this synNotch system can be enhanced by using tumor-directed scFv:TRAIL 
fusion proteins or tumor-directed PD-1/PD-L1 blocking bsAbs like PD-L1xEGFR.
In cancer immunotherapy, BiTEs represent an established antibody-based strategy to 
redirect T cells to attack cancer cells. In a BiTE, a CD3-targeted scFv antibody fragment 
is fused to a cancer-cell targeted scFv antibody fragment. Treatment with a given BiTE 
retargets and activates CD3-positive T cells to kill cancer cells that express the cor-
responding target antigen in a MHC-independent manner, irrespective of intrinsic TCR 
specificity. However, repeated challenging of BiTE-redirected T cells with fresh tumor 
cells resulted in a reduced killing capacity and upregulation of PD-1.20 Correspondingly, 
blockade of the PD-1/PD-L1 interaction improved the in vitro efficacy of BiTEs targeted 
to CEA- and CD33-expressing cancer cells.20, 21 
Of note, increased PD-L1 expression was observed in patients with acute lymphoblas-
tic B-cell leukemia (B-ALL) that were resistant to treatment with blinatumomab, a 
CD19-targeted BiTE.22 Hence, there is a clear rationale to combine blinatumomab treat-
ment with blockade of the PD-1/PD-L1 interaction. We speculate that combinations of 
blinatumomab and tumor-selective blockade of the PD-1/PD-L1 interaction (e.g. using 











therapy resistance and reduce side effects compared to combinations with conventional 
PD-1/PD-L1-blocking antibodies.
In Chapter 4, we present a novel PD-1/PD-L1-blockade approach that is based on the 
unique features of TRAIL fusion protein anti-PD-L1:TRAIL that efficiently combines reac-
tivation of anticancer T-cells with induction of tumor-selective TRAIL-mediated apopto-
sis. Previously, we and others have demonstrated that scFv:TRAIL fusion proteins gain 
full pro-apoptotic activity only after tumor-selective binding via its tumor-directed an-
tibody fragment.23, 24 Furthermore, upon binding to target antigen-positive cancer cells, 
scFv:TRAIL fusion proteins may also trigger apoptosis in neighboring target antigen-neg-
ative cancer cells (Figure 1). This so-called bystander effect, can potentially reduce the 
risk of escape of target antigen-negative cancer cells from targeted therapy.25
An appealing feature of anti-PD-L1:TRAIL is that it can convert potentially immuno-
suppressive PD-L1-expressing immune cells into TRAIL-displaying effector cells able to 
induce TRAIL-mediated apoptosis in cancer cells. This is particularly relevant for various 
types of PD-L1 expressing myeloid-derived suppressor cells which are frequently present 
in the tumor microenvironment.26, 27 The presence of such myeloid-derived suppressor 
cells is associated with poor prognosis in several cancer types.28, 29 Although not investi-
gated here, treatment with anti-PD-L1:TRAIL may inhibit PD-L1-expressing myeloid-de-
rived suppressor cells while simultaneously inducing an anticancer bystander effect in 
neighboring cancer cells that express TRAIL-Receptors (Figure 1). 
We have previously demonstrated that selective arming of immune effector cells such as 
T cells and granulocytes with an appropriate scFv:TRAIL fusion protein potently enhanc-
es their anticancer activity towards cancer cells with no or only minimal toxicity towards 
normal cells.30, 31 Since there are multiple inhibitory interactions that regulate T cell re-
sponses it may be of interest to also engineer TRAIL fusion proteins that target and block 
checkpoint molecules expressed on T cells such as PD-1, CTLA-4, TIM-3 and LAG-3. 
The anticancer efficacy of both recombinant soluble TRAIL and agonistic antibodies spe-
cific for TRAIL-R1 or TRAIL-R2 have been evaluated in early stage clinical trials in which 
favorable safety profiles were observed.32 However, these first-generation TRAIL-R ag-
onists had limited clinical efficacy, possibly due to intrinsic resistance to TRAIL and/
or acquired resistance upon treatment with TRAIL-R agonists. Furthermore, TRAIL re-
ceptors are ubiquitously expressed throughout the human body,33 limiting the accumu-
lation of TRAIL-R agonists at the tumor site. Of note, unlike membrane-bound TRAIL, 
soluble TRAIL requires cross-linking to efficiently activate TRAIL-R2. Similarly, conven-
tional TRAIL-R2 targeted antibodies appear to require additional cross-linking by Fc-re-
ceptor positive cells for effective induction of apoptosis.24 However, ubiquitous maximal 
cross-linking and signaling through TRAIL-R2 may be associated with unwanted side 
effects. For example, nanobody TAS266, that did not require secondary cross-linking 
for efficient TRAIL-R-mediated apoptosis induction,34 showed hepatotoxicity in a phase I 
clinical trial, leading to termination of the trial.35
In Chapter 3, we demonstrate that tumor-selective activation of TRAIL-R2 (DR5) can 
be achieved with a bispecific antibody directed against melanoma-associated antigen 
MCSP. BsAb MCSPxDR5 has high binding specificity for MCSP and potent TRAIL-R2-ac-
tivating activity only towards MCSP-expressing cancer cells. We showed that Fc-me-
diated cross-linking could further enhance the anticancer activity of bsAb MCSPxDR5. 
Moreover, bsAb MSCPxDR5 additionally enhanced the anticancer efficacy of NK cells 
via Fc-mediated induction of ADCC. BsAb MCSPxDR5 showed minimal activity towards 
normal cells and Fc-mediated cross-linking did not enhance activity towards MCSP-neg-
ative cells. Thus, we expect enhanced anticancer activity of bsAb MCSPxDR5 compared 
to conventional TRAIL-R2 agonistic antibodies, possibly with a more a favorable safety 
profile. BsAb MCSPxDR5 may be of particular use for treatment of melanoma and other 
MCSP-positive malignancies. 
To further enhance its anticancer activity, bsAb MCSPxDR5 may be incorporated into a 
combinatorial regime, for example with anticancer agents that upregulate TRAIL-Recep-
tor expression, sensitize cancer cells to TRAIL-R-mediated apoptosis or overcome intrin-
sic TRAIL resistance mechanisms, such as chemotherapeutics and small molecule inhib-
itors. For example, RAF inhibitors could overcome TRAIL resistance in melanoma cells in 
vitro.36 Furthermore, synergy between a TRAIL-R1 agonistic antibody and chemothera-
peutic agents gemcitabine and cisplatin was observed in a Phase I clinical trial.37 In line 
with this, TRAIL-R2 targeted bispecific antibody RG7386 showed synergy with chemo-
therapeutic agents doxorubicin and irinotecan in mouse models.38 Indeed, we observed 
Figure 1: Schematic representation of the multiple modes-of-action of TRAIL fusion proteins. Upon 
binding of its scFv domain to the relevant target antigen, TRAIL fusion proteins activate TRAIL recep-
tor-mediated apoptosis in the same cell (1) and in surrounding cancer cells (2). Importantly, once 
bound to the target antigen, displayed TRAIL fusion proteins can also activate TRAIL receptors on 
antigen negative cancer cells (3) in a so-called bystander effect. Similarly, the bystander effect can 
be exploited by immune effector cells that express the target antigen (4).
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synergy of bsAb MCSPxDR5 with several anticancer agents in vitro, including epigenetic 
drug valproic acid that has shown potent anticancer activity in pre-clinical studies.39   
The therapeutic activity of antibodies is strongly influenced by the interaction of their Fc 
domain with the appropriate Fc receptors (FcR) on immune effector cells. Therefore, en-
gineering of the IgG domain has been used to modify Fc-mediated effector mechanisms 
such as ADCC, ADCP and CDC. For example, interaction with inhibitory receptor FcγRIIb 
was found to be critical for agonistic antibodies that target TNFR family members such 
as TRAIL-R2 or co-stimulatory TNF family members such as CD40.40, 41 In line with this, 
mutations in the IgG1 domain that caused a 200-fold increase in affinity for FcγRIIb en-
hanced the agonistic activity of a 4-1BB targeted antibody.42 Incorporation of such IgG1 
mutations into the Fc domain of bsAb MCSPxDR5 may be of interest to further enhance 
its anticancer activity. 
In contrast, binding to FcγRIIb reduces the therapeutic efficacy of antibodies that directly 
target antigens on cancer cells as FcγRIIb is an important negative regulator of ADCC.43 
Therefore, such antibodies have been engineered to have a mutant IgG1 domain, which 
preferentially binds to activating FcγRs over FcγRIIb.44 Interestingly, mutations in the 
IgG1 domain that enhanced the affinity to all FcγRs yielded up to a 100-fold increase in 
ADCC.45 Therefore, incorporation of such IgG1 mutations into bsAb PD-L1xEGFR may be 
of interest too. Since bsAb PD-L1xEGFR showed EGFR-restricted anticancer activity, we 
expect that IgG1 engineering can enhance its tumor-selective activity without increasing 
off-target side effects.
Of note, current PD-1/PD-L1 blocking antibodies are typically engineered to have a hu-
man IgG4 isotype3, 46, 47 or contain a “silenced” IgG1 domain48, 49 to avoid elimination of 
PD-1/PD-L1 expressing immune cells by ADCC. However, recent reports showed that 
PD-L1-blocking antibody avelumab, that contains a fully functional human IgG1 domain, 
induced only low levels of ADCC-mediated lysis in PBMCs in vitro.50, 51 Moreover, recent 
studies with avelumab in carcinoma patients showed promising response rates with a 
toxicity profile comparable to other PD-1/PD-L1-blocking antibodies.52-54
Despite recent advances, treatment of cancer is often not curative. New insights indicate 
that this may be attributable to a small population of therapy-resistant malignant cells 
with self-renewal capacity and the ability to generate large numbers of more differenti-
ated cancer cells. These cancer-initiating cells are commonly referred to as cancer stem 
cells (CSCs). CSCs are regarded as the root of cancer origin and recurrence after seem-
ingly successful therapy. Not surprisingly therefore, current and future cancer research 
is focused on ways to specifically eliminate CSCs. 
In hemato-oncology, various CSC-associated surface antigens have been identified that 
may allow for CSC-selective therapy while sparing normal hematopoietic stem cells.55 
In this respect, it is worth mentioning that CSCs in selected cancers were found to be 
susceptible to TRAIL-mediated apoptosis,56, 57 especially while simultaneously blocking 
pro-survival IL-4 signaling.58 It may therefore be of value to construct a DR5-agonistic 
bispecific antibody with IL-4R-blocking capacity. More recently, it was reported that CSCs 
in breast and colon cancer expressed elevated levels of PD-L1 compared to non-stem like 
cancer cells.59 These results suggest that breast and colon cancer CSCs may be sensitive 
to PD-1/PD-L1 immunotherapy. In this respect, it appears of interest to develop bsAbs 
that allow for CSC-directed PD-1/PD-L1 blockade. 
In conclusion, the novel antibody-based approaches described in this thesis appear to 
have promising anticancer activity that warrants further clinical development. Tumor-di-
rected activation of pro-apoptotic TRAIL-Receptor signaling and/or tumor-directed block-
ing of the PD-1/PD-L1 checkpoint axis has the potential to enhance therapeutic efficacy 
and reduced side effects of current agents. BsAb PD-L1xEGFR, bsAb MCSPxDR5 and 
fusion protein anti-PD-L1:TRAIL each have promising multi-modal anticancer activities 
that may be further enhanced using rationally designed combinatorial therapeutic strat-
egies. 
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In tegenstelling tot wat veel mensen denken is kanker geen moderne ziekte, maar is 
zij al bekend sinds de oudheid. Zo is er bijvoorbeeld bewijs voor tumoren aangetroffen 
in Egyptische mummies. Kanker komt tegenwoordig wel veel vaker voor dan in de oud-
heid. Alleen al in 2012 werden 14 miljoen nieuwe gevallen van kanker vastgesteld en 
overleden er wereldwijd 8 miljoen mensen aan kanker. De verwachting is dat het aantal 
nieuwe kankerpatiënten met 70% zal toenemen in de komende twee decennia. Kanker 
is dan ook een van de meest voorkomende doodsoorzaken wereldwijd.
Dankzij veel onderzoek is het begrip van kanker de laatste decennia flink toegenomen. 
Kort samengevat zijn kankercellen ontspoorde lichaamseigen cellen die bestaande bi-
ologische routes misbruiken om onder andere snel te groeien, zich oneindig te blijven 
vermenigvuldigen en aan het immuunsysteem te ontsnappen. Het immuunsysteem 
is continu bezig met het opsporen en elimineren van potentieel kwaadaardige cellen. 
Kankercellen zijn echter genetisch instabiel, waardoor ze nieuwe eigenschapen kunnen 
verwerven door een opeenstapeling van mutaties. Om tot de ziekte kanker uit te kunnen 
groeien, hebben kankercellen tijdens dit proces eigenschappen verworven die er uitein-
delijk voor hebben gezorgd dat ze aan het immuunsysteem konden ontsnappen. 
Dit proces wordt ‘immunoediting’ genoemd en is in drie fasen in te delen. In de eerste 
fase (eliminatie) is het immuunsysteem nog in staat om kankercellen te herkennen en 
te elimineren. In de tweede fase (equilibrium) is er een dynamisch evenwicht tussen 
kankercellen en het immuunsysteem waardoor tumorgroei wordt beperkt. In deze fase 
is er geen sprake van een detecteerbare tumor en er wordt dan ook gedacht deze ev-
enwichtsfase soms decennialang onopgemerkt kan voortduren. Helaas ontstaat door de 
voortdurende selectiedruk uiteindelijk een kankercel (of meerdere typen kankercellen) 
die niet (meer) herkend worden door het immuunsysteem. Dit leidt tot de derde fase 
(escape) waarin kankercellen ontsnappen aan het immuunsysteem. In deze laatste fase 
kunnen kankercellen zich ongecontroleerd gaan delen waardoor grotere detecteerbare 
tumoren en uiteindelijk ook uitzaaiingen kunnen ontstaan.
Het is de laatste jaren steeds duidelijker geworden dat kankercellen niet alleen aan een 
antikanker immuunreactie kunnen ontsnappen, maar deze ook actief kunnen onderdruk-
ken. Er zijn dan ook diverse strategieën ontwikkeld om dit tegen te gaan, ook wel im-
muuntherapie genoemd. Het uiteindelijke doel van immuuntherapie is om de antikanker 
immuunreactie weer effectief aan te zetten en patiënten te genezen. Vooral immuun-
therapie die zich richt op het blokkeren van zogenaamde immuun ‘checkpoint’ interacties 
heeft veelbelovende resultaten behaald, voornamelijk in patiënten met vergevorderde 
huidkanker (melanoom). 
Immuun ‘checkpoint’ moleculen komen echter niet alleen op kankercellen voor en al-
gehele (re)activatie van immuuncellen kan daardoor tot heftige immuun-gerelateerde 
bijwerkingen leiden. Bovendien hebben veelgebruikte therapieën zoals radio- en che-
motherapie veel bijwerkingen doordat ze zich richten op álle snelgroeiende cellen in 
het lichaam. Gelukkig hebben zowel het verbeterde begrip van kanker als doorbraken 
in de biotechnologie ertoe geleid dat er steeds meer therapeutische opties beschikbaar 
zijn die zich selectief op de kankercellen richten, waaronder antilichaamtherapie. In dit 
proefschrift worden nieuwe antilichaam-gebaseerde moleculen beschreven die zijn ont-
worpen om de tumor-selectieve werking van immuuntherapie te verbeteren.
Antilichaam-gebaseerde kankertherapie
Antilichamen richten zich op zogenaamde tumor antigenen, moleculen die verhoogd tot 
expressie komen op de celmembraan van kankercellen en/of door mutaties veranderd 
zijn in vergelijking met normale cellen. Een antilichaam heeft een hoge affiniteit en 
specificiteit voor een bepaald tumor antigen, eigenschappen die het mogelijk maken om 
medicijnen te ontwikkelen die selectief kankercellen aanpakken. Er zijn diverse vormen 
van antilichaam-gebaseerde therapieën en in Hoofdstuk 2 wordt een overzicht gegeven 
van recente ontwikkelingen op dit gebied.
Helaas blijken er vrijwel geen antigenen te bestaan die exclusief op kankercellen voor-
komen. De meeste op dit moment beschikbare antilichamen richten zich daardoor op tu-
mor antigenen die méér voorkomen op kankercellen ten opzichte van normale cellen. Dit 
betekent echter dat zulke antilichamen effect kunnen hebben op normale cellen waarop 
hetzelfde antigen ook voorkomt en dit kan leiden tot ongewenste bijwerkingen. 
De tumorselectiviteit van antilichamen kan worden verbeterd door zogenaamde bispec-
ifieke antilichamen te gebruiken die zich op twee tumor antigenen tegelijkertijd richten. 
Het idee hierachter is dat de kans dat twee tumor antigenen op gezonde cellen voor-
komen veel kleiner is dan bij één tumor antigen. Antilichaamtherapie met bispecifieke 
antilichamen richt zich dus selectiever op kankercellen en zal daardoor minder bijwerkin-
gen in gezonde cellen veroorzaken. 
Een bispecifiek antilichaam kan zich echter ook richten op een combinatie van een tumor 
antigen op kankercellen en een target op immuuncellen. Er zijn op dit moment twee 
bispecifieke antilichamen op de markt die zich richten op een T-cel activerend signaal-
molecuul (CD3) en een tumor antigen. Dit soort antilichamen activeert T-cellen alleen 
als ze in contact komen met kankercellen die het tumor antigen bevatten en leidt zo tot 
selectieve eliminatie van deze kankercellen. Deze strategie heeft voornamelijk in leuke-
miepatiënten veelbelovende resultaten behaald.
Antilichamen kunnen ook worden gebruikt om therapeutische ladingen af te leveren 
op plek van de tumor. Cytokines bijvoorbeeld, zijn belangrijke signaalmoleculen van 
het immuunsysteem die significante antikankeractiviteit kunnen hebben. Echter, doordat 
cytokines geen inherente tumor-selectieve eigenschappen hebben, is de dosis waarbij 
cytokines een therapeutisch effect hebben vaak zo hoog dat er heftige bijwerkingen op-
treden. Hierdoor zijn veel cytokines niet geschikt als medicijn. Door de therapeutische 
activiteit van cytokines te combineren met de tumor selectiviteit van antilichamen met 
behulp van zogenaamde antilichaam-cytokine fusie-eiwitten, kunnen cytokines selectief 












Selectieve eliminatie van kankercellen met TRAIL-Receptor gerichte 
therapie
Een interessant cytokine voor gerichte kankertherapie is TRAIL, een eiwit dat voorkomt 
op de celmembraan van bepaalde immuuncellen. TRAIL wordt door deze immuuncel-
len gebruikt om kankercellen te elimineren via zogenaamde geprogrammeerde celdood 
(apoptose). Dit natuurlijke proces stelt het lichaam in staat om overbodige of abnormale 
cellen snel en veilig op te ruimen. Het bijzondere van TRAIL is dat het selectief apoptose 
veroorzaakt in kwaadaardige cellen en geen effect heeft op normale cellen. Het exacte 
mechanisme hierachter is nog niet geheel opgehelderd, maar heeft onder andere te 
maken met een complex systeem van tenminste 5 verschillende TRAIL-Receptoren waar 
TRAIL aan kan binden, waarbij alleen efficiënte activatie van TRAIL-R1 en/of TRAIL-R2 
tot geprogammeerde celdood leidt. 
De antikankeractiviteit van zowel niet-membraan gebonden TRAIL (sTRAIL) als antilicha-
men die de TRAIL-R1 en TRAIL-R2 kunnen activeren is onderzocht in klinische studies, 
waaruit bleek dat deze middelen inderdaad weinig bijwerkingen veroorzaakten. Helaas 
bleek ook dat de antikankeractiviteit van zowel sTRAIL als TRAIL-Receptor antilichamen 
minimaal was. Zo wordt de effectiviteit van TRAIL-Receptor antilichamen onder meer 
beperkt doordat TRAIL-Receptoren in het hele lichaam voorkomen, waardoor het over-
grote deel van het toegediende antilichaam niet op de plek van de tumor aankomt. 
In tegenstelling tot TRAIL-R1 kan binding van sTRAIL aan TRAIL-R2 alleen celdood vero-
orzaken als er ook cross-linking van deze receptor optreedt. Dit geldt ook voor an-
tilichamen gericht tegen TRAIL-R2. Maximale, niet tumor-selectieve cross-linking van 
TRAIL-R2 kan echter ongewenste bijwerkingen in de lever veroorzaken. In Hoofdstuk 3 
beschrijven we een nieuwe strategie om de effectiviteit van antilichamen gericht tegen 
TRAIL-Receptor 2 (ook wel DR5 genoemd) te verbeteren met behulp van bispecifieke 
antilichamen. Het door ons ontworpen bispecifieke antilichaam MCSPxDR5 combineert 
selectieve binding aan MCSP, een tumor antigen dat op bijna alle melanomen aanwezig is 
en onder andere de groei van melanoomcellen bevordert, met DR5 activatie. Binding van 
MCSPxDR5 aan MSCP zorgt voor effectieve cross-linking en leidt daardoor tot efficiëntere 
activatie van DR5. 
Onze experimenten lieten zien dat MCSPxDR5 inderdaad selectieve celdood van MC-
SP-positieve melanoomcellen veroorzaakte en groei van melanoomcellen kon verhin-
deren. Verder is MCSPxDR5 in staat om de antikankeractiviteit van immuuncellen te 
verhogen door middel van zogenaamde ADCC (Figuur 1). Fc-receptor binding van immu-
uncellen aan MCSPxDR5 leidt echter ook tot efficiëntere activatie van DR5 en veroorzaakt 
zo meer celdood van MCSP-positieve melanoomcellen. De meervoudige antikankeracti-
viteit van MCSPxDR5 maakt dit bispecifieke antilichaam een veelbelovende kandidaat 
voor verdere doorontwikkeling voor klinische toepassing bij melanomen. Verder kan MC-
SPxDR5 waarschijnlijk ook van nut zijn voor de behandeling van andere kankersoorten, 
aangezien MCSP ook op andere moeilijk te behandelen kankers en op kankerstamcellen 
voorkomt.
Figuur 1: De in dit proefschrift beschreven bispecifieke antilichamen bestaan uit twee scFv antili-
chaam fragmenten en een IgG1 Fc-domein. Wanneer het bispecifieke antilichaam aan de target 
antigenen op de kankercel bindt, kan het Fc-domein worden herkend door Fc-receptoren die onder 
andere op NK-cellen voorkomen. Binding van de Fc-receptor aan het Fc-domein van het antilichaam 
activeert de NK-cel en initieert zogenaamde ADCC waarbij de NK-cel de kankercel aanvalt en uitein-
delijk zal elimineren.
Figuur 2: In een TRAIL fusie-eiwit is een scFv antilichaamfragment genetisch gekoppeld aan sTRAIL. 
Op weg naar de tumor is een TRAIL fusie-eiwit niet in staat om de TRAIL-R2 te activeren. Echter, 
wanneer het scFv antilichaam fragment aan het target antigen op de kankercel bindt, lijkt het TRAIL 
fusie-eiwit op membraan TRAIL waardoor het wel in staat is om de TRAIL-R2 te activeren en apoptose 
te veroorzaken. Afhankelijk van het target antigen kan het binden van het scFv antilichaamfragment 
extra antikankeractiviteit hebben, zoals bijvoorbeeld het blokkeren van signalen die de groei van 
kankercellen bevorderen.

























Versterking van de antikanker immuunreactie met TRAIL fusie-eiwitten
De effectiviteit van niet-membraan gebonden TRAIL (sTRAIL) kan worden verbeterd 
door gebruik te maken van antilichaam-cytokine fusie-eiwitten, waarin een antilichaam-
fragment gericht tegen een tumor antigen gekoppeld is aan sTRAIL. In tegenstelling tot 
TRAIL op de membraan van immuuncellen veroorzaakt binding van sTRAIL aan TRAIL-R2 
geen receptoractivatie en dus geen apoptose (Figuur 2). In een TRAIL fusie-eiwit is 
sTRAIL dus relatief inactief. Pas na binding van het antilichaamfragment aan het tumor 
antigen op de kankercel zal TRAIL-R2 effectief geactiveerd worden (Figuur 2). Wanneer 
een tumor target antigen wordt gekozen dat een biologische functie heeft, kan binding 
van het antilichaamfragment een extra functie hebben die de antikankeractivietit van het 
TRAIL fusie-eiwit verhoogt, zoals bijvoorbeeld het blokkeren van signalen die de groei 
van kankercellen bevorderen. 
In dit proefschrift is onderzocht of TRAIL fusie-eiwitten ingezet kunnen worden om im-
muun-onderdrukkende signalen in het tumormilieu te blokkeren, zoals de interactie tus-
sen PD-L1 en PD-1 (Figuur 3). Dit zogeheten immuun ‘checkpoint’ zorgt er normaal 
gesproken voor dat een immuunreactie op tijd wordt afgeremd om te voorkomen dat 
geactiveerde T-cellen gezonde cellen elimineren. Kankercellen misbruiken dit checkpoint 
echter om aan het immuunsysteem te ontsnappen door PD-L1 tot expressie te bren-
gen. Er is bij diverse soorten kanker dan ook een relatie tussen expressie van PD-L1 
op kankercellen en een slechte prognose. Antilichamen die de interactie tussen PD-L1 
en PD-1 blokkeren kunnen de antikankeractiviteit van de onderdrukte T-cellen in het 
tumormilieu herstellen. Therapie met zulke antilichamen heeft in bepaalde typen kanker, 
met name huidkanker, indrukwekkende resultaten geboekt met zelfs genezing in een 
klein aantal patiënten. Er is echter ruimte voor verbetering aangezien de huidige PD-
L1- en PD-1-blokkerende antilichamen slechts effect hebben in een minderheid van alle 
behandelde patiënten.
In Hoofdstuk 4 beschrijven we het door ons ontworpen TRAIL fusie-eiwit anti-PD-
L1:TRAIL, dat behalve sTRAIL een PD-L1 blokkerend antilichaamfragment bevat. Uit 
onze experimenten bleek dat anti-PD-L1:TRAIL selectief celdood van PD-L1-positieve 
kankercellen veroorzaakte. Bovendien verbeterde anti-PD-L1:TRAIL de antikankeracti-
viteit van T-cellen door de interactie tussen PD-L1 en PD-1 te blokkeren. Dit zorgde in 
vitro voor verbeterde eliminatie van melanoomcellen door T-cellen afkomstig uit dezelfde 
patiënt. 
Een interessante extra functie van anti-PD-L1:TRAIL is dat het PD-L1-positieve immu-
uncellen kan bewapenen met TRAIL. Dit is interessant omdat met name immuun-onder-
drukkende immuuncellen in het tumormilieu vaak PD-L1-positief zijn. Anti-PD-L1:TRAIL 
kan zulke cellen bewapenen met TRAIL, waarna ze hiermee nabijgelegen kankercellen 
kunnen elimineren (Figuur 4). Daarnaast kan de immuun-onderdrukkende werking van 
zulke cellen worden verminderd via blokkering van de interactie tussen PD-L1 en PD-
1. Bovendien kunnen TRAIL fusie-eiwitten via het zogenaamde ‘bystander effect’ cel-
dood veroorzaken in nabijgelegen kankercellen waarop het target antigen niet voorkomt 
(Figuur 4). Kort samengevat heeft TRAIL fusie-eiwit anti-PD-L1:TRAIL veelbelovende 
meervoudige antikankeractiviteit die mogelijk de effectiviteit van PD-L1 blokkerende 











Figuur 3: Door mutaties of signalen in het tumormilieu (bijv. IFN-γ geproduceerd door geactiveerde 
T-cellen) brengen kankercellen PD-L1 tot expressie op hun celmembraan. De interactie tussen PD-L1 
op kankercellen en de bijbehorende receptor (PD-1) op geactiveerde T-cellen onderdrukt de antikan-
keractiviteit van de T-cellen waardoor de kankercellen niet geëlimineerd worden.
Figuur 4: Schematische weergave van de diverse werkingsmechanismen van TRAIL fusie-eiwitten: 
Binding van de scFvs aan het target antigen activeert TRAIL receptoren op dezelfde cel (1) of op een 
nabijgelegen kankercel (2). Echter, wanneer een TRAIL fusie-eiwit aan het target antigen gebonden 
is, kan het ook celdood veroorzaken via het zogenaamde ‘bystander effect’. Hierbij wordt celdood 
veroorzaakt in nabijgelegen kankercellen die geen target antigen maar wel TRAIL receptoren op hun 
celmembraan hebben (3). Het ‘bystander effect’ kan ook plaatsvinden wanneer het target antigen 
zich op immuuncellen bevindt (4).
immuun effector cel

































Tumor-selectieve blokkering van de interactie tussen PD-L1 en PD-1
De huidige antilichamen die de interactie tussen PD-L1 en PD-1 blokkeren hebben geen 
tumor-selectieve werking, omdat PD-1 en PD-L1 ook op gezonde cellen voorkomen. 
Dit kan verklaren waarom therapie met dit soort antilichamen soms immuun-gerela-
teerde bijwerkingen kan veroorzaken. In Hoofdstuk 5 beschrijven we een nieuwe antili-
chaam-gebaseerde therapeutische strategie die de tumorselectiviteit van PD-L1 en PD-1 
blokkerende antilichamen zou kunnen verbeteren. Met behulp van bispecifieke antilicha-
men zou het mogelijk moeten zijn om de interactie tussen PD-L1 en PD-1 selectief op 
de plek van de tumor blokkeren, waardoor er waarschijnlijk minder bijwerkingen zullen 
optreden. 
Het door ons ontworpen bispecifieke antilichaam PD-L1xEGFR bevat PD-L1- en EG-
FR-blokkerende antilichaamfragmenten. EGFR is een bekend tumor antigen dat vaak 
voorkomt op kankercellen en kankercelgroei kan bevorderen. Bovendien is recent ont-
dekt dat EGFR-mutaties kunnen leiden tot verhoogde PD-L1 expressie op kankercellen, 
wat associeert met een slechtere prognose in longkankerpatiënten. Antilichamen gericht 
tegen EGFR kunnen EGFR-signalering blokkeren en zo kankercelgroei verminderen. EGFR 
is daarom een interessant target voor tumor-selectieve PD-L1 blokkerende therapie met 
behulp van bispecifieke antilichamen.
Onze experimenten lieten inderdaad zien dat PD-L1xEGFR de interactie tussen PD-L1 
en PD-1 met name op EGFR-positieve kankercellen blokkeerde. Dit leidde tot verhoogde 
antikankeractiviteit van T-cellen tegen EGFR-positieve kankercellen, terwijl de activiteit 
tegen EGFR-negatieve cellen niet veranderde. Uit onze experimenten bleek verder dat 
behandeling met PD-L1xEGFR de groei van kankercellen kon verminderen. Bovendien 
leidde behandeling met PD-L1xEGFR tot eliminatie van kankercellen via NK-cel afhanke-
lijke ADCC (Figuur 2). 
De meervoudige antikankeractiviteit van PD-L1xEGFR leidde tot efficiëntere eliminatie 
van EGFR-positieve kankercellen vergeleken met een PD-L1 antilichaam dat al in de 
kliniek wordt gebruikt. Kort samengevat heeft PD-L1xEGFR veelbelovende meervoudige 
antikankeractiviteit die de effectiviteit van PD-L1-blokkerende therapie zou kunnen ver-
beteren, terwijl het bijwerkingen zou kunnen verminderen. 
Tot slot wordt in Hoofdstuk 6 een korte samenvatting gegeven van de resultaten uit 
hoofdstuk 3 t/m 5 en worden perspectieven voor de verdere ontwikkeling van PD-L1- en 
TRAIL-Receptor-gerichte therapieën besproken. Kort samengevat vertonen de nieuwe 
antilichaam-gebaseerde moleculen die in dit proefschrift worden beschreven veelbe-
lovende en veelzijdige antikankeractiviteit die doorontwikkeld zou kunnen worden voor 
klinische toepassing. Op basis van onze preklinische resultaten verwachten wij dat onze 
nieuwe moleculen de effectiviteit en tumor-selectiviteit van TRAIL-Receptor activeren-
de en PD-L1 blokkerende therapie kunnen verbeteren en de bijwerkingen van PD-L1 




“Sometimes it’s the journey that teaches you











Het zit erop. Dat is best wel een raar gevoel als je vier jaar intensief aan iets hebt 
gewerkt, het zal denk ik nog wel even duren voor het echt afgerond voelt. Terwijl ik dit 
typ, in Leiderdorp met een kat op schoot, bedenk ik mij dat het vooral een bijzondere 
periode was. Een promotie is sowieso een bijzondere en intense ervaring, maar wanneer 
je gedurende die periode ook dertig wordt en gaat trouwen, dan maak je wel wat mee 
zullen we maar zeggen. Vooral de laatste maanden van een promotietraject hebben wel 
iets van een eindeloze achtbaan of marathon. Dank aan alle collega’s, vrienden en fam-
ilieleden die ervoor hebben gezorgd dat ik de eindstreep heb gehaald. 
Hieronder wil ik graag iedereen bedanken die heeft bijgedragen aan het succesvol afron-
den van dit promotietraject, ik hoop dat ik niemand vergeet.
Allereerst wil ik mijn (co-)promotoren, Wijnand Helfrich en Edwin Bremer, bedanken voor 
de kans om promotieonderzoek te mogen doen. 
Wijnand, ik weet nog dat ik ergens in 2010 een college van je heb gevolgd, toen bes-
chreef je TRAIL fusie eiwitten als geleide raketjes en dat vond ik super interessant 
klinken. Tijdens de zoektocht naar een buitenlandse stage kwam ik bij je langs en ik 
weet nog goed dat je zei: een stage in het buitenland, dat is toch nergens voor nodig, 
mijn groep is ook heel leuk. Ik koos toch voor het buitenland, want na het afronden van 
een scriptie onder jouw supervisie vertrok ik naar Southampton. Gelukkig wist je me nog 
te vinden toen de groep een mooi KWF project in de wacht gesleept had. Ik had soms 
wel wat moeite met je perfectionisme maar mede door jouw hulp bij het maken van een 
goede presentatie heb ik toch maar mooi een prijs voor de beste presentatie gewonnen. 
Het was bijzonder om je oratie mee te mogen maken. Bedankt voor de fijne samenw-
erking de afgelopen jaren!
Edwin, ik denk niet dat je snel twee mensen vindt met zulke verschillende karakters als 
wij. Maar desondanks hebben we goed kunnen samenwerken en je directe doch zeer 
inhoudelijke en praktische feedback werd zeer op prijs gesteld. Ik wil je graag bedank-
en voor twee belangrijke levenslessen: 1. Je hebt me voor het eerst in mijn leven een 
deadline laten missen en me daarmee laten zien dat dat niet het einde van de wereld is. 
2. Mede dankzij jou ben ik erachter gekomen dat ik sarcasme niet begrijp en dat is goed 
om te weten. Bedankt voor de fijne samenwerking en ik wens jou en je nieuwe groep het 
allerbeste bij Hematologie.
Naast besprekingen met supervisors over de voortgang van je onderzoek ben je het 
grootste gedeelte van je promotietraject aan het werk op het lab. Ik wil graag alle Trans-
lationele Chirurgische Oncologie collega’s en alle studenten hartelijk bedanken voor de 
gezelligheid op het COL-lab, in de weefselkweek, tijdens lab uitjes, legendarische sinter-
klaasvieringen en zelfs bruiloften en een kraamvisite. 
Douwe Samplonius, wat had ik gemoeten zonder je aanstekelijke enthousiasme en jar-
enlange lab ervaring. Vermeldenswaardig is ook je olifantengeheugen voor welke stofje 
waar in onze koelkast/vriezer ligt, zonder jou zouden we nooit meer iets terugvinden. 
Bedankt voor de fijne samenwerking, al je hulp bij experimenten en geduldige antwoor-
den op mijn vele vragen. Ik wens jou en je gezin het allerbeste en als jullie ooit nog 
eens in de buurt zijn van Leiderdorp (in een huisje aan het strand ofzo), ben je van harte 
welkom!
Yuan, thank you for being my friend. In Dutch we have a saying that states that shared 
troubles are only half as bad, and that is really applicable here. It was nice to have 
someone who really understands the ordeals of doing a PhD. We had so much fun do-
ing experiments together, sharing an office and last but not least when we went to the 
conference in Manchester. I will sincerely miss our extensive discussions on literally any-
thing from vampires and Sci-Fi to more work-related topics. It was an honor to be your 
paranimph and I am very happy you were still around to return the favor. I wish you the 
best of luck finishing your post-doc and I hope to see you around, in Leiderdorp or even 
in China maybe?
Valerie, bedankt voor de fijne samenwerking vanaf dag 1. Zet hem op tijdens je verded-
iging binnenkort en heel veel succes straks in Duitsland. Ik wens jou, Daan en Minas het 
allerbeste voor de toekomst. Peter, bedankt voor je gezelligheid en onze muziek-gerela-
teerde gesprekken. Het was leuk om tijdelijk in hetzelfde orkest te spelen. Ik zal vooral 
je ‘fantastische’ cd’s met kerstnummers en Duitse smartlappen niet snel vergeten. Heel 
veel succes met de laatste loodjes! Iris, bedankt voor de fijne samenwerking. Dankzij 
jouw doorzettingsvermogen hebben we nu onder andere de mooie data uit de CMV-spec-
ifieke assays. Ik ben blij dat je mijn paranimf wilde zijn en ik wens je veel succes met 
de tweede helft van je promotieonderzoek en in je verdere wetenschappelijke carrière. 
Last but not least wil ik jou en Ilona bedanken voor het prachtige kweekflesjes kunstwerk 
dat jullie voor de bruiloft hadden geknutseld. Ilona, bedankt voor de fijne samenwerking 
die door omstandigheden kort maar krachtig was. Bedankt voor je optimisme en gezel-
ligheid. Ik wens je het allerbeste in je verdere carrière. Jurjen, ik zou je bijna vergeten, 
maar we hebben toch zeker een jaar samengewerkt. Bedankt voor je gezelligheid en ik 
ben je goede raad om me niet gek te laten maken nooit vergeten. Veel succes daar op 
het IVF lab en het allerbeste voor jou en je gezin. Hans, bedankt voor de fijne samenw-
erking en ik wens je het allerbeste bij de apotheek. Marco, bedankt voor je hulp met het 
opstarten van de TIL cultures en natuurlijk voor de prachtige illustraties bij de review. Ik 
wens je het allerbeste bij de gynaecologie.
Ik wil verder graag alle COL-collega’s en de diverse studenten hartelijk bedanken voor 
de gezelligheid op het COL-lab, in de weefselkweek en tijdens lab uitjes. Jacco, bedankt 
voor het bestellen van de eindeloze hoeveelheid spullen die nodig zijn voor onderzoek 
en je strenge doch broodnodige beheer van het lab. Janneke, bedankt voor de hulp met 
cytospot kleuringen. Petra, Suzanne en Jelle, bedankt voor de gezelligheid en de bereid-
heid om mee te denken voor lab-gerelateerde problemen. Maxi en Dafna, bedankt voor 
de gezelligheid, met name in het weekend wanneer ik toch echt dacht dat er verder nie-
mand op het lab zou zijn. Anne Marieke, het was een eer om je paranimf te mogen zijn. 











bent van harte uitgenodigd om eens langs te komen in Leiderdorp!
Last but not least wil ik Niels, Johan en Richard van de transplantatie immunologie af-
deling bedanken voor de goede zorgen en de bereidheid om bijna elke dag bloed af te 
nemen voor mijn onderzoek, of dat nou mijn eigen bloed was of dat van een collega. Er 
zit namelijk letterlijk bloed, zweet en tranen in het hiervoor beschreven werk, ik denk 
zelfs nog het meeste bloed (dat krijg je als je met immuuncellen werkt en zelf HLA-A2 
en CMV-positief bent). Na zo’n promotie weet je pas echt wat het betekent als er in een 
artikel staat dat cellen werden geïsoleerd uit het bloed van ‘vrijwilligers’.
Een belangrijk onderdeel van mijn proefschrift was het verzamelen en verwerken van 
weefsel van tumoren uit melanoom patiënten in samenwerking met chirurg Robert van 
Ginkel. Robert, ik zal niet snel vergeten dat ik mee mocht naar de operatiekamer, om-
kleden, ingewikkeld handenwassen en natuurlijk die onmogelijke manier van hand-
schoenen aantrekken. Het was erg leuk om te zien hoe die biopten precies worden afge-
nomen. Bedankt voor de fijne samenwerking. Ik zal de “biopt op de balie” Whatsappjes 
en de medische terminologie in de e-mails met o.a. “nee dat is geen melanoom dat is 
een mamma” of “de afwijking is te klein voor een biopt” nog missen. 
Uiteraard wil ik ook graag de leden van de leescommissie, Frank Kruyt, Toos Daemen en 
Otto Boerman bedanken voor het beoordelen van mijn proefschrift.
Dan wil ik hier graag van de gelegenheid gebruik maken om de mensen te bedanken die 
ervoor hebben gezorgd dat ik het überhaupt aandurfde om een promotieonderzoek in 
kankerimmunologie te gaan doen. Iedereen die me goed kent weet namelijk dat ik zelf 
de eerste zal zijn om te denken dat ik iets niet goed genoeg zou kunnen. Hieronder noem 
ik een aantal mensen die me hebben laten zien dat ik misschien wel meer in mijn mars 
had dan ik zelf dacht, al zal ik er ongetwijfeld een paar vergeten.
Surinder Sahota, thank you for the opportunity to do research in your lab in Southamp-
ton. Nicola Weston-Bell, I did not know much about cancer research before I became 
your student, many thanks for teaching me how to do tissue culture and how to analyze 
DNA sequence data. It was great fun working with you, I vividly remember an infinite 
amount of cookies and tea, and late nights with pizza when we were writing the letter. 
You convinced me that I would like to continue in science and do a PhD, preferably in 
a cancer-related subject. Nico Bos, bedankt dat je me hebt geholpen om de stage in 
Southampton te regelen.
Oscar Kuipers, Auke van Heel en Manolo Montalbán-López, bedankt voor de fantastische 
tijd in jullie groep tijdens mijn eerste masteronderzoek. Jullie gaven me het zelfvertrou-
wen dat ik een promotie zou kunnen doen en daar ben ik jullie erg dankbaar voor.
Verder wil ik graag onder andere Marco Fraaije en Bert Poolman bedanken voor de in-
spirerende biochemie colleges. Maar ik ben ook dankbaar voor de inspirende biologie 
en scheikunde lessen op de middelbare school van onder andere Soeteman, Bouwma 
en Feitsma. Mede dankzij jullie enthousiaste lessen ben ik überhaupt scheikunde gaan 
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